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SUMMARY OF WORK IN THIS THESIS 
Literature reports of studies that investigate the impact of CYP 
polymorphisms on drug pharmacokinetics and response are often conflicting and the 
importance of genetic variation in drug metabolism for drug response remains unclear. 
Johnsson & Sheiner (2002) have advocated the need for 'smarter clinical trial design' 
and showed that simulation techniques can help in this process by integrating all the 
available information. However, current examples of clinical trial simulation rely 
heavily on data already available from in vivo studies and there is a need for utilising 
pharmacokinetic information gathered earlier on during drug development. 
The aim of the current work was to integrate early preclinical data on drug 
metabolism into a clinical trial simulation paradigm in order to investigate (A) the 
impact of genetic polymorphisms in the cytochromes P450 on the pharmacokinetics 
and pharmacodynamics of 5 model drugs: dextromethorphan, (S)-warfarin, 
midazolam, omeprazole and tolbutamide, and (B) the predicted power of studies to 
detect the effects of such polymorphisms. 
SimcypS algorithms incorporate information on in vitro metabolism and in 
vivo kinetics with interindividual variability in the genetics of drug metabolising 
enzymes and other physiological and demographic features. In the curre nt study these 
algorithms were linked to pharmacokinetic-pharmacodynamic models to describe the 
ii 
time course of concentration and effect of the model drugs in virtual populations of 
subjects. The probability of detecting a statistically significant difference in the 
pharmacokinetics or response between CYP phenotypes/genotypes was assessed and 
the power of studies to detect such differences was calculated. Various aspects of study 
design (study size and enrichment) and drug characteristics (active metabolites, PD 
variability etc) were investigated in each case. 
The study powers calculated from the simulations where largely consistent 
with the observed in vivo outcomes and helped to explain the aforementioned literature 
discrepancies. In conclusion, the simulations described have demonstrated the 
usefulness of clinical trial simulations, incorporating preclinical information on the 
genetics of drug metabolism for the prediction of drug pharmacokinetics and dynamics 
in virtual populations of individuals of varying drug metabolizing capability. In the 
future, clinical trial simulation may increasingly use prior in vitro data. 
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1 INTRODUCTION 
1.1 BackLyround 
The work described in this thesis is concerned with the simulation and 
prediction of the pharmacokinetics and pharmacodynamics of selected drugs in virtual 
populations of individuals. The clearance of these drugs, as well as the fraction of drug 
escaping first pass hepatic and gut metabolism, was estimated for each individual by 
utilising in vitro data on drug metabolism. The simulations have incorporated 
variability from a number of demographic and physiological sources, in addition to 
genetic differences in drug metabolism. The pharmacokinetic data were used in 
conjunction with established pharmacokinetic-pharmacodynarnic models, to allow the 
investigation of the impact of genetic polymorphisms of drug metabolism, on the 
pharmacokinetics and pharmacodynamics of the drugs studied. The findings were then 
used as the basis for clinical trial simulations (CTS), to investigate the importance of 
size, and other aspects of design, in determining the power of studies to observe such 
genotypic and phenotypic differences. 
The aim of this introduction is to give an overview of drug development 
and how the practices of modelling and simulation can be used to support it. Clinical 
trial simulation is then discussed and its advantages highlighted. Finally, since this 
thesis is concerned with the influence of cytochrome P450 polymorphisms on drug 
pharmacokinetics and pharmacodynamics, the major elements of drug metabolism are 
discussed. 
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1.2 Dru2 Developmen 
LZI Stages ofDrug Development 
The traditional view of drug development represents the process as four 
stages designated as (i) discovery, (ii) pre-clinical research and development, (iii) 
clinical research and development and (iv) 'post-marketing' pharmacovigilance 
(Lipsky & Sharp, 2001) (Figure 1.1). 
During drug discovery, compounds are screened against biochemical 
pathways or receptors that are thought to be implicated in the causation of a particular 
disorder or group of disorders. Once lead drug candidates have been recognized, they 
proceed to pre-clinical testing. During this stage, in vitro and in vivo (in animals) tests 
are carried out to elucidate the pharmacokinetic, pharmacodynamic and toxicological 
properties of the drug. Preclinical testing takes between 2 and 6.5 years (Lipsky & 
Sharp, 2001). If the characteristics of the drug, namely its efficacy and safety, are 
satisfactory at this stage, clinical testing may begin. 
The clinical research and development stage is the longest, lasting up to 10 
years (Lipsky & Sharp, 2001). It is fdrther divided into three phases, 1,11 and III 
(Figure 1.1). 
Phase I testing or 'first in man' studies are carried out in small groups of 
young, healthy subjects. The main aim of these studies is to characterise the 
pharmacokinetic properties of the drug and assess its safety for further testing (Lipsky 
4 Sharp, 2001). 
Phase Il studies are carried out in patients who suffer from the disease or 
disorder that the drug is intended to treat. In this stage the safety, tolerability, 
effectiveness and appropriate dosage of the drug are studied in greater depth than in 
phase I (Lipsky & Sharp, 2001). A 'go/no go' decision will be made, based on the data 
gathered in phase 11, as to whether to proceed to phase III (Lipsky & Sharp, 2001). 
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Figure 1.1 Schematic representation of the drug discovery and development process. 
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The aim of Phase III is to confirm efficacy in a much larger patient group 
than in Phase II (Lipsky & Sharp, 2001). Safety data must also be collected to allow 
assessment of the benefit-risk profile of the drug. If phase III studies are completed 
successfully then the data will be submitted to the relevant regulatory body (e. g. the 
FDA) for review, who license the drug for prescription to the patient population. 
The scheme described above reflects the traditional structure of drug 
development. However, it has been recognised that in order to optimise the speed and 
cost of drug development, it is advantageous to have the stages running simultaneously 
rather than sequentially. 
1.22 Pharmacokinetics & Pharmacodynamics: Essential Elements of Drug 
Development 
Pharmacokinetics is defined as the quantitative description of the processes 
that determine the plasma concentration-time course of a drug, namely absorption, 
distribution, metabolism and excretion (ADME). 
'Dosage' is a term describing the dose and frequency at which a drug is 
administered. The dosage of a drug is determined by a number of factors but most 
importantly, it relies on the assumption that there is a functional relationship between 
the concentration of a drug at a site of action and response to the drug (Rowland & 
Tozer, 1995). The more potent and efficacious the drug, the smaller the dose required. 
However, there are complexities to this relationship and the pharmacokinetic 
parameters of the drug also influence dosage. For example, a drug may have to be 
administered more or less frequently depending on how much of it reaches circulation 
and how long it remains in the body. 
Pharmacokinetic data can be analysed using mathematical equations, 
which provide a representation of the relationship between the dose of a drug and the 
manner in which its plasma concentration changes with time. It relates the independent 
variables of time and dose to the dependent variable, concentration. Pharmacokinetic 
parameters such as clearance and volume of distribution are utilised in such models 
(Rowland & Tozer, 1995). Commonly used pharmacokinetic models can be divided 
into those that are empirical, compartmental or physiologically based. The 
compartmental type is the most frequently used, probably because it provides a 
continuous concentration-time profile in a body fluid that can be related to a 
continuous effect-time profile (Rowland & Tozer, 1995). Pharmacodynamic models 
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(Section 1.2.4) are used to describe the relationship between drug concentration and its 
effect at the site of action. 
1.2.3 The Role of Pharmacokinetics in Drug Development 
The exposure of an individual to a given drug can be obtained by 
measuring the area under the concentration time curve (AUC). The AUC after oral 
administration is dependent on the proportion of the dose that reaches the systemic 
circulation after passage from the gut and through the liver (F), the clearance (CL) and 
the dose of the drug (Rowland & Tozer, 1995) (Equation 1.1). 
AUC = 
F-D Equation 1.1 
CL 
Total CL is defined as the volume of blood that is completely cleared of 
drug per unit time, and encompasses clearance by the liver, the kidneys, the biliary 
system, the lungs and blood. 
Exposure is one of the most important factors in determining the 
pharmacodynarnic response of an individual to a particular drug. Therefore, it is 
important for drug companies to determine the pharmacokinetic characteristics of a 
drug as early as possible in drug development. However, the usefulness of 
pharmacokinetic data is dependent on the pharmacokinetic-pharmacodynamic 
relationship (1.2.4). Today, pharmacokinetics is considered at each stage of the drug 
development process, from discovery to post-marketing. The pharmacokinetic basis of 
the ADME processes, and their importance in drug development will be discussed 
finther in Section 1.3.1.1. 
LZ4 Defining the Pliarmacokinetic-Pharmacodynamic Relationship 
Several mathematical models have been developed to describe the 
relationship between drug concentration and effect. Factors that will influence the 
choice of model include the nature of the drug, the response being measured, the effect 
seen after drug or placebo administration, the degree of linearity in the concentration- 
effect curve, and the potential for achieving the maximal response. Under steady state 
conditions, the most commonly used models are (1) the linear effect-concentration 
model, (2) the log-linear effect-concentration model, and (3) the simple and sigmoidal 
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F,,, a, models (Gabrielsson & Weiner, 2000; Meibohm & Derendorf, 1997). All these 
are 'direct response' models represented by Figure 1.2. 
The two types of model utilised in the work described in this thesis are: 
The E.,., model, where the effect-concentration relationship is described 
by Equation 1.2: 
E=Eo ± 
E,,. C 
EC50 +C 
Equation 1.2 
where, 'E' is the effect at a given concentration, C, E.,,. is the maximal 
effect, C is the concentration of active moiety in the plasma or a remote effect 
compartment (see below), and the EC50 is the concentration required to elicit 50% of 
the E,.. EC50 is a measure of the potency of the drug (i. e. its affinity for a receptor), 
whereas E,,, a, reflects its activity. 
The Ea, model describes the concentration-effect relationship over a wide 
range of concentrations from EO (baseline effect) in the absence of drug, to the 
maximal effect at concentrations twice as high as the EC50- 
Sigmoidal E.. model: The sigmoidal E,, a, model is a variation of the 
simple Em. model. The relationship is sometimes known as the Hill equation: 
E=Eo ± 
E,,,,,. C 
ECY +Cr 50 
Equation 1.3 
Wherey is the shape factor describing the steepness of the curve (Rowland 
& Tozer, 1995) (Figure 1.3). The larger the value of y, the greater the change in 
response with concentration around the ECSO value (Rowland & Tozer, 1995). Wheny 
is equal to 1, the sigmoidal E,,,. model collapses to the simple Einax model. Patients 
may differ widely in their values of EC50 and y for a given drug (Chan et al., 1994; 
Moghadamnia et aL, 2003; Rostami-Hodjegan et aL, 1998) (Section 1.3.2). 
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e. g. Emax 
model 
Input Response ý-ý Output 
[Drug] 
Figure 1.2 A schematic representation of a direct response model (see Figure 1.4 for 
comparison with an indirect model) (Gabrielsson & Weiner, 2000). 
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In the two models described above, the concentration term, C, may 
represent either the drug concentration in plasma (in which case there is no delay 
between the time course of drug in plasma and the time course of effect), or the drug 
concentration in a hypothetical effect compartment (which is used to account for a time 
delay between the time course of drug in plasma and that of the effect). 
In general, the models described above are simplistic representations of 
those utilised in phannacokinetic-phannacodynainic studies. Additional complexities 
may involve the incorporation of a placebo response, the modelling of inhibitory 
response, where the effect may not exceed the baseline effect (Ea,, < EO), or the case 
where two drug molecules compete for the same receptor site (e. g. the combined action 
of parent drug and its active metabolite). These topics are described in the appropriate 
sections of this thesis, as and when they arise. 
Alternatively, response may be modeled using more mechanistic models, 
such as indirect response (turnover) models. For some drugs, the lag between the 
plasma concentration and pharmacological effect is not only the result of a delay in the 
drug in plasma reaching the effect compartment (see above). It can also represent the 
accumulation or depletion of some biological entity resulting in a build up or gradual 
loss of effect within the body. In this case, an indirect model is used when prior 
information on the mechanism of drug action is available (Gabrielsson & Weiner, 
2000). In contrast to direct response models, indirect response models are used to 
describe the action of drugs that influence the build up (or loss) of response, rather than 
acting directly on the magnitude of response (Figure 1.4). 
In such models, the measured response to a drug (E) may be due to factors 
controlling the turnover rate, k,,, (input or production), or the fractional turnover rate, 
kd, 
r , 
(loss) of the biological factor mediating response (Gabrielsson & Weiner, 2000). 
The rate of change of the response over time with no drug present can be described by 
Equation 1.4: 
dR 
=k syn - 
k,,. 
g xE Tt Equation 1.4 
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Figure 1.3 A concentration - response plot according to equation 1.3 for four 
hypothetical drugs that have the same EC50 value but different values of 
the shape factor, y (Rowland & Tozer, 1995). 
Turnover Fractional Precursor 
rate 
0 Respons.: e: 
]- 
turnover AAA 
rate 
[Drug] [Drug] [Drug] 
Figure 1.4 A schematic representation of an indirect response model (see Figure 1.2 
for comparison with a direct model). [Drug] indicates the sites of 
potential interaction between drug and target (Gabrielsson & Weiner, 
2000). 
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There are a wide range of techniques to measure response in vivo. As a 
result, measurements may take continuous or discrete forms. Continuous data may take 
on any value within a finite or infinite interval, whereas discrete data takes on values 
that are distinct and separate. The outcomes of all the pharmacodynamic models 
utilised within this thesis can be considered as continuous variables (warfarin - INR; 
midazolarn - EEG activity; orneprazole - acid secretion rate; tolbutamide - insulin 
secretion rate). The case of dextromethorphan is slightly more complex as the response 
variable (number of coughs) is strictly a discrete measurement. However, for the 
purposes of data analysis, it was modelled as a continuous variable, although the final 
results were recorded to the nearest integer (Chapter 4; Section 4.2). 
1.2.4.1 Additional Complexities of the Concentration-Effect Relationship 
In many cases plasma concentration has been known to correlate poorly 
with response. In addition to the factors discussed above (delay in drug reaching effect 
compartment or delay in drug eliciting its effect via a biological entity), a number of 
other reasons may be responsible for this poor correlation. These include the presence 
of active metabolites (as receptor agonists or antagonists (Danhof & Mandema, 1995)) 
or chirality in the drug molecule (Lee & Williams, 1990). The presence of active 
metabolites has relevance for two of the case studies outlined within this thesis. 
Active metabolites can confound the concentration-effect relationship and 
should be measured with the parent compound (if both are active), or instead of the 
parent compound (if the metabolite is responsible for all the activity of the drug). In the 
former case, the interaction between the two moieties may occur by a number of 
different mechanisms, namely, (i) competitively, where both compounds compete for 
the same receptor site, (ii) additively, where they act at different receptor sites, or (iii) 
synergistically, where the moieties act at different receptor sites as in (ii), but the 
resulting effect is greater than the sum of the effects at the two sites (Greco et aL, 
1995). 
For some drugs the maximal effect may be observed after the drug 
concentration reaches its peak in the plasma (Figure 1.5). Possible causes of such a 
delay are a poorly perfused tissue, a drug that has poor membrane permeability, or an 
indirect mechanism of action. 
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I. Z5 Biomarkers 
The use of biological markers, or 'biomarkers', to predict the relationship 
between exposure to and the safety or efficacy of a drug product offers the potential of 
accelerating and cutting the costs of drug development. A biomarker is defined as a 
"physical sign or laboratory measurement that may be detected in association with a 
pathological process and that have putative diagnostic and/or prognostic utility" (Rolan 
et aL, 2003). They facilitate the prediction of clinical responses that may be more 
difficult, costly or time-consuming to measure directly (Rolan et aL, 2003). In early 
drug development, biomarkers; may be used as a guide to dose selection and escalation, 
a process which would otherwise involve more trial and error and guess-work (Rolan 
et aL, 2003). Whether many biomarkers are sufficiently representative of the clinical 
response to a drug is a subject of much debate. 
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Figure 1.5 Representation of a time delay between drug in plasma and drug effect. 
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1.3 The Role of Interindividual Variabilitv in DruLy Response 
The individualisation of drug treatment is not a new idea. In the 1950's it 
was found that African-American soldiers who developed severe anaemia after taking 
the anti-malarial drug, primaquine, were deficient in the enzyme glucose-6-phosphate 
dehydrogenase (Beutler, 1959). Almost simultaneously, the discovery was made that 
patients who experienced prolonged effects of the anaesthetic drug, succinylcholine, 
possessed an atypical from of a cholinesterase enzyme (Kalow & Staron, 1957). Since 
this time, a large amount of research has been conducted to elicit the physiological, 
demographic, ethnic and genetic basis of individual variation in drug response. It is 
now a widely held view that the personalisation of medicine to the individual is 
inevitable to the future of therapeutic medicine. However, it is also apparent that solid 
examples of the use and success of individualised medicine are few and far between. 
There are a number of possible reasons for this: 
i) Lack of awareness on the part of clinicians. 
ii) The difficulty, complexity, and often high cost associated with 
performing the assays, necessary to determine many of the genetic factors leading to 
interindividual variability in drug response. 
iii) The rarity of many of the factors leading to the extreme or 'outlier' 
responses. 
iv) The possibility (or probability) that several, if not many, genetic, 
demographic or environmental factors may contribute to variation and the difficulty in 
characterising all of them. 
Historically, the philosophy in the clinic with regard to drug therapy has 
been the 'one size fits all' approach. It is now generally accepted that at least for some 
drugs, this attitude is not likely to lead to the best therapy. Indeed, when the average 
value of a population parameter is considered in isolation, without regard for the 
variability of the individual values around the mean, a great deal of information is lost. 
We hence have little idea of what is likely to occur in 'outlier' individuals. Given that 
these individuals are likely to be those most at 'risk' from adverse events or ineffective 
therapy, the situation is not ideal. 
There are a small number of examples of situations where genetic testing 
has been used prior to treatment to inform the clinician on how best to proceed with 
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drug therapy for a particular individual. Pharmacogenetic information is contained in 
about ten percent of labels for drugs approved by the FDA and a significant increase of 
labels containing such information has been observed over the last decade 
(http: //www. fda. gov/cder/genomics/genomic-biomarkers-table. htm). For example, in 
November 2004, the labelling of the drug Camptosar (irinotecan) was updated to 
include information on its metabolism by UGTIA. Camptosar is a drug used to treat 
colon/rectal cancer. Nearly 70% of patients require a dose reduction in order to prevent 
neutropenia. Since exposure to the drug is dependent on its metabolism by UGTIA1, 
patients with certain enzyme mutations are expected to require a lower dose of the 
drug. 
1.3.1 Pharmacokinetics as a Source of Variability 
Interindividual variability arises from a number of sources (Figure 1.6). 
These could be environmental factors (e. g. food, pollutants, time of day and season, 
location etc. ), genetics, disease, age, concomitant medication and compliance 
(Rowland & Tozer, 1995). With the exception of compliance, each of these factors 
affects variability by either altering the phannacokinetics or the pharmacodynamics of 
a particular drug (Figure 1.6). 
A major source of variability in response can be attributed to 
interindividual differences in the plasma concentration - time profiles of drugs. 
Therefore, factors affecting the ADME of drugs are of importance in understanding 
overall variability in pharmacokinetics. 
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How the variability is manifest 
Receptor interactions or 
Absorption: Metabolism: number: 
slow/rapid poor/extensive/ultra-rapid poor/efficient; low/ high Kidney function 
Drug-food or Drug-food or Drug-drug interactions Disease 
drug-drug interactions drug-drug interactions Genetics Age 
Genetics Bodv ýNci-ht 
Source of the variability 
Figure 1.6 Sources of variability in pharmacokinetics and pharmacodynamics and 
how these variabilities are manifest (Ingelman-Sundberg, 2001). 
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1.3.1.1 Drug Absorption 
Bioavailability (F) is a tenn often used to describe the absorption of a drug. 
It is defined as the proportion of an oral dose that reaches the systemic circulation and 
is described by Equation 1.5: 
F= f. xFG xFH Equation 1.5 
Where f. is the fraction of the dose that enters the gut wall (drug may be 
lost by decomposition in the gut lumen) (Rowland & Tozer, 1995), FG is the fraction of 
drug that escapes metabolism in the gut wall and enters the portal vein, and FH is the 
fraction of the drug that escapes metabolism in the liver, thus entering the systemic 
circulation. 
It follows that the extent of drug absorption will determine the amount of 
drug that reaches the systemic circulation from the gut lumen and hence, the dose 
requirement. The rate of absorption is also important in determining the time span of 
absorption, and therefore the frequency of dosing, particularly in the case of sustained 
release formulations. 
Each of the parameters, fa, Frj, and FH is sensitive to a number of factors 
that differ between individuals. For example, f, is in many cases affected by 
gastrointestinal motility (particularly for drugs with low permeability). FG is sensitive 
to variation in drug metabolising enzyme activity, diet, and active secretion of the drug 
back into the gut by the multidrug efflux pump, P-glycoprotein (P-gp), which may be 
susceptible to interindividual fluctuations in both abundance and activity. Variability in 
the first pass metabolism of the drug by the liver (FH) is a result of genetic, 
environmental and physiological (e. g. liver blood flow and size) differences in drug 
metabolism. 
Distribution 
Distribution refers to the reversible transfer of drug from one location to 
another within the body (Rowland & Tozer, 1995). Distribution of drugs to and from 
blood and other tissues occurs at different rates and to varying extents (Rowland & 
Tozer, 1995). Several factors are responsible for the distribution pattern of a drug over 
time. These include the perfusion of different tissues by blood, the ability of the drug 
to cross membranes (e. g. the blood brain barrier), drug binding in the blood and 
tissues, and partitioning into fat (Rowland & Tozer, 1995). 
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The fraction of drug that is unbound in blood (fLIB) often varies between 
individuals. For very highly bound drugs such variability can be large (Lin & Lu, 
1997), but is normally less than that of other pharmacokinetic parameters (Yacobi et 
aL, 1977). The fuB of a drug is a function of its affinity for plasma proteins (Rowland 
& Tozer, 1995), each of which has a finite number of binding sites. Because of this, 
binding is also dependent on the concentrations of both drug and protein in the blood 
(Rowland & Tozer, 1995). The concentration of protein in the plasma can vary due to 
factors such as age, liver cirrhosis, pregnancy, trauma and stress. 
Interindividual variability in the distribution of drugs is also a result of 
variations in the size and composition of different organs. For example, differences in 
body fat content between individuals, and in particular between males and females, 
may lead to differences in the volume of distribution. A highly lipid soluble drug may 
distribute more into the adipose tissue of a female with high body fat and become less 
available to the eliminating organs. Consequently, the half life of the drug may be 
higher in females compared to males. 
1.3.1.3 Drug Metabolism 
For the majority of drugs, metabolism is a major route of elimination from 
the body (Williams et aL, 2004). Some of the important questions that need to be 
answered during the development of a new drug are: (i) what are the major (and minor) 
routes of metabolism? (ii) are any active and/or toxic metabolites produced?, (iii) what 
enzymes are involved?, and (iv) are there any potentially important drug-drug 
interactions? 
It is advantageous to identify the pathways involved in the metabolism of a 
drug, the structure of the metabolites generated, and the enzymes involved, as early in 
the drug development process as possible. Such information can be used to predict the 
effect of genetic and environmental factors on pharmacokinetics, to predict the 
likelihood of clinically important drug-drug interactions, and to select appropriate 
animal species for toxicology and efficacy testing before the drug is given to humans 
(Williams & Ette, 2000). The use of in vitro systems to characterise drug metabolism 
and its extrapolation to in vivo pharmacokinetics is discussed further in Section 1.5.4.2. 
During pre-clinical development, the quantitative prediction of in vivo 
metabolic clearance from in vitro data is arguably one of the most important objectives 
of in vitro metabolism studies. Clearance can be used to assess the likelihood of 
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individual drug interactions occurring, to determine appropriate dosage regimen for in 
vivo studies, and to provide information on concentration-time profiles and on the risk 
of drug toxicity. Several methods have been employed to determine clearance from in 
vitro data (Section 1.5.4.2). 
Polypharmacy, the administration of several therapeutic drugs to a patient 
concurrently, is commonplace in the developed world, and inpatients often receive an 
average of five different drugs at any one time during their hospitalisation (Rowland & 
Tozer, 1995). Adverse drug reactions including drug interactions have been estimated 
to be one of the leading cause of death in the western world (Lazarou et al., 1998), 
although some concerns have been raised with respect to the methods of analysis of 
these data (Kvasz et al., 2000). Moreover, drug interactions are a leading cause of the 
removal of drugs from the market (Table 1.1) (www. fda. gov). 
Interindividual differences in drug metabolism are caused by a wide range 
of factors, the most important probably being induction or inhibition of enzyme 
activity by drugs and other xenobiotics, and the genetic makeup of the individual. 
Variants of genes coding for drug metabolising enzymes can result in higher, lower or 
no activity, or they may lead to a complete absence of the enzyme (Lin & Lu, 1997). 
Such genetic variation is termed a 'polymorphism' when the monogenic trait occurs at 
a single gene locus with a frequency of more than (arbitrarily) 1% (Meyer, 1991). 
Specific examples of polymorphisms of drug metabolising enzymes will be discussed 
in Section 1.4. 
Some of the potential consequences of genetic polymorphisms of drug 
metabolising enzymes are: (i) unwanted responses (toxic effects) as a result of elevated 
plasma concentrations through impaired clearance (ii) a lack of pro-drug activation, or 
(iii) a dependence on alternative routes of elimination. If these alternative routes are 
also compromised (e. g. by renal impairment, drug-drug or drug-food interactions), the 
outcome may be more severe (Dickins & Tucker, 2001). 
The extent of the consequences of such polymorphisms for the 
pharmacokinetics of a drug depends on a number of factors (Dickins & Tucker, 2001): 
(i) whether the polymorphic enzyme metabolises the parent drug or the metabolite(s) 
or both, (ii) the contribution of the polymorphic enzyme to overall elimination of the 
drug, (iii) the potency of any active metabolites, and (iv) the viability of the other, 
competing pathways of elimination. Such pharmacogenetic variability in drug 
metabolism is discussed further in Section 1.4, and its effects on pharmacokinetics and 
pharmacodynamics in Chapter 2. 
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Table 1.1 Reasons for recent withdrawals of drugs from the US market 
(www. fda. go . DDI = Drug-drug interaction 
Reason for Withdrawal 
Year Drug DDI Torsades de Points Hepato-toxicity Other 
1998 Terfenadine V/ V/ 
Mibefradil V/ V/ 
Bromfenac V/ 
1999 Asternizole 
Grepafloxacin V/ 
2000 Troglitazone V/ 
Cisapride V/ 
Alosetron 
2001 Cerivastatin 
Rapacuronium 
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Excretion 
Many drugs are eliminated from the body partly or entirely by renal (or in 
some cases biliary) excretion. In the present work, the renal route of elimination is not 
a ma or focus of attention, since it plays a relatively minor role in the clearance of the j 
drugs selected for study. The only covariates considered with respect to this route are 
those known to affect creatinine clearance (e. g. age or body weight). 
As well as being influenced by plasma drug concentration, protein binding 
and renal function, the renal clearance (excretion) of a drug is affected by urine flow 
and urine pH. These two factors vary widely between individuals, which leads to 
considerable interindividual differences in the excretion of drugs from the body 
(Rowland & Tozer, 1995). The urine flow of an individual is sensitive to fluid intake 
and to the administration of diuretic drugs. Interindividual differences in urine pH are 
brought about by differences in diet, drug intake, and clinical status, as well as being 
due to natural diurnal variation (Rowland & Tozer, 1995). 
Biliary excretion of drugs is sensitive to the ingestion of enviromnental 
substances or toxins, pathophysiological conditions that cause cholestasis (Shargel & 
Yu, 1999), and to variation in the activity of certain transporters (e. g. OATP; 
Yamashiro et aL, 2006). 
1.3.2 Pliarmacodynamics as a Source of Variahility 
Drug response is likely to be the result of a complex function of the 
influence of many genes interacting with environmental and behavioural factors. 
Whether pharmacokinetic-pharmacodynamic variability translates into clinically 
relevant differences in drug response depends on ftu-ther issues including compliance, 
the availability of alternate drugs and doctor/patient perception of side-effects (Dickins 
& Tucker, 2001). 
Sources of pharmacodynamic variability include genetics (e. g. of 
transporters or receptors) and demographics (e. g. developmental differences in the 
abundance of receptors or hormonal influence on the regulation of receptors). 
The consequence of polymorphisms in receptors that mediate drug 
response depends on a number of contributing factors (Dickins & Tucker, 2001): (i) 
the point on which the concentration-effect relationship typical concentrations arising 
from 'normal' doses fall, (ii) the therapeutic index and utility of the drug, and (iii) 
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whether pharmacokinetic variability is outweighed by phan-nacodynainic variability in 
receptor sensitivity or density, or in the turnover of a particular endogenous receptor 
ligand. 
There is substantial evidence that genetic variation in drug receptor and 
effector proteins is associated with variable drug response (Johnson, 2001; Evans & 
McLeod, 2003). Examples of genes for which genetic polymorphisms have been 
reported include those encoding P-adrenergic receptors (Liggett, 2000), g-opioid 
receptors (Hollt, 2002; Lotsch et aL, 2002) and G proteins (Johnson & Lima, 2003). 
All of these polymorphisms have the effect of altering response to drug therapy, 
independent of dose and exposure levels, and of increasing interindividual variability 
in response. 
1.3.3 Other Sources of Variability in Drug Response 
There are a number of sources of variability in human drug response that 
do not fit into either of the above two categories. These include disease status, 
compliance with the prescribed drug regimen, and variability in prescribing. These 
factors will not be discussed, since they are not considered as sources of variability in 
the pharmacokinetic-pharmacodynamic models used in this thesis. Pharmacokinetic- 
pharmacodynamic models are usually carried out either under controlled conditions in 
healthy individuals where such variables do not apply, or in hospitalised patients where 
compliance should not be an issue. 
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1.4 Variability in DruLy Metabolising Enzvmes 
A major focus of the present work is the propagation of pharmacogenetic 
differences in cytochrome P450 enzymes into pharmacokinetic and pharmacodynamic 
measures. Therefore, a background to drug metabolism and its determinants is given 
below. 
1.4.1 Background to Drug Metabolism 
The liver is the main organ responsible for drug metabolism; other organs 
that contribute to a lesser extent include the gastrointestinal tract (either via enzymes in 
the gut wall or flora that inhabit the gut), kidneys, lungs, blood, brain, skin and 
placenta. The metabolism of drugs and xenobiotics is divided into two phases, termed 
phase one and phase two. 
1.4.2 Phase One Drug Metaholism 
Phase one reactions involve the oxidation, reduction, hydrolysis and 
hydration of drug compounds. Their primary aim is to render the drug molecule more 
hydrophilic (polar), to facilitate its excretion in the urine. Phase one reactions may also 
introduce a relatively reactive group into the molecule, which then serves as a point of 
attachment for a conjugate group by the enzymes in phase two metabolism (Section 
1.4.3). The cytochrome P450 (CYP) enzymes are primarily responsible for the 
majority of phase one drug metabolism, with other hepatic enzymes such as xanthine 
oxidase, monoamine oxidase, flavin containing monooxygenase and epoxide hydrolase 
playing a lesser role. All CYP enzymes possess a porphyrin-haern complex as the 
catalytic centre, but they differ in their amino acid sequence. They are subject to 
induction, inhibition, and genetic polymorphism. Hence, a main focus of screening 
strategies within pharmaceutical drug development is on how metabolism by CYP 
enzymes may affect the pharmacokinetics of drugs. 
1.4.2.1 The Cytochromes P450 (CYPs) 
The nomenclature for the CYP's is based on amino acid sequence (Figure 
1.7). Those sequences with more than 40% homology are grouped into the same 
family (Guengerich, 1995). Within families, those sequences with 40% or more 
homology are grouped into a subfamily (Guengerich, 1995). Different genes in the 
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same subfamily are distinguished by the second Arabic numeral (e. g. CYP3A4, 
CYP3A5) and have at least 60% homology with one another. 
To date, 76 CYP gene families and 233 subfamilies have been described in 
animals (http: //dmelson. utinem. edu/CytochromeP450. html). However, a relatively 
small number of these enzymes (expressed by the CYPI, 2 and 3 gene families) are 
responsible for the majority of drug oxidations in man. 
1.4.2.2 The CYP Subfamilies Relevant to this Thesis 
The CYP2C Subfamily: CYP2C is the second most abundant protein 
in human liver after CYP3A (Rowland-Yeo et aL, 2004). It consists of four members: 
CYP2C8, CYP2C 18, CYP2C9, and CYP2C 19, each of which exhibits polymorphism 
(Daly, 2003). 
CYP2C9 plays a major role in the metabolism of a large number of 
clinically important drugs such as (S)-warfarin (Rettie et aL, 1992), tolbutamide 
(Sullivan-Klose et aL, 1996) and phenytoin. (Veronese et aL, 1993). 
Two variant alleles of CYP2C9 (CYP2C9*2 and CYP2C9*3) are common 
in Caucasians, but no null alleles (alleles that result in absent or non-functional protein) 
have been identified. Each of the two variant alleles confers a different degree of 
decreased activity as compared to the wild type (CYP2C9*1). Hence, there are six 
common genotypes of CYP2C9 in Caucasians, each associated with a different level of 
activity; the frequency of these genotypes in the Caucasian population is shown in 
Figure 1.8. Figure 1.9 shows the difference in the metabolic ratio of losartan (a 
CYP2C9 substrate) between CYP2C9 extensive (EM), intermediate (IM) and poor 
metabolisers (PM). 
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Figure 1.7 The internationally accepted method for naming CYP enzymes 
(http: //www. cypalleles. ki. se). 
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Figure 1.8 Frequencies of each of the common CYP2C9 genotypes (Lee et al., 
2002). 
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Eight alleles have been identified for the CYP2C19 gene (Wedlund, 2000) 
Individuals with two defective alleles are classed as PM's, with a frequency of around 
24% of Caucasians (Kalow, 1986). Most (CYP2C19*3, *4, *5, *6, *7 and *8) are rare 
in Caucasian populations (Wedlund, 2000). CYP2C]9*2 is the most common allele 
associated with an inactive gene product in Caucasians, accounting for up to 85% of 
those responsible for impaired metabolism (Desta et al., 2002). Most of the remaining 
PM's are the result of the *3 allele (Wedlund & Wilkinson, 1996). 
Figure 1.10 shows the differences in the metabolic ratio (MR) of 
orneprazole between CYP2C19 genotypes. 
The CYP2D Subfamily: CYP2D6 is the only member of the CYP2D 
subfamily to be expressed in human liver. Despite it only making up around 3% of 
total human liver CYP content (Figure 1.12), C-YP2D6 is probably the best understood 
of the polymorphic CYP's due to both its earlier discovery (Eichelbaum et aL, 1979; 
Idle et aL, 1978; Lennard et al., 1983), and its contribution to the metabolism of an 
appreciable percentage of marketed drugs (at least 25% of the drugs on the market; 
Rendic, 2002). 
There are a large number of variant alleles of CYP2D6. The fully 
functional alleles are CYP2D6*1 and CYP2D6*2, with CYP2D6*9, CYP2D6*10 and 
CYP2D6*41 conferring reduced activity. There are also a number of null alleles (e. g. 
CYP2D6*3, *4, *5, *6, *7 and *8), giving rise to many possible genotypes. Generally, 
those made up of the *I and *2 alleles are grouped as the EM genotypes. PM 
genotypes are those which result from a combination of two null alleles, and some 
refer to all the other combinations as IM's, although this is the subject of debate. The 
occurrence of ultra-rapid metabolisers of CYP2D6 substrates has been established, and 
results from an individual having multiple copies of the active CYP2D6 genes. PMs 
have a prevalence of about 8% in Caucasians (Cascorbi, 2003), and ultra rapid 
metabolisers a prevalence of 1 -3% in middle Europeans (Cascorbi, 2003). 
The activity of CYP2D6 is highly variable between individuals. A greater 
than 100-fold difference in activity was reported by Ingleman-Sundberg et al. (1999), 
which was mainly the result of both genetic variability and inhibition of CYP2D6 by 
other compounds (Ingelman-Sundberg et al., 1999). 
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Figure 1.9 Frequency distribution of the metabolic ratio (MR) of losartan in 
CYP2C9 genotyped subjects (PM = *2/*2, *2/*') and *3/*3; IM = *1/*2 
and *1/* 3; EM = *1/* 1) (Sandberg et al., 2004). 
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Figure I. 10 Frequency distribution of the metabolic ratio (MR) of omeprazole in 
CYP2C]9 genotyped subjects (WT = wild type; Mut = mutant allele 
either *2 or *3 )) (Sagar et al., 1998). 
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Figure 1.11 The relationship between different allelic variants of the CYP2D6 gene 
and apparent CYP2D6 enzyme activity, as measured by metabolic ratio 
(MR) of dextromethorphan. An MR is an index of metabolic activity 
calculated from the ratio of concentration/AUC of parent drug in urine to 
that of the metabolite. MR values are shown such that the antimode 
between extensive metabolisers and poor metabolisers is aligned, and the 
scales are normalized on the basis of fold variation from the antimode. 
[data from Sachse et aL (1997), represented as in Ozdemir et aL (2004)]. 
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The CYP3A Subfamily: The CYP3A subfamily has three main members, 
CYP3A4, CYP3A5 and CYP3A7 (which is only expressed in foetal tissue). CYP3A is 
the most abundant isoform present in human liver (Figure 1.12; Rowland-Yeo et aL, 
2004), and is also the predominantly expressed enzyme in the gut wall (Paine et aL, 
2006). There is marked (5 to 82 fold) interindividual variation in the hepatic activity of 
CYP3A (Gibbs & Hosea, 2003), and up to a 30 fold variation in the gut (Paine et aL, 
1997). 
CYP3A4 is the most abundant CYP enzyme in human liver (Figure 1.12). 
It also has a very broad substrate specificity, and capable of metabolising at least 60% 
of current therapeutic drugs (Rendic, 2002), including midazolain, dextromethorphan 
and omeprazole, three of the drugs studied in this thesis. Due to the presence of 
CYP3A4 in the gut, the isofonn is especially susceptible to dietary effects. Although 
CYP3A4 is polymorphic (Ingelman-Sundberg, 1999), genetic variants are rare, and 
due to the wide interindividual variability in CYP3A4 activity regardless of genotype, 
the effect of such variants is difficult to discern. 
CYP3A5 is polymorphic, and only individuals with at least one CYP3A5*1 
allele express a significant level of protein (Kuehl et aL, 2001). This is equivalent to 
around 10 - 30% of the Caucasian population (Wrighton et aL, 1990). When 
expressed, the amount of CYP3A5 in the liver constitutes a significant proportion of 
total CYP3A content (46 - 85%) (Lin et aL, 2002). Thus, CYP3A5 may contribute to 
the wide interindividual variability in CYP3A-metabolised drugs (Kuehl et aL, 2001). 
1.4.2.3 Abundances of CYP Enzymes in Human Liver 
Figure 1.12 shows the estimated relative abundance of each of the most 
common CYP isoforms based on a meta-analysis by Rowland-Yeo et al. (2004) of 
data from between 42 and 241 human livers. 
CYP3A accounts for up to 35% of the total content of the common CYP 
enzymes in the human liver (Rowland-Yeo et al., 2004). 
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Figure 1.12 Estimated relative abundance of cytochrome P450 isoforms determined 
from a meta-analysis of all reported data and those cited by Rowland- 
Yeo et al. (2004). Note that very rare CYP isoforms were not included in 
the analysis. 
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1.4.3 Phase Two Drug Metabolism 
Since a phase two pathway may sometimes be the primary route of 
metabolism for some drugs without any requirement for phase one metabolism, it has 
been suggested that the term 'phase two' is obsolete (Josephy et aL, 2005). Although 
this view is acknowledged, the traditionally tenninology has been used throughout this 
thesis. 
The primary 'aim' of phase two drug metabolism is to attach a conjugate 
to the drug molecule, to render it inactive and less lipid soluble than its precursor, so 
that it can be excreted in the urine or bile. The groups most commonly conjugated to 
drug molecules are glucuronyl, sulphate, methyl, acetyl, glycyl and glutathione. 
Many phase two enzymes have been shown to be polymorphic, such as 
thiopurine methyltransferase, N-acetyltransferase, glucuronosyltransferase. Phase two 
enzyme polymorphisms are of importance only when they are responsible for the 
primary metabolism of the compound or of a metabolite, if the latter is responsible for 
some or all of the effects of the drug. 
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1.5 Modelfinr & Simulation 
The advent of computer technology has radically changed drug 
development. However, many hold the view that we are far from utilising such 
techniques to their full potential and 'in silico' techniques are in their infancy (Smith, 
2002). A well known analogy to the use of simulation in the pharmaceutical industry 
comes from Beresford et aL (2002). The paper describes how the Boeing 777 aircraft 
was designed, manufactured and tested using only simulation, and nothing was 
physically produced until the manufacturers were confident that they had the final 
product in their electronic files (Beresford et aL, 2002). The authors argue that if such 
a feat is possible for aeronautical engineering, why not for pharmaceuticals (Beresford 
et aL, 2002)? Some argue that in the future, it will be possible to model in detail the 
complete physiology of the body, allowing us to administer drugs 'in silico'. This will 
allow us to evaluate whether they are effective and/or toxic and to determine the ideal 
dose, before they are administered to animals or humans. Just as Boeing would be 
unlikely to manufacture an aircraft, only to push it off a cliff to see if it flies, it is an 
inefficient, and unfortunate feature of the drug development process, that the 
advancement of many drugs is terminated during the later stages because of 
undesirable yet unforeseen characteristics. 
The focus of modelling and simulation in drug development within this 
thesis, will be the use of clinical trial simulation (CTS), whose main aim is to 
maximise the information content obtained during the drug development process in 
order to ensure the greatest chance of 'success' in a clinical trial (Bonate, 2000). The 
concept was first utilised by statisticians working within the field of drug development 
(Bonate, 2000). Indeed, the term clinical trial simulation is still often used, in its 
narrower sense, to describe the use of pharmacostatistical techniques within drug 
development. However, for the purposes of this thesis, a broader interpretation of the 
term will be utilised. 
The Needfor More Efficient Clinical Trials 
Declining productivity has been a concern of the phannaceutical industry 
for some time. Figure 1.13 demonstrates the apparently decreasing number of new 
chemical entities (NCEs) produced by drug companies in the United States over a ten- 
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year period (FDA, 2004). However, the amount of money spent on drug development 
appears to be increasing at an almost exponential rate (Figure 1.14). 
Figures 1.13 and 1.14 are taken from a recent whitepaper, published by the 
FDA, stating that "During the last several years, the number of new drug and biologic 
applications submitted to FDA has declined significantly; and the number of 
innovative medical device applications has also decreased. In contrast, the costs of 
product development have soared over the last decade". 
Nonetheless, Schmid and Smith (2005) have put forward a counter- 
argument to the above evidence, supporting the belief that declining innovation in the 
pharmaceutical industry may be a myth (Schmid & Smith, 2005). The authors argue 
that, whereas the total number of NCE's brought to the market does indeed appear to 
have been in decline over the 10 year period from 1993 to 2003 (Figure 1.13), a more 
representative view can be gained by looking at a longer period of time, from 1945 to 
2004 (59 years). They observe an overall increase in the number of drugs launched in 
the USA when the extended time period is analysed (Figure 1.15). 
However, despite their convincing counter argument, Schmidt and Smith 
(2005) dispute only the claim of declining innovation in the pharmaceutical industry. 
They make no attempt to dispute the problem of increasing cost. Therefore, even if 
their argument were true, it is undisputable that the cost of producing a single drug 
product is increasing at an unsustainable rate. Change is needed to improve the 
efficiency of drug development (Rooney et aL, 2001). The process could be made 
faster, and more efficient, hence reducing costs and increasing the number of new drug 
launches. Recently, Williams et aL (2006) commented on the large number of 
inadequately powered studies, carried out during drug development, to determine the 
effect of a particular drug metabolising enzyme polymorphism. on the 
pharmacokinetics of drugs. They observe that studies that claim to either prove or 
disprove the functional relevance of the polymorphism may be misleading, because the 
studies are underpowered. The authors went on to suggest that clinical trial simulation 
is a valuable tool for ensuring the use of adequately sized samples for clinical studies. 
In 2002 Johnsson and Sheiner advocated the need for 'smarter clinical trial 
design', and showed that simulation can help in this process by integrating all the 
information, in order to extract more evidence against the null hypothesis in clinical 
trials. They argued that, although greater reliance on simulations may involve a larger 
number of assumptions, and hence, give rise to less confidence in the results, this 
approach can still be effective (Jonsson & Sheiner, 2002). 
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Figure 1.13 The number of new medical entities (NMEs) with a novel chemical 
structure and the number of biologics license applications (BLAs) 
submitted to the FDA over a 10-year period (FDA, 2004). 
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in the USA over aI 0-year period. (FDA, 2004). 
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Figure 1.16 A breakdown of the costs involved in bringing one new drug to market 
from discovery to launch. The recent increase in costs is also 
demonstrated (FDA, 2004). 
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1.5.2 Clinical Trial Simulation (CTS) in Drug Development 
Clinical trial simulations are built on mathematical and statistical models 
that are essentially simplifications of the complex systems involved in drug 
pharmacokinetics and pharmacodynarnics. Clinical trial simulation is a term 
encompassing the use of premises and assumptions, to generate a large number of 
replications of virtual clinical trials that represent real clinical trials (Blesch et aL, 
2003). 
Much of the basis for modelling and simulation during early drug 
development is provided by the use of computer methods for predicting human 
pharmacokinetics from pre-clinical data. Pharrnacokinetic-phannacodynarnic models 
developed from information gathered from preclinical studies also come into play at 
this stage. Data collected using these methods can be used to optimize dosage 
regimens and to design subsequent phase I and even phase II studies. As discussed in 
Section 1.5.4, it is possible to predict the parameters describing the absorption, 
distribution, metabolism and elimination of a drug. from in vitro data., and this 
information can be used to predict the time course of a drug in plasma. 
In the very early stages of drug development the information on a 
compound can be scarce and somewhat 'patchy'. Thus, it is important that the 
available data is integrated so that coherent and comprehensive conclusions may be 
drawn from it. The information can be incorporated into physiologically based 
pharmacokinetic (PBPK) or pharmacokinetic-pharinacodynarnic models to allow 
investigators to ask 'what if questions, and evaluate the impact of study design on 
outcome (Blesch et aL, 2003). 
Once physiologically-based-pharmacokinetic and/or pharmacokinetic- 
pharmacodynarnic models have been developed, it is possible to develop them into 
more comprehensive models that can form the basis of much more extensive clinical 
trial simulation. 
Just as the data from preclinical studies can be used in the design of phase 
I or patient studies, data from the fon-ner should be utilised to design safe and efficient 
phase II and III studies. Clinical trial simulations are often based on models derived 
from early data in humans (Aarons et aL, 2001). If physiological models are made 
available in the early stages of drug development, the differences in the parameters that 
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determine variability can be determined. Therefore, it is possible to define the 
pharmacokinetics of a drug a priori in patients who are to be recruited for phase 11 and 
III studies. However, this approach is rarely utilised, because much of the data in drug 
development comes from compartmental fitting of pharmacokinetic parameters. 
In the future, virtual clinical trials may replace many of those carried out in 
humans. Furthermore clinical trial simulation may considerably cut the cost of drug 
development However, cost benefits aside, clinical trial simulation has the potential to 
change the face of drug development by making it safer (both by reducing the 
requirement for human volunteers and by ensuring that trials in human are safer and 
more efficient). 
1.5.3 Examples of Successful Applications of CTS 
1.5.3.1 Estimating Dosage 
The estimation of dosage appears to have been one of the most popular 
uses for clinical trial simulation, several examples are available in the literature 
outlining successes in this area, and some of these are outlined below. 
A new anticancer agent: Gieschke and colleagues (1997) successfully 
used clinical trial simulation to devise a dosing regimen to be used in phase III trials 
for an anticancer agent developed at Hoffinan-La Roche. The authors also described 
how the model was utilised to examine the impact of reducing the dose by 50% on 
efficacy and adverse event profiles. It was found that the lower dose was equally as 
efficacious as the higher one (Gieschk-e et aL, 1997). 
Docetaxel: Veyrat-Follet and colleagues (2000) used pharmacokinetic- 
pharmacodynamic models, developed from data gathered from phase II studies, to 
assess the advantages of a 125 mg/m2 dose over a 100 mg/m2 dose. The authors 
investigated the effect of the docetaxel dose on disease progression and survival time 
of small cell lung cancer sufferers. The simulation showed no clinical advantage of the 
higher dose over the lower one (Veyrat-Follet et aL, 2000). 
T cell dose: Gooley et aL, (1994) used clinical trial simulation to calculate 
the optimal dose of T-cells, to be administered to bone marrow transplant patients with 
HLA-mismatched unrelated donors. The authors predicted the appropriate dose and 
also showed that the standard dose-escalation regimens that had been utilised 
previously were likely to give inaccurate predictions (Gooley et al., 1994). 
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1.5.3.2 Estimating Adequate Sample Size 
Perhaps one of the most well-known examples of the successful use of 
clinical trial simulation comes from Hale et aL (1998). This group used simulation 
techniques to estimate the sample size associated with a particular power and thus 
decide on an appropriate size for their clinical trial of mycophenolate mofetil, an 
immunosuppressive agent. The simulations were based on phase 11 clinical trial data 
(Hale et aL, 1998). 
1.5.4 Incorporating Early Preclinical Data into CTS 
It is clear from the above examples that most of the clinical trial simulation 
currently carried out during drug development rely heavily on data from in vivo 
studies. However, if modelling and simulation techniques are to benefit the drug 
development process to the full, clinical trial simulation must be carried out much 
earlier during drug development. Clearly, there is a need for utilising pharmacokinetic 
information gathered earlier in drug development. 
Without data from clinical studies, there are currently two ways to extract 
the relevant information about a drug: (a) quantitative structure-property relationship 
analysis (QSPR) and (b) through the use of in vitro systems. QSPR operates on the 
basis that all of the physical and chemical and therefore, pharmacological and 
toxicological properties of a drug are related to its chemical structure, and are 
consequently, predictable. Since the present work concerns the use of in vitro data 
within clinical trial simulation to investigate the effects of genetic variability in 
metabolism on the pharmacokinetics and pharmacodynamics of drugs, the remainder 
of this section will focus on in vitro techniques. FG and FH will be discussed in the 
greatest detail, since they are the only parameters affected by genetic variability in 
drug metabolism, and hence, by polymorphisms of the CYP enzymes. 
1.5.4.1 Prediction of Absorption 
As discussed in Section 1.3.1.1, the oral absorption of a drug is dependent 
on f, FG and FH. Numerous in vitro systems (e. g. animal tissue, Caco-2 cell lines etc. ) 
have been utilised in assessing the intestinal absorption (represented by Q potential of 
new drug candidates. However, a major disadvantage of all these techniques, is that 
they do not incorporate the effect of physiological factors such as gastrointestinal 
transit time, gastric emptying rate, or gastric pH (Balimane et aL, 2000). 
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The prediction of FG can be achieved by assuming that the affinity of a 
drug for the metabolising enzymes in the gut wall, is equivalent to that in the liver. 
Thus, FG and FH can be extrapolated from in vitro data using the techniques described 
in Section 1.5.4.2. 
1.5.4.2 Prediction of Metabolism 
QSPR models may be used to predict how a molecule will interact with the 
active site of a drug-metabolising enzyme. In their review, Bugrim et aL (2004) state 
that as many as 39 molecular descriptors have been identified as correlating with 
metabolism by CYP enzymes. However, such methods are notoriously unreliable and 
are not used systematically within drug development. 
In vitro systems can provide an inexpensive, high throughput method for 
the prediction of drug clearance and drug-drug interactions during early development. 
Various systems are available including human liver microsomes, recombinantly 
expressed CYP enzymes, purified and reconstituted CYP enzymes, and isolated 
hepatocytes. Each has its own advantages and disadvantages, which are discussed 
below. The extrapolation of in vitro information to the in vivo setting is discussed 
Rifther below. 
(i) Human liver microsomes: Hepatic microsomes are widely available and 
can be easily stored at -80'C. However, a major disadvantage associated with the use 
of human liver microsomes in these studies, is the artefactual variability in CYP 
protein expression and function. This may be caused by (a) the time delay between 
tissue harvesting and freezing, (b) differences in the cause of death and medications 
taken by the donor, and (c) differences in environment, diet and lifestyle between the 
donors. Variability in the levels of CYP expression and function also arises from 
genetic differences due to polymorphisms of the CYP enzymes (Section 1.4.2.1). 
Unless genotyping of the microsomes is undertaken, investigators cannot be sure of the 
reasons underlying variability between samples. A further disadvantage of the use of 
human liver microsomes results from the presence of lipids and proteins, which can 
bind to drug molecules and cause a decrease in the free concentration of the drug in the 
medium (Venkatakrishnan et al., 2003). 
(ii) Recombinantly expressed enzymes (rCYPs): Recent advances in 
molecular biology have led to the stable expression of CYP enzymes in a wide range 
of systems including yeast, bacteria, insect and mammalian cells. The wide availability 
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of such systems offers investigators a viable alternative to the use of human tissue 
preparations as a source of hepatic enzymes. An important advantage of rCYPs is the 
reproducibility of information gained from them. However, it has become apparent that 
although rCYPs are identical to their human counterparts in terms of arnino acid 
sequence, their intrinsic catalytic activity may differ substantially from human liver 
CYPs. However, this problem can be rectified through the use of inter-system 
extrapolation factors (ISEFs; Proctor et aL, 2004). An important advantage of rCYPs 
is the availability of different genetic variants of the same CYP isoform. 
(iii) Hepatocytes: Human hepatocytes are available commercially and are a 
popular and well established tissue for drug metabolism studies. They are whole, living 
cells, containing the full complement of drug metabolising enzymes and transport 
systems, and any concentration gradients mediated by transporters that may affect 
exposure of substrate/inhibitor to enzymes, will still be present. However, hepatocyte 
systems are expensive, and some transporters rapidly lose their functional activity after 
isolation of hepatocytes. Furthermore, maintenance of hepatocyte cultures can be 
problematic (Tucker et aL, 2001; Venkatakrishnan et aL, 2003). An important 
disadvantage of the use of human hepatocytes, is that experimental results are 
dependent on the source of the hepatocytes. Thus, the activity of any enzymes and 
transporters are dependent on the genotype and environment of the human donor. 
To make use of data gathered from in vitro systems, there must be a means 
of 'scaling up' to the in vivo setting. This process is called in vitro-in vivo extrapolation 
(IVIVE), and involves the use of scaling factors. Methods for IVIVE were first 
described 30 years ago by Rane et al. (1977). The researchers used in vitro intrinsic 
clearance data from isolated perfused rat liver experiements to predict the hepatic 
extraction ratio of seven drugs in humans (Rane et aL, 1977). More recently, with the 
increased availability of human liver samples, and the advent of new technology for 
producing recombinant drug metabolising enzymes, methods for the prediction of drug 
clearance and metabolic drug-drug interactions have been refined and widely 
implemented (Iwatsubo et aL, 1996; Rostami-Hodjegan & Tucker, 2004). 
1.5.4.3 Prediction of EfficacyfFoxicity 
The extrapolation of in vitro data on drug response to human drug efficacy 
and toxicity is a relatively new area of research. However, a number of successful 
studies have demonstrated its potential usefulness for drug development (Cleton et aL, 
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2000; Cox et aL, 1998; Visser et al., 2003). For example, Cox et al. (1998) have 
predicted in vivo opioid EEG response from in vitro mu-receptor binding data. In 2003, 
Visser and colleagues utilised data on the in vitro binding affinity of benzodiazepines 
to GABAA receptors to successfully describe the in vivo properties of these drugs 
(Visser et aL, 2003). 
Methods such as these could allow the efficacy and toxicity of a drug 
molecule to be predicted in man before the drug leaves the laboratory. Mechanism 
based phannacokinetic-phannacodynarnic models will also lead to a better 
understanding of interindividual variability in human drug response (Visser et al., 
2003). A ftirther advantage of incorporating in vitro pharmacodynamic information 
into clinical trial simulation is the potential for simulating the influence of receptor 
polymorphisms such as those in the P2-adrenoceptors (Liu et al., 2003) or the herg 
channel protein (Bezzina et al., 2003), on drug response. Currently, information on 
receptor binding is not routinely available in the early stages of drug development, 
where it has the potential to be most useftil. 
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1.6 Aims and Objectives 
This thesis is intended to gauge the feasibility of incorporating a 
mechanistic approach to the extrapolation of in vitro data on drug metabolism to in 
vivo drug clearance, within the framework of pharmacokinetic-pharmacodynamic 
simulation and clinical trial simulation. The general aims of the work are to (a) expand 
the framework of clinical trial simulation, such that early information on drug 
metabolism gathered during pre-clinical drug development can be incorporated and 
used to design effective clinical studies; (b) assess whether it is possible to recover in 
vivo variability in drug response caused by genetics; and (c) provide a paradigm for 
future clinical trial simulation in drug development. The specific aims of the thesis are 
as follows: 
To gather in vitro metabolism data for selected drugs, and integrate 
these data with other pharmacokinetic and pharmacodynamic 
information to simulate and predict both pharmacokinetic and 
pharmacodynamic profiles in virtual populations of individuals. 
To enter genetic or phenotypic information on the occurrence and 
impact on drug metabolism of CYP polymorphisms into the model, 
for the purpose of investigating these genetic effects on the 
pharmacokinetic and pharmacodynamic profiles of the drugs. 
To investigate the impact of CYP polymorphisms on the 
pharmacokinetics and pharmacodynamics of the drugs, using a 
range of sample sizes, for the prediction of the outcome of 
published studies. 
To estimate the size and optimise the design of clinical studies that 
will define accurately the effect of the CYP polymorphism, on the 
pharmacokinetics or pharmacodynamics of the selected drugs. 
To use these simulations and predictions to suggest possible 
reasons for the success/failure of published studies to observe an 
effect of CYP polymorphisms on pharmacokinetics and/or 
pharmacodynamics. 
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CHAPTER 2 
The Propagation of Pharmacogenetic 
Differences in Cytochrome P450 into the 
Pharmacokinetics and Pharmacodynamics of 
Therapeutic Drugs: A Review of the Literature 
Chapter 2: Literature Review 
2 LITERATURE REVIEW 
2.1 Background 
The history of pharmacogenetics stretches as far back as 510 B. C. when 
Pythagoras noted that ingestion of fava beans resulted in a potentially fatal reaction in 
some, but not all, individuals (Nebert, 1999). In the many centuries that have followed, 
there have been numerous landmarks that have shaped this field of research, and have 
led to the current wave of interest. The latter began in the late 1970s with the discovery 
of the debrisoquine/sparteine hydroxylation (CYP2D6) polymorphism (Eichelbaum et 
aL, 1979; Mahgoub et aL, 1977; Tucker et aL, 1977). This discovery sparked a surge 
of studies which would attempt to define the pharmacokinetic characteristics of a drug 
based on interindividual differences in drug-metabolising capacity. Pharmacodynamic 
studies of the same type were close to follow when it was hypothesised that 
polymorphic drug metabolism would be a source of interindividual variation in drug 
response. Recently, the interest in this area has once again been catalysed (albeit under 
the new name of 'pharmacogenomics') with the completion of the Human Genome 
Project. 
A current area of debate has focused on the usefulness of pharmacogenetic 
testing in the individualisation of drug therapy ('personalised medicine') (Chapter 1; 
Section 1.3). Many authors strongly support such an approach, for example 
Ingelmann-Sundberg suggested in 2001 that "Because of the rapid development in the 
field it is believed that in a couple of years from now, pharmacogenetics will be a 
standard tool in drug development and clinical practice" and recently, Eichelbaurn and 
colleagues stated that "With the complete sequence of the human genome available, 
individualized medicine may soon become reality" (Eichelbaum. et aL, 2006; 
Ingelman-Sundberg, 2001). 
However, such opinions are not supported by substantive evidence and 
others take a more circumspect view. For example, Holtzman (2001) has stated that 
"there are few cases where testing patients for certain enzymes involved in drug 
metabolism may help but ... other factors, such as diet and smoking, are as importanf ', 
and Tucker (2004) has suggested that "the promise of pharmacogenetics has largely 
remained unfulfilled" (Holtzman, 2001; Tucker, 2004). 
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Many studies have been published on the influence of CYP 
polymorphisms on drug pharmacokinetics and pharmacodynamics. Recently, Williams 
et aL (2006) have emphasized the importance of adequate sample size in such studies. 
Ensuring adequate statistical power becomes an even greater issue with respect to 
defining the influence of pharmacodynamic outcomes because variability in 
pharmacodynamics is generally greater than that in pharmacokinetics (Levy et al., 
1994) (Table 2.1). 
A result of underpowering of studies may be the generation of false 
negative results or, where more than one study has been performed, conflicting data. 
The main aims of this chapter were to summarise and evaluate critically 
the published literature on the influence of CYP polymorphisms on drug 
pharmacokinetics and pharmacodynamics to help clarify the available evidence in 
support of such effects. Because they are the subject of the work described in this 
thesis, the examples of DEX, (S)-warfarin, MDZ, OMZ and TLB will be discussed in 
some detail. 
Using the results of the simulations described later in this thesis, it may be 
possible to explain why some studies have failed to detect an influence of CYP 
polymorphisms on drug pharmacokinetics or pharmacodynamics, where others 
investigating the same drug have shown differences between phenotypes/genotypes 
(Chapter 1; Section 1,6). 
The purpose of the research was not to provide an exhaustive list of all the 
reported studies that detail investigations into the influence of CYP polymorphisms on 
drug pharmacokinetics and/or pharmacodynarnics, but to gather a large enough sample 
of such studies to be representative of the real situation and to allow inferences to be 
made. 
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Table 2.1 Pharmacokinetic and pharmacodynamic variability in humans (adapted 
from Levv et aL H 994). 
Drug n ZI 
Coefficient of Variation (%) 
Phan-nacokinetics Pharmacodynamics 
(total CL or AUC) (EC50, IC50 or slope) 
Reference 
Prednisolone 7 17.4 (low dose) 37.2 (cortisol suppr. ) Wald et al., 1992 
9.8 (high dose) 48.4 (basophil suppr. ) 
81.6 (T-helper suppr. ) 
Deacetylmetipranolol 6 40.1 63.9 Janku eta[, 1992 
6 31.6 112 
Ibuprofen 38 34 137 Kaufftnan & Nel- 
son, 1992 
Hydroxymidazolarn 8 8.0 45.2 (EEG) Manderna et al., 
57.1 (s. e. m) 1992 
Diltiazern 32 29.5 (low dose) 76.6 Dias eta[, 1992 
27.2 (high dose) 
Labetalol 7 34.3 46.8 (systolic b. p) Saotome eta[, 1993 
41.9 (diastolic b. p) 
s. e. m = saccadic eye movement; b. p = blood pressure 
DRUG 
cyps... IN 
BLOOD PID 
variability imi variability 
41-0 
Figure 2.1 A diagram to illustrate that population variability in drug response is 
often greater than variation in plasma drug concentrations. 
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2.2 Methods 
A literature search was carried out in the electronic databases OVID 
MEDLINE (1966-2006) and WEB OF SCIENCE (1981-2006) using the following 
combination of keywords "(cytochome P450 or CYP*), (pharmacokinetic*, 
pharmacodynamic* or response), and polymorphism7' (Figure 2.1). 
The drug name and CYP enzyme identified in each of the initial papers 
were included as key-words in a second stage search in place of the words 
'pharmacokinetic*, pharmacodynamic* or response' along with the words 
'polymorphism' and 'cytochrome P45 0 or CYP'. 
Key reviews were also scrutinised for further reports of studies on the 
influence of CYP polymorphisms on the pharmacokinetics and/or phannacodynamics 
of drugs. In total, 2283 reports were identified, and their titles and, if necessary, their 
abstracts were reviewed to determine whether they should be included in the analysis. 
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V Stage: OVIDE MEDLINE and WEB OF SCIENCE searched: 
Keywords: 
CYP 
Phannacokinetic 
polymorphism + 
cytochrome P450 
+ Pharmacodynamic* 
Response 
n= 265 reports selected from 17335 reports identified 
2"1 Stage: Using the drug name and specific CYP identified in 1 11 stage reports: zn C, b 
Keywords: 
CYP 
polymorphism + cytochrome P450 + [Drug name] 
+ [name of CYP] 
n- 78 extra reports selected from 536 reports identified 
3rd Stage: Bibliographies of key reviews searched for further references 
n- 12 more reports identified 
Total = 355 reports 
Figure 2.2 A schematic representation of the three stages of the literature search. 
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2.3 Results 
Two hundred and thirty pharmacokinetic studies encompassing 115 drugs, 
and 124 pharmacodynamic studies of 54 drugs were identified. Details of these studies 
are shown in the appendix (Table 2.10 and Table 2.11). 
Out of 230 pharmacokinetic studies, 70 (encompassing 70 drugs) were 
reports of a drug/CYP relationship that had not been investigated by others. These are 
subsequently referred to as 'unique' studies. The remaining 160 pharmacokinetic 
studies (involving 44 drugs) described drug/CYP relationships that had been 
investigated previously, and reported in at least one of the other 159 studies. These 
reports are subsequently referred to as 'repeated' studies. 
The results from 78 (52%, involving 44 drugs) 'repeated' studies were 
consistent' with one another, in that they reported similar outcomes (Figure 2.1). The 
results from the 82 (48% involving 21 drugs) 'repeated' studies were 'inconsistent' 
with one another, in that the outcomes were opposing (Table 2.2, Figure 2.3). 
Out of the 78 'consistent', 'repeated' pharmacokinetic studies, 7 (9%, 
involving 3 drugs) report negative results (i. e. no significant relationship between CYP 
pheno/genotype and drug pharmacokinetics), and 71 (91%, involving 20 drugs) report 
consistently positive results. 
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Table 2.2 A list of 'repeated' studies into the effect of CYP polymorphisms on drug 
PK. 
CYP Drug 
+ 
Studies 
Number of 
studies 
Outcome 
IA2 Clozapine 1 1 2 Inconsistent 
2136 Bupropion 1 1 2 Inconsistent 
lbuprofen 2 2 Consistently positive 
2C9 Repaglinide 1 1 2 Inconsistent 
Celecoxib 1 1 2 Inconsistent 
Diclofenac 2 4 6 Inconsistent 
Glimepiride 3 3 Consistently positive 
Glyburide 3 3 Consistently positive 
lbuprofen 1 1 2 Inconsistent 
Losartan 3 1 4 Inconsistent 
Phenprocoumon 2 2 Consistently positive 
Phenytoin 5 5 Consistently positive 
Tolbutamide 6 6 Consistently positive 
Warfarin 4 1 5 Inconsistent 
Amitriptyline 3 3 Consistently positive 
2C 19 Diazepam 4 1 5 Inconsistent 
Fluvoxamine 2 2 Consistently negative 
Hexobarbital 2 2 Consistently positive 
Imipramine 2 2 Consistently positive 
Lansoprazole 8 8 Consistently positive 
Mephobarbital 2 2 Consistently positive 
Omeprazole 14 1 15 Inconsistent 
Phenobarbital 1 1 2 Inconsistent 
Phenytoin 3 4 7 Inconsistent 
Proguanil 4 4 Consistently positive 
Rabeprazole 5 5 Consistently positive 
Tolbutamide 2 2 Consistently negative 
2136 Amitriptyline 1 1 2 Inconsistent 
Carvedilol 1 1 2 Inconsistent 
Dextromethorphan 5 5 Consistently positive 
Fluvoxamine 1 1 2 Inconsistent 
Haloperidol 2 2 Consistently positive 
Metoprolol 5 5 Consistently positive 
Mianserin 2 2 Consistently positive 
Propranolol 1 1 2 Inconsistent 
Risperidone 2 1 3 Inconsistent 
Tamoxifen 2 2 Consistently positive 
Midazolarn 3 3 Consistently negative 
Paclitaxel 1 2 3 Inconsistent 
3A5 Cyclosporine 3 2 5 Inconsistent 
Midazolam 3 4 7 Inconsistent 
Saquinavir 1 1 2 Inconsistent 
Sirolimus 2 2 Consistently positive 
Tacrolimus 6 6 Consistently positive 
ý+' & 'positive' indicate studies that detected a significant difference in the 
pharmacokinetics of the drug between CYP phenotypes/genotypes; '-' and 'negative' 
indicate studies that did not detect a significant difference in the phannacokinetics of 
the drug between CYP phenotypes/genotypes. 
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25 
20 
15 
10 
5 
0 L_ - 
Consistent; all positive 
Consistent; all negative 
Inconsistent 
Total 
345678 more 
Number of Repeated Studies for Same Drug 
Figure 2.3 Frequency of 'repeated' pharmacokinetic reports that were ý consistent' 
and 'inconsistent' with each other. 'Consistent' studies have been divided into two 
groups - 'all negative' and 'all positive' to indicate whether they consistently 
observed a significant difference in drug pharmacokinetic between CYP 
phenptypes/genotypes or they consistently did not detect a difference. 
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Out of 124 pharmacodynamic studies, 30 (encompassing 30 drugs) were 
'unique' and the remaining 94 (involving 23 drugs) were of a 'repeated' nature. Of the 
latter 'repeat' studies, the results of 22 studies (23%, involving 8 drugs) were 
geonsistent', in that they reported similar outcomes (Figure 2.4). The results of the 
remaining 72 repeat studies (77%, involving 15 drugs) were 'inconsistent' with one 
another (Table 2.3; Figure 2.4). 
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Table 2.3 A list of 'repeated' studies into the effect of CYP polymorphisms on drug 
pharmacodynamics. 
Studies 
CYP Drug 
+ 
Number of Outcome 
studies 
IA2 Clozapine 1 1 2 Inconsistent 
Acenocoumarol 6 6 Consistently positive 
Glyburide 2 2 Consistently positive 
2C9 Glimepiride 1 1 2 Inconsistent 
Irbesartan 1 1 2 Inconsistent 
Phenprocounion Consistently negative 
Phenytoin 2 1 3 Inconsistent 
Tolbutamide 1 2 Inconsistent 
Warfarin 17 1 18 Inconsistent 
Cyclophospharnide 2 2 Consistently positive 
2C19 Lansoprazole 4 1 5 Inconsistent 
Omeprazole 9 2 11 Inconsistent 
Proguanil 1 2 Inconsistent 
Rabeprazole 3 5 8 Inconsistent 
Tolbutamide 2 2 Consistently negative 
Codeine 2 2 Consistently positive 
Dextromethorphan 2 2 Consistently negative 
2D6 Haloperidol 1 1 2 Inconsistent 
Metoprolol 2 2 4 Inconsistent 
Phenfonnin 1 1 2 Inconsistent 
Propafenone 3 3 Consistently positive 
Risperidone 1 2 Inconsistent 
3A5 Sinivastatin 1 1 2 Inconsistent 
ý+' & ýpositive' indicate studies that detected a significant difference in the 
pharmacodynamics of the drug between CYP phenotypes/genotypes; '-* and 'negative' 
indicate studies that did not detect a significant difference in the phannacodynamics of 
the drug between CYP phenotypes/genotypes. 
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12 
10 
8 
cr u 
4 
2 
0 
Consistent; all positive 
M Consistent; all negative 
Inconsistent 
Total 
MnI 
45678 more 
Number of Repeated Studies for Same Drug 
Figure 2.4 Frequency of 'repeated' phan-nacodynamic reports that were 'consistent' 
and 'inconsistent' with each other. 'Consistent' studies have been divided into two 
groups - ýall negative' and 'all positive' to indicate whether they consistently 
observed a significant difference in drug pharmacodynamics between CYP 
phenotypes/genotypes or they consistently did not detect a difference. 
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Fifty four studies reported both phannacokinetic and pharmacodynamic 
results (Table 2.4; Figure 2.5). In 20 (35%) of these, a significant difference in the 
phannacokinetics but not the pharmacodynamics between phenotypes/genotypes was 
reported (Table 2.4; Figure 2.5). 
None of these studies reported a significant relationship for 
pharmacodynamics but not for pharmacokinetics. Ten (19%) studies reported no 
relationship between CYP phenotype/genotype and both the pharmacokinetics and the 
phannacodynarnics of the drug, and 24 studies reported significant results for both 
pharinacokinetics and phannacodynamics (Table 2.4; Figure 2.5). 
The journals in which the clinical studies were reported are also listed in 
Table 2.10 and Table 2.11, for reasons to be explained later (Chapter 9; Section 9.3). 
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Table 2.4 List of studies for which both pharmacokinetic and phannacodynamic 
data were reported. If the study showed a significant difference in pharmacokinetics 
or phannacodynarnics between phenotypes/ genotypes, a 'V' was recorded. If there 
was no significant difference, a 'JO was recorded. PK - phannacokinetics; PD - 
phannacodynamics 
CYP Drug Reference PK PD 
IA2 Clozapine Van der Weide et at, 2003 
2B6 Methadone Crettol et at, 2005 x 
2C8 Repaglinide Niemi et at, 2003 x 
2C9 Diclofenac Kirchheiner et at, 2003 
Fluvastatin Kirchheiner et aL, 2003 
Glimepiride Suzuki et at, 2006 
Niemi et at, 2002 
Glyburide Kirchheiner et aL, 2002 
Yin et at, 2005 
Ibuprofen Kirchheiner et 42002 V/ 
Irbesartan Chen et at, 2006 V/ -w/ 
Losartan Sekino et al., 2003 V/ VII 
Methadone Crettol et al., 2005 x x 
Nateglinide Kirchheiner et al., 2004 V, x 
Tolbutamide Kirchheiner et al., 2002 x 
Shon et al., 2002 
Lee et al., 2002 x 
Warfarin Sconce et al., 2005 V/ 
Scordo et al., 2002 
Kamali et al., 2004 
Takahashi et al., 2003 
2CI9 Lansoprazole leiri et al., 2001 
Methadone Crettol et al., 2005 
Omeprazole Chang et al., 2005 V, V, 
Hu et at, 2005 V, 
Kita et al., 2001 
Furuta et at, 1999 V/ 
Shirai et at, 2001 V/ 
Proguanil Kaneko et at, 1999 VI" V/ 
Kaneko et at, 1999 -v/ ic 
Rabeprazole Horai et at, 2001 V/ V/ 
Hu et at, 2005 V/ x 
Ieiri et at, 2001 V, V/ 
Tolbutamide Kirchheiner et aL, 2002 Jc Jc 
Shon et at, 2002 x 
2D6 Dextromethorphan Abdul-Manap et at, 1999 -v/ 
Capon et at, 1996 V/ 
Donepezil Varsaldi et at, 2006 
Flecainide Tenneze et at, 2002 
Haloperidol Brockinoller et at, 2002 V, 
Panel at, 1999 %/ 
Metoprolol Zineh et at, 2004 V, 
Kirchheiner et aL, 2004 V/ %/ 
Fux et at, 2005 V/ x 
Mianserin Mihara et al., 1997 %/ 
Nateglinide Kirchheiner et aL, 2004 x 
Phenfonnin Oates et at, 1983 V/ V, 
Propafenone Cai et at, 2002 v %/ 
Propranolol Huang el at, 2003 V/ x 
Risperidone Reidel et at, 2005 
Kakihara et at, 2005 
Timolol Nieminen et at, 2005 x 
Tolterodine Brynne et at, 1998 
3A5 Alprazolam Park et al., 2006 
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(A) 
PD 
70( 
(B) 
PK only 
176(59%) Neither PK nor PD successful 
10(19%) 
PD only successf 
0% 
PK only successful 
20(37%) 
both PK & PD successful 
24(44%) 
Figure 2.5 (A): The number of studies reported in the literature that provide only 
pharmacokinetics, only pharmacodynamics or both pharmacokinetic and 
pharmacodynamic data (B): The success (siginificant differences between 
phenotypes/genotypes observed) or not of studies that report both pharmacokinetics 
and pharmacodynamics. 
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2.4 Discussion 
2.4.1 Conflicting Results 
The percentage of drugs for which there is conflicting evidence was high 
(48 and 77% for pharmacokinetic and pharmacodynamic studies, respectively). This 
suggests flaws in the design or conduct of the studies. The discrepant data are likely to 
be related to the power of these studies to detect differences in the pharmacokinetics or 
pharmacodynamics of drugs between different phenotypes or genotypes. Studies of the 
same drug vary in size substantially, for example, from 47 (Takahashi et aL, 2003) to 
561 (Taube et al., 2000) in reports of the effect of CYP2C9 genotype on the 
pharmacodynamics of warfarin. 
Furthermore, investigators commonly set the significance level at 5%. 
Consequently, 5% of studies are likely to be subject to type I errors, giving false 
positive results. Thus, out of the 230 pharmacokinetic studies, and 124 
pharmacodynamic studies identified, around 12 and 6, respectively, will result in false 
positive outcomes. When a number of different outcomes are used (e. g. AUC, Cn,,,,, 
CL for pharmacokinetic studies or several response measures for pharmacodynamics 
studies) the likelihood of false positive outcomes is even greater. 
Many authors have been somewhat selective when reviewing reports of the 
impact of CYP polymorphisms on the pharmacokinetics and/or pharmacodynamics of 
drugs, concentrating on 'positive' and less on 'negative' outcomes. Conflicting data 
from two or more studies may indicate (i) a type I error in the studies showing a 
positive outcome, or (ii) the presence of only small difference between 
phenotypes/genotypes, which may be difficult to observe and clinically unimportant. 
In 63% (42/67) of the drugs investigated in the present work (including both 
pharmacokinetic and pharmacodynamic studies) for which there was more than one 
report, at least one study was in evidence that suggested a negative result. 
The majority of the 115 drugs (61%; pharmacokinetic) and 54 drugs (56%; 
pharmacodynamic) had not been investigated independently by different groups. 
Considering the inconsistencies uncovered by the present analysis, good practice 
should ensure that 'repeat' studies are adequately powered to detect any hypothesised 
difference between phenotypes/ genotypes. Assessment of power is much easier to 
carry out if based on the results of a previous study. 
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'Repeated' pharmacokinetic reports involving only 20 drugs (45%) were 
consistent with each other, all independently showing a link between 
phenotype/genotype and pharmacokinetics. The corresponding number for 
pharmacodynamic reports was 5 (22%). 
Because it is often overlooked that pharmacokinetic and pharmacodynamic 
variability are additive, investigators may be less likely to observe differences in 
pharmacodynamics between CYP phenotypes/ genotypes than in pharmacokinetics, 
when using similar study sizes. This is supported by the results from the 54 studies for 
which both pharmacokinetic and pharmacodynamic information was available (Table 
2.4), in that 37% detected a significant link between CYP phenotype/genotype and 
pharmacokinetics but have been unable to demonstrate a similar link for 
pharmacodynamics. 
In conclusion, it is apparent that review authors often make the erroneous 
assumption that a significant relationship between pharmacokinetics and 
genotype/phenotype implies a significant relationship between phenotype/genotype 
and pharmacodynamics. Furthermore, investigators should pay close attention to 
pharmacodynamic variability and power their studies accordingly. 
2.4.2 The Model Drugs 
In order to investigate the value of clinical trials simulation in the design 
and conduct of studies investigating differences in pharmacokinetics and 
pharmacodynamics between different CYP phenotypes/genotypes, specific drugs were 
chosen based on 
(i) The availability of comprehensive in vitro enzyme kinetic data, 
preferably from studies carried out in recombinant systems. 
(ii) The availability of a pharmacokinetic-phannacodynarnic model 
obtained by fitting in vivo data. 
(iii) The presence of literature reports that have investigated the influence 
of CYP phenotype/genotype on the pharmacokinetics and/or pharmacodynamics of the 
drug. 
Based on the criteria above a number of drugs were selected and 
prioritised so that those for which the most data were available and those that were 
most widely used clinically, were investigated first. Within the time constraints of this 
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thesis, 5 drugs were studied, and these were dextromethorphan (DEX), (S)-warfarin, 
tolbutaimde (TLB), midazolam (MDZ) and omeprazole (OMZ). Published 
pharmacodynamic data were available for all these drugs (Table 2.10 & Table 2.11), 
except for MDZ. 
2.4.2.1 Dextromethorphan 
All five studies investigating the effect of CYP2D6 phenotype on the 
pharmacokinetics of DEX have shown significant differences using 22,6,7,65 and 50 
subjects, respectively (Abdul Manap et aL, 1999; Capon et aL, 1996; Casner, 2005; 
Desmeules et aL, 1999; Pope et aL, 2004). Only two corresponding pharmacodynamic 
studies have been performed, both reporting no significant differences 'between 
CYP2D6 phenotypes, using 6 and 22 sub ects (Abdul Manap et aL, 1999; Capon et aL, j 
1996). 
2.4.2.2 (S)-Warfarin 
Of the five drugs selected, most studies have been published on warfarin. 
Five have investigated the impact of CYP2C9 genotype on (S)-warfarin 
pharmacokinetics and 18 on the pharmacodynamics of the drug. The results for both 
sets of studies generally show genotypic differences. However, since there are 6 
common CYP2C9 genotypes, for a study to be recorded as 'positive', only one of the 
comparisons between the wild-type genotype and any other single genotype needs to 
be significantly different. One pharmacokinetic study and one pharmacodynamic study 
produced negative findings. However, the data for (S)-warfarin are more complex than 
those for DEX This is because, instead of simply comparing one phenotype with the 
other as is the case for CYP2D6 and DEX, all 6 common CYP2C9 genotypes must be 
evaluated. Therefore, it becomes difficult to define 'success' in discerning the effect of 
CYP2C9 genotype on (S)-warfarin pharmacokinetics and pharmacodynamics. For 
example, whereas a study may differentiate (S)-warfarin pharmacodynamics between 
subjects of *1*3 genotype and wild type subjects, the same study may not be 
adequately powered to detect differences between *2*2 genotype and the wild type. 
Owing to its rarity in the Caucasian population, it is likely that no subjects with the 
CYP2C9 *2*2 genotype will be present in the relatively small number of subjects 
normally recruited for these types of studies (see Chapter 5). 
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Table 2.5 Summary of studies recovered that have investigated the effect of 
CYP2D6 phenotype on (A) the pharmacokinetics, and (B) the pharmacodynamics 
of DEX. 
(A) Significant effect of genotype? 
CYP Reference Yes No 
Table 2.6 Summary of studies recovered that have investigated the effect of 
CYP2C9 genotype on (A) the pharmacokinetics, and (B) the pharmacodynamics of 
(S)-warfarin. 
(B) Significant effect of genotype? 
CYP Reference Yes No 
2C9 Aqilante et aL, 2006 VII 
Khan et aL, 2004 
Joffe et aL, 2004 
Aithal et aL, 1999 V/ 
Tabrizi et aL, 2002 V/ 
Loebstein et aL, 2001 V//x 
Peyvandi et aL, 2004 V/ 
Margaglioni et aL, 2002 
Higashi et aL, 2002 
Lindh et aL, 2005 
Hillman et aL, 2004 V/ 
Taube et aL, 2002 V/x 
Sconce et aL, 2005 
Karnali et aL, 2004 
Takahashi et aL, 2003 x 
Chem et aL, 2006 
King et aL, 2004 
Scordo et aL, 2002 
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2.4.2.3 Midazolam 
Seven studies have investigated the influence of CYP3A5 genotype on 
MDZ pharmacokinetics. Of these, only three found significant differences between 
genotypes. The 'successful' trials used 19,31 and 64 subjects (Goh et al., 2002; Wong 
et al., 2004; Yu et al., 2004) whereas those that were 'unsuccessful' used 21,39,57 
and 58 subjects (Eap et aL, 2004b; Floyd et aL, 2003; Lepper et aL, 2005; Shih & 
Huang, 2002). These findings suggest that the power of the studies may have been 
low, but not so underpowered as to render the effect of phenotype on the 
pharmacokinetics of MDZ impossible to detect. There are no published studies 
investigating the influence of CYP3A5 polymorphisms on the pharmacodynamics of 
MDZ. 
The three studies that have investigated the influence of CYP3A4 
genotype on MDZ pharmacokinetics (Eap et al., 2004b; Floyd et al., 2003; Lepper et 
al., 2005) were all 'unsuccessful' in detecting differences between genotypes (Table 
2.7). The wide interindividual variability in the activity of CYP3A4 (5 to 82 fold in 
vitro) (Gibbs & Hosea, 2003) may account for these negative findings. 
2.4.2.4 Omeprazole 
All except one of the 13 reports that have investigated the effect of 
CYP2Cl9 genotype/phenotype on the pharmacokinetics of OMZ showed significant 
differences, study sizes ranging from 6 (Kita et al., 2001) to 160 (Chang et al., 1995) 
subjects. 
Of the 10 studies on the effect of CYP2Cl9 phenoype on the 
pharmacodynarnics of OMZ, 8 reported 'positive' results, using between 6 and 160 
subjects (Chang et al., 1995; Egan et al., 2003; Furuta et al., 1999b; Hu et al., 2005; 
Kita et al., 2001; Shimatani et al., 2003; Sim et al., 2006; Tanigawara, et al., 1999). 
The two 'unsuccessful' studies recruited 119 and 174 subjects (Miyoshi et 
aL, 2001; Ohkusa et aL, 2005). However, in contrast to the 'unsuccessful' studies, 
most of the pharmacodynarnic studies (as well as many of the pharmacokinetic studies) 
that found significant differences between CYP2Cl9 genotypes/phenotypes, used 
'enriched' populations, in that they had higher abundances of certain genotypes than 
are present in Caucasian populations. Thus, subjects were either pre-selected based on 
their genotypes, or studies were carried out in other ethnic groups. 
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Table 2.7 Summary of studies recovered that have investigated the effect of 
CYP3,45 genotype on the pharmacokinetics of MDZ. 
Significant effect of genotype? 
CYP Reference Yes No 
3A5 Lepper et al., 2005 x 
Goh et al., 2002 
Wong et aL, 2004 
Shih et aL, 2002 
Eap et aL, 2004 
Floyd et aL, 2003 
Yu et aL, 2004 
Table 2.8 Summary of studies recovered that have investigated the effect of 
CYP2CI9 phenotype on (A) the pharmacokinetics, and (B) the 
pharmacodynamics of OMZ. 
(A) 
CYP Reference 
Significant effect of genotype? 
Yes No 
2CI9 Qiao et aL, 2006 
Fu et aL, 2004 
Fu et aL, 2003 V/ 
Hu et aL, 2005 
Ohnishi et aL, 2005 
Zhou et aL, 1999 V/ 
Chang et aL, 1995 V/ 
Yasuda et aL, 1995 V/ 
Andersson et aL, 1998 V/ 
Furuta et aL, 1999 V/ 
Kita et aL, 2001 
Shirai et aL, 2001 
Yin et aL, 2004 V/ 
Tybring et aL, 1997 
Sakai et aL, 2001 
(B) 
CYP Reference 
Significant effect of genotype? 
Yes No 
2CI9 Shimatani et aL, 2003 
Chang et aL, 1995 
Hu et aL, 2005 
Egan et aL, 2003 V//x 
Ohkusa et al., 2005 
Miyoshi et al., 2001 
Kita et aL, 2001 V/ 
Furuta et aL, 1999 
Tanigawara et aL, 1999 
Sim et aL, 2006 V/ 
Kita et aL, 2001 
Shirai et aL, 2001 
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2.4.2.5 Tolbutamide 
All of the 6 studies that investigated the effect of CYP2C9 genotype on 
TLB pharmacokinetics were 'successful' and used study sizes of 15 (Lee et al., 2002), 
16 (Lee et al., 2003), 18 (Shon et al., 2002), 23 (Kirchheiner et al., 2002a), 23 (Jetter et 
al., 2004) and 63 (Wang et al., 2005a). However, as is the case for (S)-warfarin, and 
since there are 6 common CYP2C9 genotypes, only one of the comparisons between 
the wild-type genotype and any other single genotype needed to be significantly 
different for the study to be recorded as 'successful'. 
The pharmacodynamic studies appear to have been somewhat 
underpowered. Only one out of the three studies investigating the influence of 
CYP2C9 genotype on TLB pharmacodynamics (Shon et al., 2002) was successful. All 
used similar numbers of subjects (15; Lee et al., 2002), (18; Shon et al., 2002) (23; 
Kirchheiner et al., 2002a). 
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Table 2.9 Summary of studies recovered that have investigated the effect of 
CYP2C9 genotype on (A) the pharmacokinetics, and (B) the pharmacodynamics of 
TLB. 
(A) Significant effect of genotype? 
CYP Reference Yes No 
2C9 Shon et aL, 2002 V/ 
Jetter et aL, 2004 V/ 
Kirchheiner et aL, 2002 
Lee et aL, 2002 
Lee et al., 2003 V/ 
Wang et al., 2005 V/ 
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CHAPTER 3 
General Methods for the Prediction of Drug 
Clearance from In Vitro Data 
Chapter 3: General Methods 
3 GENERAL METHODS 
This thesis is concerned with the use of in vitro drug metabolism data to 
simulate and predict pharmacokinetic differences between CYP phenotypes/genotypes. 
Pharmacokinetic parameters were then used in pharmacokinetic-pharmacodynamic 
models to simulate drug response. With some minor variations, the processes involved 
in predicting drug clearance and the use of clearance to predict elimination rate 
constants are common to each of the 5 drugs investigated in this thesis. This chapter 
will describe the process of extrapolation of human drug clearances (and elimination 
rate constants) from in vitro data using SimcypS algorithms (www. simcyp. com). The 
use of elimination rate constant data within full pharmacokinetic-pharmacodynamic 
models to simulate and predict human concentration- and response-time profiles is 
specific to the 5 drugs studied and is described in the methods sections of the relevant 
chapters (Chapters 4 to 8). 
Simcyp@ algorithms allow the creation of populations of virtual individuals 
with genetic, physiological, and demographic characteristics that are derived from 
literature sources using Monte Carlo Simulation. The latter involves the generation of 
'pseudo random' values, which can take on one of a range of parameters defined by a 
population distribution. Parameters relevant to the scaling process of in vitro in vivo 
extrapolation (IVIVE) are obtained for each virtual individual in the population 
(incorporating population variability) and are then used, together with the relevant in 
vitro metabolism data, to obtain values for the whole liver intrinsic clearance. These 
data are then converted into values for hepatic clearance (CLH) using a liver model 
(Section 3.3.2.1). Between subject variability in first pass gut metabolism (where 
applicable) and renal clearance were estimated as described in Sections 3.3.1.2. & 
3.3.3, and combined with the estimate of hepatic clearance to generate overall 
clearance values following intravenous (i. v. ) or oral (p. o. ) administration (CL, CLp.,,. ). 
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Table 3.1 Primary drug specific parameters used in the IVIVE scaling process. The 
secondary parameters, which the primary parameters are used to 
calculate, are also indicated and the section in which further information 
is given is listed in the 3 rd column. 
Primar y Parameter Secondary Parameter Section 
fu fUB 3.1.1.3 
fU13 FH; EH; CLj. v; CLp.,. 3.3.2.1; 3.3.3 B: P fuB; CLi.,; CLp. o. 3.1.1.3; 3.3.3 fa CLp. o. 3.3.3 V. a,, [CYP] [route] 
CLUH, int; CLUG, im; EH; FH; FG; CLp. oji., 3.3.1.1; 3.3.1.2; 3.3.2.1; 3.3.3 Km CLUH, int; CLUG, ffit; EH; FH; FG; CLp.,, ji., 3.3.1.1; 3.3.1.2; 3.3.2.1; 3.3.3 
fumic CLUH. 
int; CLUG, int; EH; FH; FG; CL,., /i., 3.3.1.1; 3.3.1.2; 3.3.2.1; 3.3.3 
fu = fraction unbound in plasma; fUB = fraction unbound in blood; B: P = blood to 
plasma partition ratio; fa = fraction absorbed; 
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3.1 Drug Specific Information 
Drug-specific data (Table 3.1) were collated from the Published literature 
after identifying sources using OVID MEDLINE (1966-2006) and WEB OF 
SCIENCE (1981-2006). Drugs were selected based on the criteria outlined in Chapter 
2; Section 2.4.3. In addition to these conditions, the substrate also had to fulfil several 
other criteria: (i) that the primary route of elimination is catalysed by a CYP enzyme, 
(ii) that the substrate is a recognized probe for a specific CYP enzyme and, (iii) that the 
drug does not exhibit non-linear kinetics in vivo. 
3.1.1 In Vitro Data Collection and Manipulation 
3.1.1.1 In Vitro Metabolism Data 
Studies providing metabolic data in the form of values of V.. (pmol min-' 
pmol-1 CYP) and Km (mM) were selected. Data obtained from experiments using 
microsomes prepared from recombinant systems expressing human CYPs (e. g. 
Escherichia coli, lymphoblastoid, baculovirus or yeast cells) were preferred over those 
from experiments carried out in human liver microsomes (HLM). In experiments in 
recombinant enzymes, Vm. values are expressed in the units of 'per pmol CYP'. In 
contrast, Vm,,., values derived from HLM experiments are expressed 'per mg protein'. 
Conversion of the values from HLM experiments to a rate 'per pmol CYP' is achieved 
by using CYP abundance data. However, since very few HLM studies have reported 
CYP abundances in individual livers, it was necessary to estimate this parameter in 
each individual using known population distributions. This involves making the 
additional assumption, that the HLM samples were pooled from large enough numbers 
to be representative of the population average. Assuming this to be the case, mean 
population abundance values could be used to estimate clearance, but this introduces a 
possible source of error in the scaling process. Because adequate recombinant data 
were available for all 5 drugs studied, HLM data were not used. 
Where K. and V.. data were available for a particular metabolic pathway 
from several different studies, it was necessary to find the weighted mean (WX) of 
these values. This was achieved using Equation 3.1, or when a drug had multiple 
metabolic pathways, kinetic data were combined to give 'global' values expressing the 
overall contribution of each CYP to net metabolism using Equations 3.2 and 3.3: 
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n 
Yn, xx, 
wx - n ýn, 
J=j 
Equation 3.1 
where nj is the number of observations and xj is the mean value of thejth study. 
n 
Uuj, t(global) C, Luit =± 
V-- Equation 3.2 
x=1 x=1 
(K 
where subscripts x (I to n) are the different metabolic routes. 
3.1.1.2 Microsornal Binding 
Non-specific binding of substrates to the experimental apparatus and to proteins in in 
vitro enzyme kinetic experiments may lead to an underprediction of intrinsic clearance. 
Thus, values of the fraction unbound in microsomes (fu,, 1i', ) were used to adjust data to 
account for such non-specific binding. These data were kindly provided by Simcyp 
Ltd. In the absence of experimentally determined values, Equation 3.3 was used to 
estimate fuý,, ic (Austin et aL, 2002): 
1 fu 
mic cX1o0.56 log PID-1.41 + 
Equation 3.3 
where C is the microsomal protein concentration (mg ml-1) and log P/D is the 
log P of the drug if it is a base, or the log D7.4 of the drug if it is neutral or an acid. 
Experimental Log P and logD7.4 values were experimental values reported in the 
literature. 
In the absence of experimental data for microsomal protein concentration, a 
default value of 0.25 mg/mL was chosen, as it is the most commonly used 
concentration in rCYP experiments. 
3.1.1.3 Fraction Unbound in Blood 
Values of the fraction of unbound drug in blood (fuB) were calculated from 
the fraction unbound in plasma (fu) divided by the blood to plasma concentration drug 
ratio (B/P; ). Values of fu and B: P were obtained from ex-vivo studies reported in the 
literature. Where B: P values were not available, a default value of 0.55 (representing 
no drug uptake into erythrocytes at an haernatocrit of 45%) was used. 
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3.2 Population Specific Information 
Plasma drug clearance values (CLi., CLp... ) and their variances were 
generated for virtual populations with age ranges and male to female ratios consistent 
with those documented in the in vivo studies with which the simulated data were to be 
compared. If in vivo data were not available, a default age range of 20 to 50 years was 
used based on that commonly observed in the in vivo studies, and a default male to 
female ratio of 0.5 was chosen to correspond with the general population. The 
population specific parameters necessary for IVIVE simulation are listed in Table 3.2. 
3.2.1 Generation of Populations 
3.2.1.1 Demographic Parameters. 
For a given population where the age distribution is known, it is necessary to 
estimate height and weight based on age, to aid subsequent assignment of anatomical 
and physiological parameters. In the current model, height was calculated from age 
and body weight from height. 
Briefly, height and weight data based on 19,564 individuals were obtained 
from the Health Survey for England 1998 (Erens & Primatesta, 1999) (Figure 3.1). 
Height was modelled based on age and quadratic relationships were derived for both 
men and women (Figure 3.1). A normal distribution of height was assumed and 
variability was added at each age to generate individual values. Weight was modelled 
against height using an exponential function (Figure 3.1). 
Since body surface area (BSA) is known to be better correlated with many 
physiological functions, organ sizes and blood flows, than with height or weight alone 
(Barger-Lux & Heaney, 2005; Seo et aL, 2000; Wu et aL, 2004), a value of BSA was 
calculated for each individual based on the Du Bois and Du Bois equation (Du Bois & 
Du Bois, 1916): 
BSA, (m') = weight, 
(kg)0.425 
x Height, 
(CM)0.725 
xO. 007184 
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Table 3.2 Primary population specific parameters used in the IVIVE scaling 
process. The secondary parameters, estimated from the primary 
parameters, are also listed, together with references to the appropriate 
sections of this thesis. 
Primary Parameter Secondary Parameters Section 
n Used to generate population 
Male: Female ratio Height; BW; BSA; LV; LW etc. 3.2; 3.2.1.1; 3.2.1.2 
Age Height; BW; BSA; LV; crCL etc. 3.2; 3.2.1.1; 3.2.1.2; 3.3.3 
Height BW; BSA; LV; LW; CI etc. 3.2; 3.2.1.1; 3.2.1.2; 3.2.1.3 
Body Weight BSA; LV; LW; Cl; CO; crCL etc. 3.2.1.1; 3.2.1.2; 3.2.1.3; 3.3.3 
BSA LV; LW; CI; CO; QnOrt; QA, etc. 3.2.1.1; 3.2.1.2; 3.2.1.3 
BSA = body surface area; CI = cardiac index; CO = cardiac output; crCL = creatinine 
clearance. 
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Figure 3.1 Data from 19-564 individuals showing the relationship between age and 
height, and height and body weight in males (females not shown). 
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3.2.1.2 Anatomical Parameters 
Individual liver volume (LV) was estimated from BSA using the following equation, 
which relates liver volume (LV) to BSA, based on data from 1332 autopsy livers from 
Gennan subjects (Heinemann et aL, 1999): 
LVI = 1.0728 x BSA, (M2) -0.3457 Equation 3.5 
LV was then converted to liver weight (LW) by multiplying by liver density: 
LWj (g) = LVj x density (g/L) Equation 3.6 
where density is 1,080 g/L (Heinemann et al., 1999). 
3.2.1.3 Physiological Parameters 
It was necessary to calculate cardiac output in order to estimate liver blood flow (for 
use in the well-stirred liver model; Section 3.3.2.1). The equation that describes cardiac 
index (CO m-2 BSA) as a function of age (for adults aged greater than 20 years) was 
based on the relationship reported by Guyton et al. (1973): 
Cardiac indexi (I min-'m') =3+ (-0.01 (agei (years) - 20)) Equation 3.7 
Individual cardiac index values were then converted to CO by multiplying by BSA: 
COj (I h-') = cardiac indexi (I min-'m') x 60 x BSAj (I M-2) Equation 3.8 
Total CO was subsequently used to estimate the portal and hepatic artery 
blood flows (Qp., t and QAn, respectively) in each individual. Qpot and QAt were 
assumed to constitute 6 and 21% of the total CO, respectively (Valetin, 2002). Total 
blood flow to the liver (QH) was calculated from the sum of Qp,,, t and QAt: 
QH ý QPort + QArt Equation 3.9 
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Table 3.3 Primary physiological parameters used in the IVIVE scaling process. The 
secondary parameters, estimated from the primary parameters, are also 
listed, together with references to the appropriate sections of this thesis. 
Primary Secondary Parameter Section 
Parameter 
LV LW; V,,,; CLUH, int; CLuGi, t; FH; 
FG; 3.2.1.2; 3.1.1.1; 3.3.1.1; 
CLp. O. /j. v. 3.3.1.2; 
3.3.2.1; 3.3.2.2; 3.3.3 
Liver density LW; V. a,; 
CLUH, int; CLUG, int; FH; FG; 3.2.1.2; 3.1.1.1; 3.3.1.1; 
CLp. Ojj. v. 3.3.1.2; 
3.3.2.1; 3.3.2.2; 3.3.3 
LW V, 
a,; 
CLUH, int; CLuG, int; FH; FG; CLp. o. /j., 
3.1.1.1; 3.3.1.1; 3.3.1.2; 
3.3.2.1; 3.3.2.2; 3.3.3 
MPPGL Vmax; CLUH, int; CLuG, it; FH; FG; CLp. O. /j.,. 
3.1.1.1; 3.3.1.1; 3.3.1.2; 
3.3.2.1; 3.3.2.2; 3.3.3 
[CYPIH abund. Vma,; CLUH, int; FH; CLp.,,. /j.,. 3.1.1.1; 3.3.1.1; 
3.3.2.1; 3.3.3 
[CYP]r, abund. Vma,; CLUG, int; FG; CLp. (). 
3.1.1.1; 3.3.1.2; 3.3.2.2; 3.3.3 
Cl CO; QPort; QArt; QH; FH; CLp. o. /j, 3.2.1.3; 3.3.2.1; 
3.3.3 
CO QPort; QArt; QH; FH; CLp., ji. v. 3.2.1.3; 3.3.2.1; 
3.3.3 
Qp. rt 
QH; FH; CLp. o. h. v. 3.2.1.3; 3.3.2.1; 3.3.3 
QAft QH; FH; CLp. o. /i. v. 3.2.1.3; 
3.3.2.1; 3.3.3 
QH FH; Cl, p. o. /j. v. 
3.3.2.1; 3.3.3 
CLUH, int 
FH; CLp. o. /j. v. 
3.3.2.1; 3.3.3 
CLur,, i, t FG; CLp. o. 
3.3.2.2; 3.3.3 
GFR CLR; CLp,. /i. v. 
3.3.3 
Creatinine CL CLR; CLp. oji. v. 
3.3.3 
Renal CLR; CLp. o. /j. v. 
3.3.3 
Function 
CLR CLp. Ojj. v. 
3.3.3 
QgUt FG; CLp. o. 
3.3.2.2; 3.3.3 
FH Up., 3.3.3 
FG CLp. o. 
3.3.3 
MPPGL = milligrams microsomal protein per gram of liver; [CYPIH abund. 
hepatic CYP abundances; [CYP]G abund. = gut CYP abundances; Cl = cardiac index; 
CO = cardiac output; Qpot = portal vein blood flow; Qkft = hepatic artery blood flow; 
QH = hepatic blood flow; CLUH, int = unbound hepatic intrinsic clearance; CLuG, int 
unbound gut intrinsic clearance; GFR = glomerular filtration rate. 
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3.3 Scaling of Human in vivo Clearance 
3.3.1.1 Hepatic Metabolism 
In order to scale intrinsic in vitro clearance data to whole liver values, a 
number of scaling factors are required such as enzyme abundances, liver weights and 
the number of Milligrams of microsomal Rrotein per grarn of liver (MPPGL). The 
calculation of individual intrinsic hepatic clearance (CLUH, ftL) was achieved using the 
following equation: 
CLUH, 
int, l = 
[ýýISEFj xCLUH, int(rCYPJ)XCYPj abundance ix MPPGLj x LWj Eq 3.10 
Lj=1 , fu Mic 
where there are j CYPs with corresponding CLui,, t(global) values, calculated from 
enzyme kinetic parameters for different pathways in each recombinant system (Section 
3.1.1.1; Equation 3.2). 
It is widely accepted that CYPs have different turnover numbers in 
recombinant systems and HLM. Accordingly, inter-system extrapolation factors 
(ISEFs) (Proctor et al., 2004), which account for differences in intrinsic activity per 
unit enzyme, were applied to the in vitro metabolism data generated by rCYP systems. 
Median values specific to the expression system and each particular CYP were used. 
Where no CYP-specific data were available, the median ISEF value for that expression 
system was applied (Proctor et al., 2004). 
The CYPJ abundance is the amount of the jth CYP enzyme per mg 
microsomal protein (pmol/mg) in the livers of each individual within the virtual 
population. As rates of metabolism arising from in vitro experiments in recombinant 
enzymes are expressed per unit enzyme (pmol P450), values for abundance are 
required to convert this value to the rate of metabolism per mg of microsomal protein. 
Abundance values (pmoICYP per mg protein) for each enzyme in FILM 
(mean and coefficient of variation - CV) were derived from a meta-analysis of 
published data (Rowland-Yeo et aL, 2004) [mean values (pmolmg-1): CYPIA2 (52), 
CYP2136 (11), CYP2C8 (24), CYP2C9 (73), CYP2C1 8 (1), CYP2Cl9 (14), CYP2D6 
(8), CYP2E1 (61), CYP3A (155)], and were used with their variabilities to generate 
values for each individual in the virtual population. The abundance of a particular CYP 
enzyme for a genotypic "poor metaboliser" (PM) was assumed to be zero (unless 
otherwise stated in Chapters 4 to 8). In the case of CYP2D6 ultra-rapid metabolisers 
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(UMs), the abundance of the enzyme was assumed to be twice that in extensive 
metabolisers (EMs). Frequencies of PM phenotypes for relevant CYP enzymes in 
Caucasians were accounted for, and abundance values were adjusted accordingly 
CYP2136 (0.1), CYP2C9 (0.06), CYP2Cl9 (0.03), CYP2D6 (0.06)) and that for the 
CYP2D6 ultrarapid metabolizer (UM) phenotype (0.01). 
MPPGL is required to scale the rate of metabolism per mg of microsomal 
protein to the rate per gram of liver. The rate per whole liver is obtained by multiplying 
the latter by liver weight (LW). The mean (29.3) and CV (25%) of MPPGL measured 
in 20 livers (Wilson et aL, 2003) was used to assign a value to each individual. 
3.3.1.2 Gut Metabolism 
Intestinal metabolism contributes significantly to the clearance of many 
CYP3A substrates (Masica et aL, 2004). Although other CYP enzymes such as 
CYP2C9 and CYP2D6 have been detected in the gut (Paine et al., 2006), the amounts 
are negligible compared to that of CYP3A (which contributes up to 82% of the total in 
the gut) (Paine et aL, 2006). Gut intrinsic clearance (CLuG, int) was calculated using 
Equation 1.22: 
CLu, CLu,,, 
(CYP3A)x CYP3A abundance, i (gut) 
fumic 
Equation 3.11 
where CLui,, t and fu ir are the in vitro parameters used to calculate hepatic 
clearance (Section 3.1.1). 
The assumption that the intrinsic clearance per pmol CYP is the same in both 
Dit and liver is supported by the observation that the rates of formation (per pmol P --- 
CYP) of verapamil metabolites in HLM were not significantly different to those 
observed in intestinal microsomes (Yang et aL, 2004). Because CYP3A abundance 
represents the total amount of enzyme in the gut (pmol/total gut), no additional scaling 
factors were required. 
Using a mean value of 70 000 pmol P450/total gut (Paine et aL, 1997), 
CYP3A abundance in gut was calculated using the equation: 
Individual CYP3A Average CYP3A x Individual GSA 
gutabundance gutabundance Average GSA Equation 3.12 
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where GSA is the surface area of the small intestine, calculated by 
multiplying the lengths of the ileum, jejunum and duodenum [3.5,2.5 and 0.205 
meters, respectively (Martini, 1998) by their diameters [0.025,0.025 and 0.033 meters, 
respectively (Marieb, 1997)] and by 7r (assuming the sections of gut are, on average, 
perfectly cylindrical). Variability was added to the mean values of the lengths of the 
three sections of gut (Martini, 1998). 
3.3.2 Liver and Gut Clearance Models 
3.3.2.1 Liver model 
Several liver models have been developed for the estimation of hepatic 
clearance (CLH, j) and the fraction of the amount of drug reaching the liver escaping 
hepatic metabolism (hepatic availability; FH, i). These are the well-stirred model 
(Wilkinson & Shand, 1975), the parallel tube model and the dispersion model. The 
performance of each of these models is drug dependent. However, the well-stirred 
model appears to be the most consistent and is recommended for use when predicting 
in vivo drug clearance from in vitro data (Ito & Houston, 2004). Accordingly, this 
model was chosen for the present work. 
In the well-stirred model, instantaneous and complete mixing of the drug is 
assumed to occur within the liver (Wilkinson & Shand, 1975): 
CLH. 
1 ý-- 
QH, 
l X fUB, j x 
CLUH, 
intj Equation 3.13 
QHJ +TfU 13,1 x CLU Hjnt, l 
FH, j =- 
QH. 1 
____ Equation 3.14 QW+ (fL' B, i xC LU H, Int, i 
) 
F-H, 
I -- 
fU 
B, I xC 
LU 
H, int, l Equation 3.15 
QH, j 
+(fUBi xCLUH, int, l) 
where QHJ is the hepatic blood flow in the ih individual (Section 3.2.1.3), fUB, i 
is the free fraction of drug in blood in each individual (Section 3.1.1.3) and CLUH, inýi is 
calculated as described in 3.1.1.1. 
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3.3.2.2 Gut model 
To estimate the individual fraction of drug escaping metabolism in the 
intestinal wall (intestinal availability; FG, j), a model of 'first-pass' gut metabolism 
(Rostami-Hodjegan & Tucker, 2002), similar to the 'well-stirred liver' model was used 
for CYP3A substrates (Equation 3.15). 
The gut model, in contrast to the liver model incorporates a flow term (Qvt), 
which represents a nominal blood flow and is a hybrid parameter reflecting drug 
absorption rate from the gut lumen, removal of drug from the enterocyte by the 
enterocytic blood supply, and the volume of enterocytes (Rostarni-Hodjegan & Tucker, 
2002). The free fraction of drug within the enterocyte is represented by the fug,, t term: 
FG, 
j = 
Qgut, 
l 
Qgutj + (fugut x CLUG, Int, l) 
Equation 3.16 
In the absence of any infon-nation on active drug uptake into the enterocyte, 
fu, t was set at a default value of 1 (which assumes that there is insufficient time for 
binding to plasma protein or erythrocyte uptake before the drug is removed from the 
basolateral side of the enterocyte). 
,,, t value of 
20 1 h-1 was calculated for midazolam based on in vivo data A QF 
obtained after both intravenous and oral administration (Yang et al., 2004). This value 
approximates the blood flow to enterocytes (10-15% of mesenteric blood flow). 
Assuming that a proportional relationship exists between Qg,, t and permeability (Papp) 
obtained using Caco-2 cells, Qpt values for other drugs were estimated by comparing 
their Papp at concentrations estimated to occur in the gut lumen with that of midazolam 
(data kindly provided by Simcyp Ltd). Any information on the affinity of the drug for 
P-glycoprotein was also taken account of when deciding on the value of Qg,, t value. A 
default value of 10 1 h-1 was assumed in the absence of any permeability data. 
3.3.3 Human Plasma Drug Clearance 
Renal clearance values were obtained from the literature or were calculated 
from the fraction excreted unchanged in the urine (fe) multiplied by CLj.,. Renal 
clearance was individualized by adjusting for renal function. This involved the 
estimation of creatinine clearance as follows (Cockcroft & Gault, 1976): 
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Creatinine Clearance, = (140 - Age, )x 
BW Equation 3.17 
70 
where BWi is the individual body weight. 
Renal function was expressed as a function of creatinine clearance relative to 
average glomerular filtration rate (GFR = 120 ml min"; Rowland and Tozer, 1995): 
Creatinine clearance, Renal Function, = GFR 
Equation 3.18 
Renal clearance value was then multiplied by renal function. 
Total plasma clearances after oral and intravenous administration were 
calculated for each individual subject using the corresponding organ clearances and 
associated availabilities, after correction for B: P: 
CLI. 
v., i ý 
(CLH. 
1 + 
CLRj) x B: P 
CL 
J CLH, 
i + 
CLRJ) 
P. O.. i T. x 
-FG xB: P 
x FHj 
Equation 3.19 
Equation 3.20 
where fa is the fraction of drug available for absorption from the dosage form 
and CLRj is the individual renal clearance. In the absence of lower values indicated in 
the literature, a default value forfa of 1, representing complete absorption from the gut 
lumen into the gut wall was assumed for each of the 5 drugs studied. 
3.3.4 Conversion of CL Into Rate Constants 
Individual values of CLi. v., i were converted to elimination rate constants (kio) 
for use in the pharmacokinetic-pharrnacodynatnic model (Equations 3.21 and 3.22). 
Two different approaches were applied, depending on the availability of data. Values 
of volume of distribution (mean and standard deviation) linked to bodyweight (V/kg) 
were available from the literature for (S)-warfarin, MDZ, OMZ and TLB and thus the 
following equation was used: 
k10,1 =- 
CLI.,., Equation 3.21 
Vi x BW, 
where Vi is the initial volume of distribution in the ifl'individual. 
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However, for DEX, no data for V were available in this form. Since no 
correlation exists between V and CL (Chapter 4; Section 4.2.2.1), it was deemed 
appropriate to use a non-weight normalised value for V (taken from the literature) and 
the following equation was used: 
CLi,,, 
klo, i = VI 
Equation 3.22 
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3.4 Defining Parameter Distributions for Monte Carlo Simulation 
Population values are generally considered to be log normally distributed 
(Aitchison & Brown, 1966). For such a distribution, the geometric mean (GM) and 
geometric standard deviation (GSD) represent the central tendency and variation, 
respectively. Algebraically, the GM and the median are identical for a log normal 
distribution. A 90% confidence interval can also then be calculated using g and a, the 
natural logarithms of GM and GSD. These values were determined from the weighted 
mean (WX) and overall SD as follows: 
In 7- (0.5 * 07 2) Equation 3.23 
a= Vln(l + CV') Equation 3.24 
where: 
Coefficient of variation (CV) = 
SD Equation 3.25 
3ý 
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3.5 Reference Values for Validatiny Predicted Clearance 
To evaluate predictions of clearance, the simulated outcome (predicted) was 
compared with experimental values (observed). However, in some cases, experimental 
values were obtained from several reports. These were combined to calculate an 
overall reference value, as described below. 
Clearance data (oral and/or intravenous) were obtained from reported in vivo 
studies performed in healthy Caucasian sub ects. Where data from more than one study j 
were available for the same route of administration, weighted mean values (VVXý were 
calculated using Equation 3.1 (Section 3.1.1.1) and the overall SD was calculated from 
the equation: 
Overall SID =VN 
of squares Equation 3.26 
where 
1 )2 
+ 
ýXj )2 (WX)2 Overall sum of squares Dj 
]xnj]-N. Equation 3.27 
where N is the total number of observations from all studies, and SDj is the 
standard deviation from thejth study. 
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4 DEXTROMETHORPHAN 
4.1 Introduction 
Dextromethorphan (DEX) is widely available over-the-counter as a cough 
suppressant. Its efficacy has been confirmed in both clinical cough (Aylward et al., 
1984; Cass & Frederik, 1953; Cass & Frederik, 1956; Matthys et aL, 1983) and in 
experimental cough challenge studies (Grattan et aL, 1995; Kartunnen et aL, 1987). 
CYP2D6 is responsible for most of the O-demethylation of DEX to its active 
metabolite, dextrorphan (DOR). DOR then undergoes glucuronide formation 
(Barnhart, 1980) (Figure 4.1). DEX is also N-demethylated to form 3- 
methoxymorphinian (Figure 4.1). This pathway is primarily catalysed by CYP3A4 but 
CYPs 2C9 and 2C19 also contribute (Gorski et aL, 1994; Schmider et aL, 1997; Von 
Moltke et aL. 1998a; Von Moltke et aL, 1998b) (Figure 4.1). Both DOR and 3- 
methoxymorphinian are ftirther metabolised to 3-hydroxymorphinian, by CYP3A4 and 
CYP2D6, respectively (Jacqz-Aigrain et aL, 1993) (Figure 4.1). DEX is commonly 
used as an in vitro probe to provide estimates of kinetic parameters for CYP2D6 
(Tucker et aL, 2001). It has also been used widely in in vivo phenotyping studies of 
CYP2D6 and CYP3A4 (Evans & Relling, 1991; Streetman et aL, 2000). 
As discussed in Chapter 2 (Section 2.4.3.1), a number of studies have 
investigated the effect of CYP2D6 phenotype on the pharmacokinetics and 
pharmacodynamics of DEX. At least three have observed a significant difference in the 
AUC of DEX between (i) CYP2D6 EM and PM phenotypes (Capon et aL, 1996) or, 
(ii) a group of EM individuals before and after treatment with quinidine to produce PM 
phenocopies (Abdul Manap et aL, 1999; Capon et aL, 1996; Pope et aL, 2004). 
However, studies have not detected differences in the antitussive AUEC of DEX 
between CYP2D6 phenotypes. (Abdul Manap et aL, 1999; Capon et aL, 1996). The 
reason for this disparity may be related to the relatively small size of the studies. 
Larger numbers of subjects may be necessary to observe differences in 
pharmacodynamics than in pharmacokineties (Chapter 2; Section 2.4.2). 
The aim of the present study was to simulate the pharmacokinetics and 
pharmacodynamics of DEX in virtual populations of human subjects. These 
simulations were used to estimate the power of in vivo studies to differentiate the 
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pharmacokinetics and pharmacodynarnics of DEX between CYP2D6 phenotypes. 
Whereas DOR is generally considered to be pharmacologically active, there are some 
concerns regarding its potency and how this may affect the DEX concentration- 
response relationship. Because of this, the models described in this chapter were also 
used to investigate the outcome of studies in which the proportional contribution of 
DEX and DOR to the antitussive activity was altered. The sensitivity of study power to 
pharmacodynamic variability and to changes in the contribution of CYP2D6 to the 
overall elimination of DEX, were also investigated. The overall aim of the work was to 
explain the failure of in vivo studies to detect differences in the pharmacodynamics of 
DEX between CYP2D6 phenotypes by assessing the effect of several factors on study 
power. 
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Figure 4.1 The metabolism of DEX in humans with all known pathways being 
shown. Each symbol represents an enzyme and the size of the symbol is 
indicative of the relative contribution of that enzyme to the metabolic 
route. Data were taken from Yu et al. (200 1) 1, Wang & Unadkat (1999)2, 
Schmider et al. (1997) 3, Schadel et al. (1995 )4, Jacqz-Aigrain et al. 
(1993)", Jacqz-Aigrain & Cresteil (1992)6, Yu & Haining (2001 )7, Von 
Moltke et al. (1998b)8, McGinnity et al. (2000)9, Kerry et al. (1994)10, 
12 13 Gorski et al. (1994)11, Jones et al. (1996) , 
Lutz et al. (2004) , 
Ching et 
al. (1995) 14 . 
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4.2 Materials and Methods 
4. ZI The IVIVE Model Parameters 
As described in Chapter 3, several key parameters are required for input 
into the model as part of the IVIVE process. These include both in vitro parameters 
(such as Kn, and V.. ) and parameters gathered from in vivo experiments (such as 
CLR). These were collected from the literature and either entered directly into the 
model or utilised as part of a meta-analysis. The following section describes the 
parameters and their uses. 
4.2.1.1 In vitro Data 
Data on the in vitro metabolism of DEX (in the form of K.,, and Vma,, ) were 
collected from published reports (Delaporte et aL, 2001; Hayhurst et aL, 2001; 
Mankowski et aL, 2000; Von Moltke et aL, 1998b; Yu et aL, 2001; Yu & Haining, 
2001) (Table 4.1). 
Intersystem extrapolation factors (ISEFs), were applied as described by 
Proctor et aL, (2004) to correct for any differences between the intrinsic activities of 
recombinantly expressed CYP enzymes and human liver microsornes (Table 4.2). To 
account for the non-specific binding of DEX to microsomal protein, a value of fumic 
was calculated and applied to the data as described in Chapter 3; Sections 3.1.1.2 and 
3.3. Values of ISEF and fumic are shown in Table 4.2. A meta-analysis was then 
conducted to determine the overall Vmzx and Km values for the metabolism of DEX by 
each CYP isoform. 
4.2.1.2 Additional Parameters Required for IVIVE 
The parameters listed in Table 4.3 were required for scaling the in vitro 
data to human whole body clearance and to the elimination rate constant (Chapter 3). 
These values were the entered into the pharmacokinctic-pharmacodynamic model 
described below (Sections 4.2.2 & 4.2.3). 
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Table 4.1 Parameters describing the in vitro metabolism of DEX. 
DOR formation 3-MM formation 
Reference CYP Vmax Km Vmax Km 
Von Moltke et al., 1998 2D6 10.8 5.20 4.07 838 
2C9 7.16 229 2.10 254 
2C19 0.84 32.9 1.45 49.2 
Mankowski et al., 2000 2D6 36.0 0.70 - - 
Delaporte et al., 2001 2D6 27.0 1.60 - - 
Hayhurst et al., 2001 2D6 8.16 2.00 - - 
Yu et al., 2001 2D6 8.50 1.90 - - 
Yu and Haining, 2001 2D6 11.9 3.70 38.5 1290 
3A4 5.40 157 21.3 232 
2B6 0.50 243 29.9 105 
2C9 3.40 222 1.00 343 
2C19 1.30 219 1.90 237 
2CI8 2.40 453 17.2 354 
DOR - dextrorphan; 3-MM - 3-methoxymorphinian; Vý2 - pmol/min/pmol P450; 
Km - ktM. 
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Table 4.3 Mean pharmacokinetic parameter values for DEX obtained directly or 
calculated from the literature. 
Parameter Value References 
fu 0.5 Capon et aL, 1996 ; Section 3.1.1.3. 
B: P 0.55 Default valuef (Section 3.1.1.3). 
fUB 0.90 Section 3.1.1.3. 
CLR (L/h) 0.375 Barnhart, 1980; Moghadamnia et aL, 2003; Schadel et aL, 
1995; Tenneze et al., 1999; Section 3.3.3. 
V (L) 961 (167)* Moghadamnia et aL, 2003; Section 3.3.4. 
*Mean (SD); fu = fraction unbound in plasma; B: P = Blood to Plasma concentration 
drug ratio; fiJB = fraction unbound in blood; CLR = renal clearance; tNo reported 
values were available, and thus, no distribution of drug into erythrocytes was assumed. 
Table 4.4 Additional literature values describing the pharmacokinetics of DEX and 
DOR. 
Parameter Value* Reference 
V(DOR) P 3533(1201) Unpublished datat 
ký, (h- 1) 2.6(0.9) Moghadamnia et al., 2003 
tlag (h) 0.8(0.1) Moghadamnia et al., 2003 
k12 0.126 (2.14 x 10-4) Unpublished datat 
k2i 0.062 (4.32X 10-5) Unpublished datat 
kofDOR (11-1) 0.51(0.21) Moghadamnia et al., 2003 
*Mean (SD); 'I From work carried out within the Department of Pharmacology - 
University of Sheffield 
Table 4.5 Literature data describing the pharmacodynarnics (antitussive effect) of 
DEX and DOR used in the modelling of response to DEX. 
Parameter Value* Reference 
E,,,. (/o) 37.7 (18.47) (CV = 49) Moghadamnia et al., 2003 
ECso (ng/mL) 3.2 (0.64) (CV 20) Moghadamnia et al., 2003 
n 3.9 (7.61) (CV 195) Moghadamnia et al., 2003 
k, o (h") 0.41 Moghadamnia et al., 2003 
Potency(DoR) 38 (26) (CV 69) Moghadamnia et al., 2003 
BaseCough (no. coughs) 10.7(l. 5) Rostami-Hodjegan et al., 2001 
ScaleCough 7.56(4.79) Rostami-Hodjegan et al., 2001 
tlagCough (h) 1.09(l. 03) Rostami-Hodjegan et al., 2001 
k, ough (males) (If 0.29(0.19) Rostami-Hodjegan et al., 2001 
k, 
-ouph 
(females) (h-1) 0.34(0.16) Rostami-Ho4iegan et al., 2001 
*Mean(SD 
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4. Z2 The Pharmacokinetic Model 
4.2.2.1 Concentrations of DEX in the Systemic Compartment 
Plasma concentrations of DEX in each individual (C(t)j) were generated 
using a two-compartment model with first order absorption and a lag time: 
f, - 
FH, 
- 
FGi 
-kýj -D C(t)i =. V, x 
(Ali + A2, + A31) Equation 4.1 
Wheref, is the oral bioavailability of DEX (set to 1), FHi is the fraction of 
the amount of DEX reaching the liver escaping hepatic metabolism in each individual 
(calculated using Simcyp@ algorithms; Equation 3.14; Chapter 3), D is the oral dose of 
DEX (30mg of DEX hydrochloride), k,, i, and Vi are the first order absorption rate 
constant and the central volume of distribution in the i th individual, respectively (Table 
4.4). Ali, A2j and Mi are given by: 
k21J -a, -a,. (t-tiag, ) All = (kaj -a, ). (, fl, - a, )xe 
Equation 4.2 
A2j = 
k2l, 
i -A x e'A-0-Uag) Equation 4.3 (k 
a, I-A)-(ai -A) 
A31 = 
k2l. 1 - ka, j xe Equation 4.4 (P., 
- k,., 
) 
- 
(ai 
- k., j) 
where k2jj and kl2, i are the transfer rate constants from the peripheral to the 
central compartment and central to peripheral compartment, respectively and ai and Pi 
are the hybrid rate constants associated with the distribution and elimination phases, 
respectively (Equations 4.5 and 4.6; Gabrielsson & Weiner, 2000). 
a, =0.5x[(kl2,, +k2l, l +klo, j)-V(kl2. i 
+k21J +kjO. jy -4-k2l, l -kjO. j 
I Equation 4.5 
fl, = 0.5 x 
[(k, 
2,, + 
k2l. 
1 + klo, j)+ 
V(kl2,1 + k2l, l + klo, jy -4 -k2l, i - klo, j 
I Equation 4.6 
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where kjOj is the individual elimination rate constant estimated using 
SimcypS algorithms as outlined in Chapter 3. 
Throughout this thesis, values of V for the compounds investigated are 
expressed in the form of weight normalised values (L/kg). However, in the case of 
DEX, such information was not available. If an absolute value of V (L) is used, this 
may lead to an unrealistic, lack of correlation between V and CL (since clearance is 
also related to body weight). This may result in possible over-estimation of the 
variability in kinetic parameters such as half life. Although Moghadamnia et al. (2003) 
did not report any weight normalised values of V, individual kinetic parameter values 
from that study were available to us. Therefore, a preliminary investigation was carried 
out to define any relationship between oral CL and V. No significant correlation was 
found (data not shown) and hence, absolute values of V (together with random 
variability) were incorporated into our simulations. 
4.2.2.2 Concentrations of DOR in the Systemic Compartment 
Equation 4.6 describes the plasma concentration - time course of DOR: 
C(t)DOR, 
l ý 
C(t)DOR(Istpassli + C(t)DOR(systemicli Equation 4.7 
where C(t)DOR(Ist pass) and C(t)DOR(systemic) are first-pass and systemic 
components described by Equations 4.7 and 4.12, respectively: 
C(t)DOR(systemicp 
-D 
FG, j - FH, j - fmi - klo., - k,,. i x [Al M, + A2m, + A3m, + A4m, ]Equation 4.8 V(DORJI 
A value for V(DOR) was calculated as part of the studies by Moghadamnia 
et aL (2003) and although it was not provided in the published report, it was available 
to us (Table 4.4). The fraction of DEX converted to DOR after an iv bolus dose in the 
i"' individual (fini) was calculated from: 
fm, = 
CLMDOR. 
1 
CLi Equation 4.9 
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where CLmDOFi is the metabolic clearance of DEX to DOR in the ih 
individual, and CLi is the total clearance of DEX (including renal clearance) in the ih 
individual (both values were estimated using the Simcyp(R) algorithm). Almi, A2mi, 
A3mi and A4mj are given by: 
Alm, =- 
k21.1 -ai 
--ýI x e""'("1"91) Equation 4.10 (k,., - al (A - ai )' (k (DORII -a 
A2mj =- 
k2l, 
l -A --xe, 
A. (t-lag, ) Equation 4.11 (kaj 
-A)'(al - A) * 
(k(DOR), 
i --fli) 
A3m, =- 
k2l, 
l - 
kaj 
-- x e-A. 
(t-lag, ) Equation 4.12 
(fli -ka, l)'(al -ka, l) ' 
(k(DORýi kalj) 
A4m, =k 
21J -k (DORII x e-A-(Wag) Equation 4.13 (kaj 
- 
k(DORII )' (fli 
-k (DORli 
)' (a, 
-k (DORII 
) 
where k(DoR)i is the elimination rate constant of DOR (Table 4.4). 
The plasma concentration of DOR as a result of its first-pass formation is 
given by: 
CMDOR(lstpassý! 
- 
D. ka, j -EHDOR. 1 Xý 
e -k(DORjI'(t't1a9, 
) -k,,. (t-tlag, ) 
Equation 4.14 V(DORji (kaj 
-k(DORII) 
' (k(DORII 
-ka, 
j) 
4.2.2.3 Concentrations of DEX in the Effect Compartment 
The following equation was used to calculate the concentration of DEX in 
a hypothetical effect compartment: 
Ce(t)(DEX), 
FHi - FG, - k. i -D-k. 01 x (Ali + A21 + A3, + A4i) Equation 4.15 V, 
where koi is the rate constant defining removal of DEX from the effect 
compartment (Table 4.5). Ali, A2i, Mi and Mi are given by: 
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All = 
k2l, 
i - CtI 
x e'a"(t-Uag, 
) 
(kaj - aj - (fl, - ai). (keO, I - al) 
A2, = 
k21J 
-A -xeA. 
(t-Uag, ) 
(k,., - A) - (ai - A) - (k. o, i - A) 
A3, = 
k2l, 
i - k,,., xe -Ri k a, l)'(ai k a, l)'(k e0j k 
-, ý, 
A4i =k 
21, i k e0j 
xe -ko.,. 
(t-tiag, ) 
(kaj 
- keo. 
j. (fl, 
- keO, I)* 
(ai - 
ke-OlD 
4.2.2.4 Concentrations of DOR in the Effect Compartment 
Equation 4.16 
Equation 4.17 
Equation 4.18 
Equation 4.19 
Equation 4.18 was used to calculate the concentration of DOR in the same 
hypothetical effect compartment as DEX: 
CeMOOR(sys), 
I ": 
D-f, -FG, j -FH, j - k., j - fm. - k10,1 - 
ke0i 
x (Al m, + A2m, + A3m, + A4m, + A5M, ) 4.20 V(DOR)i 
where the rate of removal of DOR from the effect compartment was 
assumed to be the same as that for DEX (kO - Table 4.5). Almi, A2mi, A3mi and A4mi 
are given by: 
Alm, = 
(k 
21J - C11 
)xe 
-ai. (t-tlag, ) Equation 4.21 
_ 
(kaj 
- aj - 
(fl, 
- aj) - 
(k(DORji 
- al) - (k. Oýj - a-I, 
] 
A2mj =- 
(k2l, 
l -A) -xe, A-(t-tla9) Equation 4.22 
_ 
(k,, 
i - A)* (a, - A), 
(k (00Rýi - A) - (k eo', - 
-fllýj_ 
A3m :-- 
(k2lj 
- k., j) 
-xe 
-k,,,. (t-tlaa) Equation 4.23 (a, 
-kk,. I), 
(k (DORýl - k, 'j) - 
(k, 
o. i --k, 
ý 
A4mi 
(k 
21j -k (DORIi 
xe -k(D0Rýj-(t-tlag, 
) Eq 4.24 
- 
(k 
a', -k (DORji 
k (DORI! 
)* (a! 
-k (DORýi 
)' (k, 
o. i -k (DORJJ] 
ill 
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A5mj =- 
(k2lj 
- kýO, j) xe 
k.,.,. (t-tlag, ) Equation 4.25 
-(k,, i 
- kO, j)- 
keO, i)'(ai - 
keO, 
i)* 
(k(DOR)i 
- 
keO,! )] 
The contribution of the first-pass fonnation of DOR to its effect 
compartment concentration is described by: 
CeWDOR(I, 
tp... ýl - 
D-keO, 
i - 
kaj 
- 
EHDORJ 
x Bl, + B2j + B3, Equation 4.26 V(DORji 
where: 
Bli =e 
k(DORjI-(t-tlag, ) 
Equation 4.27 
(k,, i - 
k(DORli ) +(k, o. i - 
k(D 
0R 
-ýýi 
B2j =ek,., 
. (t-tlag, ) 
Equation 4.28 
(k (DORli -k aj 
)+ (k, 
O, j - k,, I) 
B3j =ek. 
O. j. (Wlag, ) 
Equation 4.29 
(k (DORli -k eO, j 
)+ (k 
aj -kO, i 
4.2.3 The Pharmacodynamic Model 
4.2.3.1 Modelling of the Placebo Response 
The placebo effect was differentiated from drug effect, and defined by 
Equation 4.30, as described by Rostami-Hodjegan et al. (2001). Values for scalei, 
baselinei, tlagi(placebo) in the ih individual and the appearance/disappearance rate 
, hi) were 
included in the model (Table 4.5) and assigned random constant (k.,,, 
variability: 
Placebo effect, =BaseCoughi-(ScaleCough, xkcough)X[t-tlagiCough]xe 
-k-IGh-(t-Vag, Cough) 4.30 
where the first-order rate constant for nonlinear suppression of cough 
response and return to baseline, k,,,,, gh, was sex-dependent and was described by 
Equation 4.31 (Rostami-Hodjegan et aL, 2001): 
kcough(h-')= 0.049 x sex(male=1; female= 2)+ 0.238 Equation 4.31 
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4.2.3.2 Modelling of Overall Response 
Concentrations of DEX and DOR were calculated in a hypothetical effect 
compartment (Equation 4.15,4.20 and 4.26). The pharmacokinetic and 
pharmacodynarnic data were linked assuming a sigmoidal E,, Ia,, model such that the 
response to DEX in each individual (E) was described by Equation 4.32. 
El = placebo effect, x 
[I 
- E,, x, l x 
(Cei/EC50, 
I) 
n, 
Equation 4.32 
1+ (Cei/EC50,, T' 
. i, and 
EC50j, and ni are the concentration of the active where Cei, Eý,, a, 
moiety (DEX and/or DOR) (Equation 4.15,4.20 and 4.26), maximal antitussive effect 
(Table 4.5), the concentration of active moiety in the effect compartment associated 
with half the E,,,,,, (Table 4.5), and the Hill-coefficient (Table 4.5), respectively, in each 
individual. The combined effects of DEX and DOR were modelled assuming 
competitive interaction at the same receptor site: 
Ei = placebo effect, x1- 
Emaxj X 
(CeDEx, j/EC50j 
+POtDOR. i 
CeD()R, 
i 
/EC50, )n, 
n, 
4.33 
1 
1+(Cel)Fx,, /EC50,1+POtDOR, I. CeDOR, I/EC, 50, i) 
] 
where POtDORj is the potency of DOR relative to DEX in the ihindividual 
[ECso(DEX)/ECso(DOR)] (Table 4.5). Based on the analysis of Moghadamnia et aL, 
(2003), the potency of DOR was assumed to be 0.38 (+/- 0.26) that of DEX in the 
default case. This value was varied to assess its effect on the discriminatory power of 
the different studies. A measurement error in the cough response (assumed to be a 
normal random distribution with a mean of zero and a standard deviation of 0.5) was 
used based on studies using the citric acid cough model (Rostami-Hodjegan et aL, 
2001). 
Due to the design of the pharmacokinetic-pharmacodynamic model, it was 
necessary to generate the pharmacodynamic effect (number of coughs) as a continuous 
output. However, since it is more realistic for the number of coughs to be integer 
values, the figure was rounded to the nearest whole number for the purposes of data 
analysis. 
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4. Z4 Study Design 
Individual plasma DEX and DOR concentration and response vs. time 
profiles following the administration of DEX were simulated for all time points 
between 0 and 24h. For the purposes of data-analysis, samples were taken every hour 
(24 samples). The simulated profiles in EMs and PMs (with equal numbers of each 
phenotype in each study arm) were compared using populations sizes (n) of 2,4,6,8, 
22,50,100,200 or 500. Twenty simulations were run for each study size. 
4.2.5 Sensitivity of the Study Power to Changes in Drug Specific Parameters 
In addition to the simulations and analysis described above (which will 
now be referred to as the 'default setting'); ftu-ther simulations were carried out to 
assess the sensitivity of the study power to: 
(a) the relative contribution of the polymorphic pathway to the overall 
metabolism of the parent compound (Section 4.2.5.1), 
(b) the relative pharmacological activity of the polymorphically formed 
metabolite compared to parent compound (Section 4.2.5.2), and 
(c) variability in pharmacodynamics (Section 4.2.5.3). 
Overall, 3600 simulations were completed, involving more than 350,000 
virtual subjects. 
4.2.5.1 Contribution of the Polymotphic Pathway to Metabolism of the Parent 
Compound 
The contribution of CYP2D6 to the overall metabolism of the drug was 
modified and metabolism was shifted to non-polymorphic pathways. This value was 
increased to 100% and then decreased to 50%. In the default setting, the CYP2D6 
pathway catalysed about 90% of the metabolism of DEX. The Km and Vmax values 
for CYP2D6 and CYP3A4 were altered such that the CLint due to CYP2D6 increased 
whereas that due to CYP3A4 decreased, total CLint being made to remain the same. 
4.2.5.2 The Relative Potency of Metabolite Compared to Parent Compound. 
The relative activity of DOR used in the default setting was 38% that of 
DEX. The activity of DOR (formed via the polymorphic route) was then varied 
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between 0 (inactive) and 10,000%. The case where the metabolite is the only active 
compound was also investigated. The sensitivity of study power (to detect differences 
in the AUEC of the parent compound between CYP2D6 phenotypes) to the potency of 
the active metabolite was thereby observed. 
4.2.5.3 Variability in Pharmacodynamics 
In the default setting, the variability in the phannacodynatnic parameters 
ranged from 20 to 130%. Simulations were also carried out with this value changed to 
30% and to 0%. 
4. Z6 Data Analysis 
Values of the area under plasma drug concentration-time (AUC) and 
effect-time (decrement in cough response) curves (AUEC) to 24 h were calculated 
using the trapezoidal rule. The probability of detecting statistically significant 
differences in pharmacokinetics and pharmacodynamics between CYP2D6 phenotypes 
was assessed using ANOVA. The number of studies from the 20 simulations that led 
to a statistically significant difference in AUC (or AUEC) between EMs and PMs was 
recorded as the power of that particular trial. 
Concentration-time and effect-time profiles were compared with those 
observed in vivo by Abdul-Manap et aL (1999) and Capon et aL (1996). The accuracy 
of the simulated data was assessed subjectively by a visual comparison of the observed 
and the simulated concentration- and response-time curves, and statistically by 
comparing some of the key simulated parameter values with those observed in vivo. 
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4.3 Results 
4.3.1 Model Validation 
Comparisons of observed (Abdul Manap et aL, 1999) plasma 
concentration - time curves of DEX and DOR (in EMs and PMs) and a representative 
set of corresponding simulated data are shown in Figure 4.2 and Figure 4.3, 
respectively. 
Figure 4.4 shows a comparison between the mean concentration-time 
curves of DEX from 10 clinical trial simulations and the mean data from the in vivo 
study (Abdul Manap et aL, 1999) in EMs and PMs. The corresponding plots for DOR 
are shown in Figure 4.5. A similar plot comparing the simulated concentrations with 
those observed by Capon et aL, (1996) is shown in Figure 4.6. 
Comparisons of observed (Abdul Manap et al., 1999) and simulated effect 
- time curves in EMs and PMs are shown in Figure 4.7 and Figure 4.8, respectively. 
The comparison between the mean simulated effect-time curves from 10 
simulations and the observed data (Abdul Manap et aL, 1999) in EMs and PMs is 
shown in Figure 4.9. 
A summary of the mean (± SD) pharmacokinetic parameters that describe 
the data in EMs and PMs compared with those reported in the literature are given in 
Table 4.6. 
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Figure 4.2 Observed( .... 0 .... ) (Abdul Manap et aL, 1999) and predicted (. ) 
plasma concentration-time profiles of DEX over 24 hours in (A) 22 real 
and 22 virtual EMs and (B) the same number of PMs. 
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Figure 4.3 Observed( .... 0 .... ) (Abdul Manap et aL, 1999)) and predicted 
plasma concentration-time profiles of DOR over 24 hours in (A) 22 real 
and 22 virtual EMs and (B) the same number of PMs. 
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Figure 4.4 Observed (Abdul Manap et aL, 1999) and predicted mean concentration- 
time plots of DEX over 24 hours. The means of ten clinical trial 
simulations involving 22 EMs (- -) and 22 PMs (- -) are compared 
with the mean (± 95% Cl) in vivo data from Abdul-Manap et aL, 1999 in 
EMs (-) and PMs (-) (n = 22 of each). 
5 
P. 
0 
048 12 16 20 24 
Time (h) 
Figure 4.5 Observed (Abdul Manap et aL, 1999) and predicted mean concentration- 
time plots of DOR over 24 hours. The means of ten clinical trial 
simulations involving 22 EMs (- -) and 22 PMs (- -) are compared 
with the mean (± 95% CI) in vivo data from Abdul-Manap et aL, 1999 in 
EMs (-) and PMs (-) (n = 22 of each). 
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Figure 4.6 Observed (Capon et aL, 1996) and predicted mean concentration-time 
plots of DEX over 24 hours. The means of ten clinical trial simulations 
involving 6 EMs (_ -) and 6 PMs (_ -) are compared with the mean 
95% Cl) in vivo data from Capon et aL, 1996 in EMs (-) and PMs 
(-) (n =6 of each). 
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Figure 4.7 Observed (Abdul Manap et aL, 1999) and predicted effect-time profiles 
for cough suppression over 12h after administration of 30mg DEX 
hydrobromide in 22 real (. ) and 22 virtual ( .... 0 .... ) EMs. 
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Figure 4.8 Observed (Abdul Manap et aL, 1999) and predicted effect-time profiles 
for cough suppression over 12h after administration of 30mg DEX 
hydrobromide in 22 real (-) and 22 virtual ( .... 0 .... ) PMS. 
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Figure 4.9 Observed (Abdul Manap et aL, 1999) and predicted mean effect-time 
plots over 12 hours. The means of ten clinical trial simulations involving 
22 EMs (_ -) and 22 PMs (_ -) are compared with the mean (± 95% 
CI) in vivo data from Abdul-Manap et aL, 1999 in EMs (-) and PMs 
(. ) (n = 22 of each). 
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Table 4.6 Observed (Abdul Manap et aL, 1999) and predicted pharmacokinetic and 
pharmacodynamic parameter values for DEX and DOR. Predicted values 
are the average of the mean values from 10 clinical trial simulations. 
Phenotype Parameter Predicted* Observed* 
EM tmax (h) 2.00(0.40) 2.00(l. 70) 
Cmax (ng/mL) 3.2(3.2) 4.3(4.4) 
AUCo-12 (ng/mL/h) 19.8(15.3) 25.6(28.2) 
AUCMO-12 (ng/mL/h) 10.9(7.5) 16.9(10.3) 
CL (L/h) 71.6(10.7) 75.2(13.9) 
FH 0.17(0.07) 0.22(0.15) 
AUEC 207(52) 203(174) 
E, ý, ax 10.5(l. 6) 10.5(2.2) 
PM tmax (h) 2.00(0.40) 3.00(0.90) 
C.. (ng/mL) 9.2(3.5) 18.6(6.3) 
AUCO-12 (ng/ML/hr) 63.3(27.4) 142.7 (42.4) 
AUCmo-12 (ng/mL/hr) 2.81(2.72) 12.82 (8.62) 
CL (L/h) 43.3(12.8) 20.4(9.8) 
FH 0.53(0.14) 0.78(0.12) 
AUEC 208(58) 299(194) 
Emax 10.6(2.2) 10.8(l. 7) 
*Mean (SD) 
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4.3.2 Default Setting - Dextromethorphan 
The simulations indicated that approximately 5 subjects would be adequate 
to achieve 80% power to detect a significant difference in the AUC of DEX between 
the two CYP2D6 phenotypes (Figure 4.10). A power of 100% was obtained when 
comparing 22 EMs with 22 PMs. The power to observe a difference in the AUEC of 
DEX between EMs and PMs was 75% at the maximum sample size investigated (500 
of each phenotype) (Figure 4.10). 
4.3.3 Contrihution of the Polymorphic Pathway to Metaholism of the Parent 
Compound 
Changing the proportional contribution of CYP2D6 to the overall 
metabolism of DEX from 90% in the default model to 50% caused a corresponding 
decrease in the power to detect a difference in antitussive effect between phenotypes to 
a maximum of 20% with a study size of 500. Increasing the proportional contribution 
of CYP2D6 to 100% increased the power to 80% for a study size of 90 of each 
phenotype (Figure 4.11 (B)). The corresponding plots for differentiating differences in 
pharmacokinetics between the phenotypes are shown in Figure 4.11 (A). 
4.3.4 Changing the Relative Activity of Metabolite Compared to Parent 
Compound 
When the primary metabolite was inactive or its relative potency was 
increased to 100 or 200%; the power of studies to determine a difference in response 
between the phenotypes remained relatively unchanged (Figure 4.12). However, when 
only the metabolite was assumed to be active, the power of studies to detect a 
statistically significant difference in antitussive effect between CYP2D6 EM and PM 
phenotypes was re-established. Increasing the relative potency to 1000% decreased the 
probability of discerning a difference in AUEC between phenotypes to between 0% 
and 5% for all study sizes (Figure 4.12). 
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Figure 4.10 The power (%) of simulated studies to show significant differences in the 
AUC of DEX (*) and DOR (0) and the AUEC (0) between CYP2136 
phenotypes vs. the number of subjects in each study arm (n). The arrows 
indicate the size of published studies: (a) Capon et al., (1999) and (b) 
Abdul-Manap et al., (200-3). 
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Figure 4.11 The influence of the proportional contribution of CYP2D6 (90% 
50% - 13; 100% - *) to the overall clearance of parent drug on the power 
(%) to detect differences in (A) the AUC of DEX (B) The AUEC of DEX 
and DOR between CYP2D6 phenotypes. 
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Figure 4.12 The influence of the relative potency of DOR to DEX on the power of 
studies to detect differences in the AUEC between CYP2D6 phenotypes. 
The default value (38% - 0) is compared to values of 0% (only DEX is 
active; +), 100% (11), 200% (, L), 1000% (X) and to the case where only 
the metabolite is active (*). 
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Figure 4.13 The influence of pharmacodynamic variability on the power (%) to detect 
differences in the AUEC of DEX and DOR between CYP2D6 
phenotypes. In the default setting, variability on different 
pharmacodynamic parameters ranged from 14 to 195% (40); this 
variability was fixed at either 330% (*) or 0% (13) to investigate the 
impact of such variability. 
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4.3.5 Variability in Pharmacodynamics 
In the default model the variability in the pharmacodynamic parameters 
ranged from 14 to 195% according to the literature values. Assigning a fixed low 
variability of 30% to all pharmacodynamic parameters, while keeping measurement 
error unchanged, did not have an appreciable effect on study power (Figure 4.13). 
However, a ftirther decrease to 0% allowed 80% power to be reached with a sample 
size of 25 (Figure 4.13). 
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4.4 Discussion 
Using clinical trial simulations the power of in vivo studies to determine 
differences in the disposition of DEX and its antitussive effect between CYP2D6 
phenotypes was examined. Using a metabolic clearance derived from in vitro data 
predicted the plasma concentration-time profiles with reasonable accuracy (within 2- 
fold) both in EM and in PM individuals, although those for PMs were underpredicted 
to some extent (Figure 4.2 to Figure 4.5). Nevertheless, the estimates of study power 
were consistent with the findings of published reports. Capon et al., (1996) 
demonstrated a difference in the AUC of DEX between 6 EM and 6 PM subjects, but 
failed to detect a significant difference in antitussive response between these groups or 
between EMs and the same individuals phenocopied to PMs by administration of 
quinidine. Abdul Manap et al. (1999) carried out a similar study with a larger number 
of 22 EM subjects, who were phenocopied to PMs, and also detected a significant 
phenotypic difference in pharmacokinetics but not pharmacodynamics. The present 
work indicates that these two studies had powers of 95 and 100%, respectively, to 
detect differences in the pharmacokinetics of DEX between EMs and PMs, but powers 
of only 10 and 15%, respectively to detect differences in pharmacodynamics. Even 
when all DEX was assumed to be metabolised by CYP2D6 or when pharmacodynamic 
variability was zero, study sizes remained prohibitive with regard to detecting 
pharmacodynamic differences between phenotypes. The results suggest that 22 
subjects would not have been sufficient to achieve acceptable statistical power in any 
of the conditions examined, and that between 30 and 500 subjects are necessary to 
detect significant differences in the AUEC. 
The relative potency of DOR had only a small influence on the power of 
studies to detect differences in the AUEC of DEX. Since the circulating concentrations 
of DOR are different to those of the parent compound (see Figure 4.2 and Figure 4.3), 
the lowest power in discriminating between response to DEX does not necessarily 
occur when the two compounds are equipotent. For example, if a metabolite has 200% 
the activity of the parent compound but is present in the plasma at 50% of the 
concentration of the parent drug then the 'effective' concentration of the metabolite is 
likely to be similar to that of the parent drug, and therefore little difference will be seen 
in response between EMs and PMs. This is illustrated in Figure 4.12, which indicates 
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that the lowest power is observed when the metabolite is 10 times more potent than the 
parent drug. 
It might have been expected that setting interindividual pharmacodynamic 
variability to zero would have resulted in a similar power to detect phenotypic 
differences in pharmacodynamics to that observed for pharmacokinetic differences. 
However, this was not the case (Figure 4.13), mainly for two reasons. First, in the 
absence of any interindividual differences in pharmacodynamic parameters, error is 
still associated with the measurement of response. Second, because the relationship 
between concentration and response is not linear, large differences in concentration 
will not translate to significant variation in response when the latter asymptotes to its 
maximum. 
In conclusion, the results of this study have provided a basis for the 
discrepancy in the ability of in vivo studies to detect differences in the 
pharmacokinetics and phannacodynamics of DEX between CYP2D6 phenotypes. 
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5 WARFARIN 
5.1 Introduction 
In the UK warfarin is the anticoagulant treatment of choice for a variety of 
cardiovascular disorders (Greaves, 2005). Clinically, it is given as a racemic mixture of 
(R)- and (S)-warfarin. For the purposes of this work, the (S)-isomer of warfarin was 
assumed to be the major active moiety inhibiting blood coagulation (Breckenridge et 
al., 1974; Eble et aL, 1966; O'Reilly, 1974) although a limited number of reports have 
suggested similar (or at least appreciable) activity by (R)-warfarin (Chan et al., 1994). 
The effect of warfarin is mediated through the inhibition of vitamin-K 
reductases that are linked to the vitamin K-dependent carboxylation of glutamic 
residues on certain coagulation proteins (e. g. prothrombin) (Holford, 1986). This has 
the effect of decreasing the concentration of active prothrombin complex, which, is 
monitored using 'prothrombin time' (PT) (the time taken for blood to clot - after the 
addition of a thromboplastin-containing mix). The international normalised ratio (INR) 
was introduced as an alternative to PT in order to standardise the measurement of 
coagulation and is calculated using the following equation: 
INR = 
(patient PT)ls' 
GMNPT 
Equation 5.1 
where PT is the prothrombin time of the test plasina, GMNPT is the 
geometric mean normal PT, that is, the geometric mean PT of 20 healthy adult plasma 
samples and ISI is the international sensitivity index, a measure of the sensitivity of the 
thromboplastin used in that particular laboratory (Guidelines on oral anticoagulation: 
third edition, 1998). 
It is usually recommended that INR values are kept within a therapeutic 
range of 2.0 to 3.0 (Guidelines on oral anticoagulation: third edition, 1998). 
The use of warfarin is associated with a large number of adverse drug 
reactions (ADRs) which occur as a result of over-anticoagulation (Holford, 1986). 
These effects can be attributed to the very narrow therapeutic index of the drug and/or 
the wide interindividual variation in response resulting from similar doses of the drug. 
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Age (Gurwitz et al., 1992), body weight (Kamali et al., 2004), vitamin K intake 
(Kamali et al., 2000), concurrent medication (e. g. amiodarone) (Heimark et al., 1992; 
Naganuma et al., 2001) and genetic factors (Loebstein et al., 2001) are thought to 
contribute to this variability. 
(S)-warfarin is metabolised by CYP2C9 (Takahashi et al., 1998). 
Polymorphisms in the CYP2C9 gene have been implicated as an important source of 
genetic variation in the disposition of (S)-warfarin and therefore in anticoagulation 
response to the drug (Sconce et aL, 2005; Takahashi et aL, 2003; Taube et aL, 2000). 
There are a considerable number of retrospective studies that demonstrate a significant 
link between CYP2C9 genotype and therapeutic outcome (e. g. INR or bleeding events) 
or maintenance dose requirements for warfarin treatment (for references, see summary 
in Table 5.1). However, observations from these studies are inconsistent, and have not 
established a similar relationship between CYP2C9 genotype and the in vivo 
pharmacokinetics of the drug (Table 5.1). This disparity may be due to the small 
number of subjects employed in the pharmacokinetic studies, thus limiting their power. 
More recently, several studies incorporating both CYP2C9 and vitamin K 
epoxide reductase complex subunit I (VKORC1) genotypes have been published 
demonstrating that interindividual variation in dose requirements of warfarin can be 
fin-ther accounted for by incorporating the latter into regression models (Aquilante et 
aL, 2006; D'Andrea et aL, 2005; Li et al., 2006; Tham et al., 2006; Vecsler et al., 
2006). 
The aim of the study presented in this chapter was to simulate the 
pharmacokinetics of (S)-warfarin and the anticoagulant response to the drug in virtual 
populations of human subjects. These simulations were used to mimic the in vivo 
studies and to estimate their power to identify differences in the pharmacokinetics and 
pharmacodynamics of (S)-warfarin between CYP2C9 genotypes. The sensitivity of 
study power to changes in both the pharmacodynamic variability and the extent of the 
contribution of CYP2C9 to the overall metabolism of warfarin were also investigated. 
The ultimate aims of the work were to facilitate a more comprehensive understanding 
of the relationship between drug phannacokinetics/pharmacodynarnics and CYP2C9 
genotypes, using (S)-warfarin as a model drug, and to investigate the impact of study 
size on the likelihood of success in defining differences in the pharmacokinetics and 
response of (S)-warfarin between CYP2C9 genotypes. 
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Assuming that adverse effects resulting from warfarin treatment are related 
to plasma drug concentrations, it might be beneficial to define a steady state 
concentration that is associated with a high likelihood of over-anticoagulation. To our 
knowledge, such information is not available because of practical and ethical issues 
that prevent the measurement of (S)-warfarin in plasma at the time of bleeding 
complications. Therefore, the IVIVE model has been utilised for the simulation of 
steady state concentrations in a population of individuals, some of whom experienced 
adverse effects. This information was then integrated into a threshold model of adverse 
reactions to warfarin therapy. 
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Table 5.1 A summary of studies investigating the relationship between CYP2C9 
genotype and warfarin response, maintenance dose and 
pharmacokinetics. 
Relationship studied References 
CYP2C9 genotype and Aithal et aL, 1999; Higashi et aL, 2002; Joffe et aL, 2004; 
therapeutic outcome Khan et aL, 2004; Lindh et al., 2005; Loebstein et al., 
2001; Margaglione et al., 2000; Peyvandi et al., 2004; 
Taube et al., 2000. 
CYP2C9 genotype and Aithal et aL, 1999; Higashi et aL, 2002; Hillman et aL, 
maintenance dose 2004; Joffe et aL, 2004; Karnali et aL, 2004; Khan et aL, 
2004; King et aL, 2004; Margaglione et aL, 2000; 
Peyvandi et aL, 2004; Sconce et aL, 2005; Scordo et aL, 
2002; Siguret et aL, 2004; Tabrizi et aL, 2002; Taube et 
aL, 2000. 
CYP2C9 genotype and Karnali et aL, 2004; Sconce et aL, 2005; Scordo et aL, 
(S)-warfarin 2002; Takahashi et aL, 2003. 
pharmacokinetics 
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5.2 Materials and Methods 
5. ZI The IVYVE Model Parameters 
As described in Chapter 3, as part of the IVIVE process, several key 
parameters are required for input into the model. These include both in vitro 
parameters (such as K. and Vý,, a,, ) and parameters gathered from in vivo experiments 
(such as CLR). These were collected from the literature and either entered directly into 
the model or utilised as part of a meta-analysis. The following section describes the 
parameters and their uses. 
5.2.1.1 In Vitro Data 
Data on the in vitro metabolism of (S)-warfarin (in the fonn of Km and 
V., 
_, 
) were collected from published reports (Sullivan-Klose et al., 1996; Takahashi et 
al., 1999; Takahashi et al., 1998; Takanashi et al., 2000; Yamazaki et al., 1998) (Table 
5.2). 
Intersystem extrapolation factors (ISEFs), were applied as described by 
Proctor et al. (2004) to account for any differences between the intrinsic activity of 
recombinantly expressed CYP enzymes and human liver microsomes (Table 5.3). To 
account for the non-specific binding of (S)-warfarin in the experiments described in 
Table 5.2, a value of fumic was calculated and applied to the data as described in 
Chapter 3; Sections 3.1.1.2 and 3.3. ISEF values and values of fumic are shown in Table 
5.3. A meta-analysis was then conducted to find the overall V. ax and Krn values for the 
metabolism of (S)-warfarin by CYP2C9. 
5.2.1.2 Additional Parameters Required for IVIVE 
The additional parameters listed in Table 5.4 were required for scaling the 
in vitro data to human whole body clearance and to the elimination rate constant 
(Chapter 3). These values were the entered into the pharmacokinetic- 
pharmacodynamic model described below (Sections 5.2.3 & 5.2.4). 
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Table 5.2 Parameters describing the in vitro metabolism of (S)-warfarin and the results 
of a meta-analysis to determine the relative activity of the enzyme in each of 
the CYP2C9 genotypes. All studies were carried out in recombinant 
CYP2C9 expressed in yeast microsomes. 
Allele No. 
Vmax 
(pmol/min/ Ký Changein Reference Observations 
pmol P450) 
(ýtm) CL,,, 
1 2 0.22 18 Yarnazaki et al. (1998) 
1 3 0.1333 11.6 Sullivan-Klose et al. (1996) 
1 3 0.282 1.86 Takahashi et al. (1999) 
1 3 0.248 5.8 Takanashi et al. (2000) 
1 3 0.28 2.6 Takahashi et al. (1998) 
*2 2 0.11 22 160.6 Yamazaki et al. (1998) 
*2 3 0.1656 12.5 T 11.4 Sullivan-Mose et al. (1996) 
*3 2 0.067 53 190.9 Yamazaki et al. (1998) 
*3 3 0.181 92.3 183.9 Sullivan-Mose et al. (1996) 
*3 3 0.111 21.6 187.7 Takanashi et al. (2000) 
*3 3 0.067 10.4 194.1 Takahashietal. (1998) 
Table 5.3) ISEF and fu,, i, values that were applied to the data shown in Table 5.2, 
resulting in the revisedVrna, and K,, values shown here. The final values 
entered into the IVIVE algorithms are indicated in bold type at the bottom of 
the table. 
Protein New Vinax New 
Reference Conc fUmi, ISEF (pmol/min/ K,,, 
(mg/mL) pmol P450) (ýIm) 
Yamazaki et al. (1998) 0.1 0.989 2.66 0.585 17.8 
Sullivan-Klose et al. (1996) 0.25* 0.973 2.66 0.355 11.3 
Takahashi et aL (1999) 0.1 0.989 2.66 0.750 1.84 
Takanashi et aL (2000) 0.25 0.97' 3 2.66 0.660 5.6 
Takahashi et aL ( 199 8) 0.1 0.989 2.66 0.745 2.6 
*A default value of 0.25 mg/mL was assumed if no specific value was available 
(Chapter 3; Section 3.1.1.2). 
Table 5.4 Mean pharmacokinetic parameter values of (S)-warfarin taken or calculated 
from the literature. 
Parameter Value References 
fu 0.007 Abernethy et al., 199 1; Chan et al., 1994; Section 3.1.1.3. 
B: P 0.55 Obach, 1999; Section 3.1.1.33. 
fUB 0.013 Section 3.1.1.3. 
CLR (L/h) 0.0032 Abernethy et al., 199 1; Heimark et aL, 1992; Section -3 ). 3.3. V (L/kg) 28.9 (5.5)* Chan et al., 1994; Section' ). 3.4. 
*Mean (SD); fu = fraction unbound in plasma; BT = Blood to Plasma concentration 
drug ratio; fiJB = fraction unbound in blood; CLR = renal clearance; V= initial volume 
of distribution. 
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5.22 Genotype Frequencies andActivities 
A meta-analysis of the published literature was carried out to determine the 
relative activity of the enzyme expressed by each CYP2C9 allele with respect to the in 
vitro metabolism of (S)-warfarin. Mean values of the activity of each allelic form were 
weighted for study size. As shown in Figure 5.1, percentage decreases in intrinsic 
clearance (CLuint) with respect to wild type (* 1 /* 1) enzyme were calculated assuming 
that the in vitro activities of heterologously expressed variant enzymes represented 
those in the respective homozygous genotype. Values of CLui,, t in heterozygous 
genotypes were assumed to be the average of those for homozygotes (Figure 5.1). A 
summary of the studies included in the meta-analysis is given in Table 5.2 (Sullivan- 
Klose et aL, 1996; Takahashi et aL, 1999; Takahashi et aL, 1998; Takanashi et aL, 
2000; Yamazaki et aL, 1998). 
The prevalence of each of the 6 established, common CYP2C9 genotypes 
in Caucasians were taken from a review by Lee et al. (2002) (Table 5.5). (S)-warfarin 
elimination was assumed to be mediated exclusively by CYP2C9 with a small 
contribution from renal clearance [0.0032 L/h in the average man (Abernethy et al., 
1991)]. This information was entered into a physiologically-based pharmacokinetic- 
pharmacodynamic model. 
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Figure 5.1 A schematic representation of the procedure to calculate the % reduction 
in CLint for different CYP2C9 genotypes compared to the wild type. The 
% CLi,,, of (S)-warfarin relative to *I* I was calculated by assuming the 
in vitro activity of rCYPs represented the respective homozygous 
genotype in HLM. 
Table 5.5 Frequency and relative enzyme activity of each of the common CYP2C9 
genotypes. Zn 
Genotype Frequency Relative 
(%)* Activity (%)t 
*l/*I 6 5.3) 100 
*1/*2 20.4 85 
*1/*3 11.6 55 
*2/*2 0.9 70 
2/* 
-33 1.4 40 *n/*. l 0.4 10 
*From (Lee et al., 2002); 'iCalculated from a meta-analysis of literature 
data (Sullivan-Klose et al., 1996; Takahashi et al., 1999; Takahashi et al., 
1998; Takanashi et al., 2000; Yamazaki et al., 1998). 
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5.2.3 Development of the Pharmacokinetic Model 
Plasma concentrations after oral administration of rac-warfarin (assuming 
that (S)-warfarin is responsible for 100% of the activity of the racemate) were 
generated by inputting values of the elimination rate constant (kio, j) and FH, i (both 
calculated using SimcypQD algorithms; Chapter 3) into a one-compartment model with 
first order absorption and a lag time (adapted from Chan et aL, 1994). 
Steady state plasma concentrations of (S)-warfarin after multiple doses of 
rac-warfarin, administered at a dosing interval (r) of 24 hours, were generated using a 
one compartment model with first order absorption and a lag time (Chan et aL, 1994). 
Thus, values in the i0l individual were given by the equation: 
fi- FH, l '(P- 
C,, 
arf, i(t) 
a, 2 
') - kaj 
. 
(e -k, o.,. (t-dag, ) e'k.,, . (t-flag, ) 
Equation 5.2 
Vi - BW, * 
(kaj 
- klo, l) 1- e'kl*ý, 
*r 1-e -k.., r) 
where C,, ý, f, #), tlag, fij, FHJ, Di, kaj, Vi, BWj and kjoj are, plasma drug 
concentration at time t, the lag time between administration and appearance of drug in 
the plasma (Table 5.6), the fraction of the dose absorbed (set to 1), the fraction 
escaping first-pass metabolism, the dose, a first-order absorption rate constant (Table 
5.6), the steady state volume of distribution (Table 5.6), body weight and a first-order 
elimination rate constant in the ih individual, respectively. The symbol, r represents 
the dosing interval. 
FH, i, BWj and kjOj were calculated using the Simcypg algorithm (Chapter 
3). Two different dosing regimens were used: (i) where a fixed dose was given to all 
virtual subjects, or (ii) D was defined as a distribution of likely doses that individuals 
would receive depending on their genotype (for detail see Section 5.2.5.3). All other 
parameter values were taken from Chan et aL (1996). 
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Table 5.6 Literature values describing the pharmacokinetics of (S)-warfarin. 
Parameter Value* Reference 
t1ag (h) 0.8(0.54) Chan et al., 1994 
k,, (h-1) 
-3 ). 
15 (1.6 8) Chan et al., 1994 
T 24 Arbitrary 
*Numbers in parenthesis indicate standard deviations. 
Table 5.7 Different pharmacodynamic models for warfarin. 
Model References 
Linear Sheiner (1969) 
Power Wiegman & Vossepoel (1977) 
Log-Linear Nagashima et al. (1969); Svec et al. (1985); 
Theofanous & Barile (197' )) 
E,,,,,, Abbrecht et al. (1982); Powers et al. (1980) 
Sigmoidal Ema,, Chan et al., 1994 
G 
E 
N 
0 
T 
y 
p 
E 
Figure 5.2 Schematic representation of the pharmacokinetic-pharmacodynamic 
model indicating propagation of metabolic differences between CYP2C9 
genotypes into (S)-warfarin clearance and its anticoagulant effect. For a 
full explanation of the methods used in scaling of in vitro data to in vivo 
clearance values see Chapter 3; Materials and Methods. CLuj, ', unbound 
intrinsic clearance; mppgl, milligrams microsomal protein per gram of 
liver; WRF Conc, plasma (, ý)-warfarin concentration; PC, prothrombin 
complex; R, yn, rate of synthesis of PC; kd, rate constant of degradation of 
PC; PT, prothrombin time; INR, international normalized ratio. 
140 
Chapter 5: Warfarin 
5. Z4 Selection of the Pharmacodynamic Model 
Several pharmacodynamic models for warfarin have been suggested and 
some of these are summarised in Table 5.7. The sigmoidal E.,. model suggested by 
Chan et al. (1994) was deemed the most suitable for a number of reasons. Some of the 
other models are overly simplistic (e. g. the Linear or Power models), some of them are 
only useful within the range 20 to 80% of the maximum effect (e. g. the Log Linear 
model) and all models except the sigmoidal E.. do not separate the effects of the two 
isomers of warfarin. 
Prothrombin complex activity (PCA) in the blood over time was simulated 
using an indirect response model in which PCA is the net effect of synthesis and 
degradation of the complex expressed as a percentage of maximum response 
(Nagashima et aL, 1969) (Figure 5.2). 
The change in PCA with time as a function of (S)-warfarin concentration 
was simulated using the following equation: 
dPCA kdj 100 
__ PCAI Equation 5.3 
dt 
1+ 
Cwarfj M ( 
CU50.1 
where kdj is the degradation rate constant of the prothrombin complex, 
Cu5Oj is the unbound concentration of drug required to produce a 50% inhibition of 
PCA synthesis andyi is a measure of the steepness of the concentration-response curve 
(Hill coefficient) in the id' individual (Table 5.8). 
5.2.4.1 Conversion of PCA to INR 
PCA was converted to Prothrombin Time (PT) using the following 
equation derived by Chan et al. (1994): 
PCA (% normal) =a PT(seconds) -b 
In which a and b are constants with variability (Table 5.8). 
Equation 5.4 
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Table 5.8 Literature values describing the pharmacodynamics (PCA and 
prothrombin time) of (S)-warfarin (from Chan et al. 1994). 
Parameter Value* 
kd (h-1) 0.054 (0.015) 
Cu5o (mg/L) 0.0026 (0.0015) 
7 0.90(0.23) 
a 426(128) 
b 7.75 (2.333) 
*Numbers in parenthesis indicate standard deviations. 
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Figure 5.3 Age distribution of a sample of the healthy UK population (Census, 
2001) (0) and of male (0) and female (EI) stroke patients. 
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This equation was rearranged to allow calculation of values of PTi in the 
ith individual from PCAi data. 
In turn, PT was converted to INR (Figure 5.2) using the following 
relationship (determined in a single laboratory) (adapted from Adcock & Duff (2000). 
An additional 10% arbitrary variability was added to the constants A (0.242) and B 
(9.5981) to account for differences between laboratories: 
INRj = 
PTj +A Equation 5.5 
B 
5. Z5 Study Design 
5.2.5.1 Study Population 
In contrast to the many pharmacokinetic and pharmacodynamic studies 
carried out in healthy subjects, the majority of those for warfarin have been performed 
in patient groups. In the warfarin model, the demography of the virtual patient 
population was mimicked by matching the age distribution proportion of male to 
female patients to that which might occur in the real patient population. This was 
achieved by using data from the Health Survey for England (http: //www. dh. gov. uk) to 
calculate the Weibull distribution for the age ranges of stroke patients (data kindly 
provided by Trevor Johnson at Simcyp Ltd. ). A Weibull distribution is a continuous 
probability distribution described by two parameters (scale - A; and shape - B), it was 
used to model the age distribution of the stroke population. The age distribution was 
described by a Weibull function if the individual was (i) male (A = 2.76; B= 30.3), or 
(ii) female (A = 2.13; B= 31.8). 
Stroke is clearly not the only disorder to be treated with warfarin. 
However, it was assumed that this age and sex distribution would be closer to the 
general warfarin-treated population than that of healthy subjects (Figure 5.3). 
5.2.5.2 Sampling Schedule 
Individual plasma (S)-warfarin concentration and response vs. time profiles following 
daily administration of oral warfarin were simulated from hourly samples over 24h. A 
number of design elements were investigated as described in Section 5.2.5.3, Section 
5.2.5.4 and Section 5.2.5.5. As the majority of simulations were undertaken using 
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'uniform dosage' and 'random recruitment' (see below for definitions), this 
combination will be referred to as the 'default condition'. 
5.2.5.3 Warfarin Dosage Regimens 
a) Uniform dosage for each individual regardless of CYP2C9 
genotype: Each individual in the virtual population received 3 mg of (S)-warfarin per 
day. This dose was chosen based on half of the weighted average dose of rac-warfarin 
calculated from (Holford, 1986). This study design was chosen to simulate a 
prospective clinical trial where all individuals receive the same dose, assuming that 
dose requirement for each CYP2C9 genotype is not known. 
b) Genotype related dosage: The distribution of commonly prescribed 
warfarin doses in a typical patient population of 292 patients from two large general 
hospitals in Merseyside, England, was kindly provided by Prof. M Pirmohammed, of 
the University of Liverpool (Figure 5.4). No fin-ther information (e. g. CYP2C9 
genotype) was available on these patients, but they were assumed to be representative 
of a general population being treated with warfarin patients. A random number 
generator operating on a description of these data by a Weibull function was used to 
assign a maintenance dose to each virtual individual (A = 2.25; B=4.361; Section 
5.2.5.1) (Figure 5.4). 
Several retrospective studies have indicated that the average dose of 
warfarin varies between different CYP2C9 genotypes. Accordingly, a meta-analysis of 
the data shown in Table 5.9 was carried out to assess the probability of each CYP2C9 
genotype falling within four different dose bands, representing the interquartile ranges 
of the dose frequency distribution (low (0-3mg), medium-low (3.1-4.5mg), medium- 
high (4.6-6.4) and high (6.6+)). Thus, the probabilities shown in Figure 5.5 were used 
to assign a CYP2C9 genotype to a given individual at a given dose. This study design 
will be referred to as 'genotype related dosage'. 
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Figure 5.4 Observed (0; n= 292) and predicted (M; n= 292) distribution of 
warfarin doses in a patient population from two large general hospitals 
(data supplied by Dr. M. Pirmohamed, University of Liverpool). 
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Figure 5.5 The probability (%) of each CYP2C9 genotype being found in each of the 
four dose groups described in Section 5.2.5.3), and calculated from a 
meta-analysis of literature data (Aithal et al., 1999; Higashi et al., 2002; 
Karnali et al., 2004; Loebstein et al., 2001; Margaglione et al., 2000; 
Siguret et al., 2004; Taube et al., 2000). 
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5.2.5.4 Subject Recruitment Strategy 
a) Random Recruitment: The majority of subjects included in published 
studies examining the influence of genetic variation in CYP2C9 on warfarin 
pharmacokinetics or pharmacodynamics were selected randomly from a Caucasian 
population, and not on the basis of CYP2C9 genotype. Therefore, the probability of 
having adequate numbers of a certain genotype in the study population for comparison 
with other genotypes is dependent on the natural frequency of that genotype in the 
general population. Virtual populations were simulated based on this 'random 
recruitment' design. 
b) Enriched Recruitment: This type of recruitment involves selecting 
subjects based on their genotype to give enriched abundances of particular genotypes. 
In practice, it would require the prior screening of many subjects, particularly with 
regard to the rarer genotypes, in order to carry out subsequent selective recruitment of 
small groups of individuals. This trial design was simulated with virtual populations 
enriched with specific genotypes. For example, a population of 10 *3/*3 individuals 
was compared to a population of 10 wild type subjects. This design will be referred to 
as 'enriched recruitment'. 
5.2.5.5 Study Size 
Simulated plasma drug concentration- and response-time profiles in the 
different CYP2C9 genotypes were compared using a range of population sizes (n). For 
'random recruitment', n was set at 10,25,50,100,250 or 550, to correspond 
approximately to the sizes of the published studies. For 'enriched recruitment' n was 
set at 2,3,5 or 10. No measurement error was assumed. 
5.2.5.6 Null Hypothesis 
The null hypothesis that there is no true association between genotype and 
drug clearance was tested using a set of control simulations to evaluate the possibility 
of false positive outcomes. These simulations used the same study sizes employed in 
the 'random recruitment' simulations described above (n = 10,15,50,100,250 or 550) 
and 'uniform dose' conditions. Half the population were classed as 'extensive 
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metabolisers' (*1*1) and half were 'poor metabolisers' (*3*3), but no difference in 
enzyme activity between the genotypes was introduced. 
5.2.5.7 Contribution of CYP2C9 to the Metabolism of (S)-warfarin 
In this section, the default setting was altered and the contribution of 
CYP2C9 to the overall metabolism of the drug was modified, metabolism being 
shifted to non-polymorphic pathways. In the default setting, CYP2C9 metabolised 
about 99% of (S)-warfarin. The K.. and V. a,, values for CYP2C9 were altered so that 
the CLi,, t due to CYP2C9 decreased, whereas renal clearance was made to increase, 
with total CLint remaining the same. 
The contribution of CYP2C9 to the overall metabolism of (S)-warfarin was 
decreased from 99% to 50% and 25%. 
5.2.5.8 Influence of VKORCI Genotype 
Since pharmacodynatnic variability in the response to warfarin is known to 
depend upon VKORCI genotype (Aquilante et aL, 2006; D'Andrea et aL, 2005; Li et 
aL, 2006; Tham et aL, 2006; Vecsler et aL, 2006) as well as that for CYP2C9, further 
simulations were carried out to assess the impact of the former on study power. In the 
default model, the variability in kd was set at 27% (Chan et al., 1994; Table 3). To 
allow for the increase in certainty arising from a knowledge of VKORCI genotype, 
this was decreased to 15%, based on the weighted average of the results of studies 
indicating that the total variability in warfarin dose due to VKORC1 genotype (after 
subtracting variability due to CYP2C9 genotype) is 18 to 26% (Aquilante et aL, 2006; 
D'Andrea et aL, 2005; Vecsler et aL, 2006). The simulations were carried out under 
'random recruitment' and 'uniform dosing' conditions. 
5.26 Data Analysis 
Twenty simulations were run for each study size (800 simulations) 
involving a total of 119,000 virtual patients. Pharmacokinetic and pharmacodynamic 
data were available up to 24h post dose in the simulations, values of the areas under 
the plasma drug concentration-time curves (AUC) and effect (INR)-time curves 
(AUEQ were calculated up to 12h (trapezoidal rule) with twice-hourly samples in 
order to maximize consistency with in vivo study design in literature reports on 
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warfarin. The probability of detecting statistically significant differences in 
pharmacokinetics and pharmacodynamics between the wild type (*I/*I) and the 
combination of the other CYP2C9 genotypes was assessed by comparing values of 
AUC and AUEC, respectively, using ANOVA (SPSS v 12; SPSS Inc, Chicago 2003). 
The corresponding probabilities of detecting differences in AUC or AUEC between 
the wild type and any other single genotype were calculated using Tukey's post hoc 
test for multiple comparisons. The percentage of studies out of the 20 simulations that 
led to a statistically significant difference in AUC (or AUEC) between CYPC9 
genotypes, was recorded as the power of that comparison. 
Clearance values obtained from the model were compared with those 
values observed in vivo (Scordo et aL, 2002; Takahashi et aL, 2003). The accuracy of 
the resulting effect-time profiles were assessed by comparing the mean INR values of 
the virtual populations with those reported in vivo (Jiang et aL, 2005; LiIja et al., 2005; 
Lindh et aL, 2005; Priskorn et aL, 1997; Simonson et aL, 2005; Vadher et aL, 1999). 
5.2.7 Defining a Hypothetical Concentration Thresholdfor the Occurrence 
ofAdverse Reactions Due to Warfarin 
As described in Section 5.2.5.3, the distribution of commonly prescribed 
warfarin doses in a typical patient population was made available to us (n = 292) 
(Figure 5.4; Section 5.2.5.3), as was the proportion of patients in this population who 
were admitted to hospital with adverse drug reactions (ADRs) to warfarin. It is 
assumed that the latter may occur as a result of elevated plasma (S)-warfarin 
concentrations. Therefore, it was possible to develop a simple 'threshold model', based 
on steady state (S)-warfarin concentrations. Using the IVIVE model for this purpose, a 
series of steady state plasma concentrations (Css; n= 292) were simulated 20 times. 
Assuming that the proportion of observed ADRs were associated with the 
highest concentrations of (S)-warfarin, the proportion of Css values that were expected 
to elicit ADRs was applied and a threshold concentration was estimated in each 
simulation set. The mean threshold value from twenty simulations was taken as the 
value of Q, (± SD) above which, serious ADRs are most likely to occur. 
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5.3 Results 
5.3.1 Model Validation 
The meta-analysis of the enzyme activities associated with the variant 
alleles of CYP2C9 indicated mean decreases in CLuint of 15% and 45% compared to 
wild-type activity, respectively, for every *2 and *3 allele present in an individual 
(Figure 5.1). The results for the different CYP2C9 genotypes are shown in Table 5.5 
and Figure 5.1. Propagation of these values through the SimcypV algorithm resulted in 
mean values of unbound oral clearance for (S)-warfarin from 100 individuals from one 
simulation of 19.9 (* l/* 1), 17.1 (* 1/*2), 10.8 (* 1/*3), 14.8 (*2/*2), 7.6 (*2/*3) and 1.9 
(*3/*3) L/h. These predicted values were all within 2-fold of those reported from in 
vivo studies (Kamali et aL, 2004; Scordo et aL, 2002) as shown in Figure 5.6. The null 
hypothesis simulations resulted in 0 to 5% power to detect differences in the AUC of 
(S)-warfarin between genotypes. 
A comparison of simulated unbound oral clearance values with those 
reported by Scordo et aL 2002 is shown in Figure 5.7. 
The simulated PT- and INR-time profiles obtained from the 'uniform dose' 
model with 'random recruitment' in 50 virtual subjects are shown in Figure 5.8 and 
Figure 5.9. 
Figure 5.8 and Figure 5.9 also demonstrate direct comparisons between the 
simulated data and observed data from three different reported studies (Jiang et aL, 
2005; LiIja et al., 2005; Priskom et al., 1997). 
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Figure 5.6 Observed [Scordo et al., 2002; Takahashi et al., 2003* (0)] and 
predicted (0; n= 100) unbound oral clearance values. Solid lines 
indicate the medians of one set of simulated data. The size of the circles 
reflects the number of subjects included in the meta-analysis (described 
in Chapter 33; Section 3.5). 
*The study by Takahashi et al. (20033) was conducted in both Japanese and 
Caucasians, but only the latter population was included in the meta- 
analysis. 
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Figure 5.7 Observed [Scordo et al., 2002 (EJ)] and predicted (M; n= 93) distribution 
of unbound oral clearances for (S)-warfarin in (A) wild type subjects, (B) 
subjects with one mutated allele, and (C) subjects with two mutated 
alleles. 
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Figure 5.8 Simulated response (PT)-time profiles from 50 virtual wild type subjects 
each line representing a single subject), the virtual population 
mean and the mean observed PT vs. time profiles in wild type 
individual-s (LiIj a et al., 2005)) (*; n= 10) and (Priskorn et al., 1997) (M; 
n= 12). 
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Figure 5.9 Simulated response (INR)-time profiles from 50 virtual wild type 
subjects (---; each line representing a single subject), the virtual 
population mean (-), and the mean observed INR vs. time profiles in 
wild type individuals from (Jiang et aL, 2005) (*; n= 50). 
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5.3.2 Gen otypicDifferences in (S)-warfarin A UCIAUEC Using theDefault 
Setting (Uniform Dosage'and 'Random Recruitmentq 
Approximately 90 subjects were needed to detect a difference in AUC 
between the wild type (*I/*l) and the combination of all other genotypes (Figure 
5.10). 
The power to differentiate between wild type and any other single 
genotype was less than that for the comparison between wild type and a combination 
of all non-wild type genotypes (Figure 5.11 (A)). For example, about 450 subjects 
were required to detect a difference in AUC between the *2/*3 genotype and the wild 
type with a power of 80% (Figure 5.11 (A)). However, with the same number of 
subjects, a power of only about 25% was achieved when comparing the *2/*2 
genotype with the wild type (Figure 5.11 (A)). 
Corresponding powers to detect differences in AUEC between CYP2C9 
genotypes are shown in Figure 5.10 and Figure 5.11 (B). The maximum number of 
subjects investigated of 550 was enough to achieve only 70% power to detect a 
difference between wild-type and any other genotype (Figure 5.10). The power to 
detect differences in AUEC between specific genotypes is shown in Figure 5.11 (B). 
For example, about 100 subjects are required for 80% power to detect a difference 
between the *1/*3 genotype and the wild type. By comparison, the same number of 
subjects gave a power of 10% when comparing the *3/*3 genotype with the wild type 
(Figure 5.11 (B)). 
Ninety-five comparisons of the pharmacokinetics or pharmacodynamics of 
(S)-warfarin between the wild type and any single other genotype have been reported 
in the literature (Table 5.10). Of these, 20 (21%) involved the observation of 
significant differences (Table 5.10). In the present simulations 19 out of 95 (20%) 
comparisons were expected to achieve a power of greater than 50% (more likely to 
succeed than fail) (Table 5.10). A chi squared test indicated no difference between the 
experimental and simulated proportions (p = 0.80). More specifically, in 76 cases out 
of 95, the expected power matched the observed result (Table 5.10). There were 10 
false negative and 9 false positive predictions (Table 5.10). 
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5.3.3 Genotype Adjusted Dose 
Using the genotype adjusted model with 'random recruitment' the power 
to determine differences in drug clearance between wild type and all the other 
genotypes was the same as that seen under 'default conditions'. However, this was not 
the case for AUC (a parameter that is dependent on both dose and clearance) or 
AUEC, where the powers to determine differences between CYP2C9 genotypes were 
decreased under 'genotype related dosage' conditions compared to 'uniform dosage' 
(Figure 5.10). The power to detect a difference in AUEC (comparing wild type and the 
combination of other genotypes) with the maximum study size reported in the 
literature (550 individuals) was 65%. 
5.3.4 Enriched Recruitment 
To investigate the effect of 'enriched recruitment' under 'uniform dose' 
conditions, *3/*3 individuals were compared directly with wild type genotypes. As 
expected, this resulted in much higher power compared to that achieved with 'random 
recruitment'. Thus, to achieve 80% power in detecting a significant difference in AUC 
between the two genotypes, only 3 subjects in each group were required (Figure 5.12). 
The corresponding number needed to detect differences in AUEC was 5 per group 
(Figure 5.12). 
5.3.5 Effect of Changing the Contrihution of CYP2C9 to the Metaholism of 
(S)-warfarin on Study Power. 
Changing the proportional contribution of CYP2C9 to the overall 
metabolism of (S)-warfarin from 99% in the default model to 25% caused 
corresponding decreases in the power to a maximum of 60% with a study size of 550. 
5.3.6 Influence of VKORCI Genotype 
Values of study power arising from these simulations were slightly higher 
than those from the equivalent 'uniform dosage', 'random recruitment' simulations 
described in Section 5.3.2 (Figure 5.14). For example, with the maximum study size 
investigated of 550,100% power was reached when VKORCI genotype was taken into 
account compared to 90% power when it was not. 
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Figure 5.10 Under conditions of 'random recruitment', the power (%) of simulated 
studies to show significant differences in AUC (under uniform dosage 
(*) and adjusted dosage (13) conditions) and in AUEC (under uniform 
dosage (0) and adjusted dosage (-, ', ) conditions) between the wild type 
and a combination of the other CYP2C9 genotypes vs. the number of 
subjects in the study population (n). Dashed line represents 80% power 
which is typically used in designing clinical studies. 
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Figure 5.11 Under conditions of 'uniform dosage' and 'random recruitment', the 
power (%) of simulated studies to show significant differences in (A) 
AUC, and (B) AUEC between the wild type and any single other 
CYP2C9 genotype vs the number of subjects in the study population (n). 
Wild type was compared with: *l/*2 (*), *1/*-') (0), *2/*2 (0), *2/*-') 
(2, ), (+). Dashed line represents 80% power, which is typically 
used in designing clinical studies. 
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Figure 5.12 Under conditions of 'enriched recruitment', the power (%) of simulated 
studies to show significant differences in the AUC (13) and AUEC (0) 
between the wild type and the genotype vs. the number of subjects 
in each study (n). 
100 
80 
60 
40 
20 
o 
Figure 5.13 The influence of the proportional contribution of CYP2C9 to the overall 
clearance of (S)-warfarin on the power (%) of simulated studies to detect 
significant differences in AUEC (under uniform dosage conditions) 
between the wild type and a combination of any other CYP2C9 
genotypes vs. the number of subjects in the study population (n). 0= 
default condition; 0= 50% contribution of CYP2C9; 25% 
contribution of CYP2C9. 
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Figure 5.14 The influence of pharmacodynamic variability on the power (%) of 
studies to detect significant differences in the AUEC (under uniform 
dosage conditions) of (S)-warfarin between CYP2C9 genotypes, not 
taking account of (0), and taking account of (O)VKORCI genotype. The 
default value was 27%, decreasing to 14% when knowledge of VKORCI 
genotype was added to the model. 
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5.3.7 Defining a Hypothetical Concentration Thresholdfor Adverse Drug 
Reactions (ADRs) to Warfarin 
Simulated C,, values in 292 patients given typical doses of warfarm are 
shown in Figure 5.15, as are the threshold C,, values from different simulations, and 
the mean threshold. Sixty two (21%) out of 292 patients suffered an ADR, which 
translated into a threshold total plasma (S)-warfarin concentration above which serious 
ADRs are more likely to occur of 0.8 mg/L (CV = 6%), and translating into an 
unbound concentration of 0.0104 mg/L. 
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Figure 5.15 Simulated steady state total plasma (S)-warfarin concentrations (n 292 
representative individuals). The threshold values from each of the 20 
simulations are shown () with the mean threshold value 
above which ADRs are most likely to occur. 
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5.4 Discussion 
Using clinical trial simulation that incorporated data on in vitro drug 
metabolism into a mechanistic population based phannacokinetic-phannacodynarnic 
model, we have examined the power of in vivo studies to determine differences in the 
disposition of (S)-warfarin and its anticoagulant effect between CYP2C9 genotypes. 
Values of metabolic clearance associated with different genotypes derived from in 
vitro data predicted those from in vivo studies with good accuracy. High concordance 
between the observed and expected response vs. time profiles was also observed. This 
was also apparent when the range of peak INRs observed by (Lindh et al., 2005) (1 to 
5.5) and (Vadher et al., 1999) (1.2 to 4.7) are compared with the simulated range of 1.3 
to 8.2. A wider range in the simulated results is expected due to the larger study size 
employed. 
Previous experimental findings are fully consistent with the present power 
data. There were 4 and 7 false negative cases in pharmacokinetic and 
pharmacodynamic studies, respectively (indicated by the cells highlighted in red in 
Table 5.10). In these, the simulations suggested a lack of adequate power to detect 
differences between wild type and the respective non-wild-type genotype, but the in 
vivo study found a statistically significant difference. However, such an outcome may 
occur by chance, as the level of type 1 error is set at 5%, and hence every 1 out of 20 
studies may indicate a difference that is not a true difference. On the other hand, the 
11 % rate for false negative cases vs the 8% rate for false positives (Table 5.10) may 
indicate some conservatism in our power calculations. These findings might reflect 
some overestimation of the variability in the model parameters. The variances in the 
parameters of the pharmacodynarnic model used in our simulations were based on data 
from only 6 healthy subjects. Nevertheless, there was good overall concordance 
between the predicted and observed percentage of studies (20% vs 21%) successful in 
differentiating (S)-warfarin pharmacokinetics or pharmacodynarnics between the wild 
type and any single other genotype. 
The IVIVE of (S)-warfarin clearance in the different genotypes only took 
into account of in vitro differences in the intrinsic clearance, and possible differences 
in the expression of CYP2C9 between genotypes was not considered. Although some 
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authors have suggested that such a difference may exist (Coller et al., 2002), the 
available data (Coller et al., 2002; Tang et aL, 2001) was not complete enough for 
incorporation into the simulations. In addition, a meta-analysis of the data from these 
studies indicated little or no difference in the extent of CYP2C9 expression between 
the genotypes, thus having a minimal impact on the outcome of the simulations (Figure 
5.16) (Coller et al., 2002; Tang et al., 2001). 
The model prediction indicated that, under the assumptions of 'uniform 
dosage' and 'random recruitment' conditions, at least 90 subjects would be required to 
detect a difference (with 80% power) in the AUC of (S)-warfarin between wild 
genotype and the combination of all other genotypes (Figure 5.7). For the 'genotype 
related dosage' condition, the power is less (over 550 subjects required for a power of 
80%). Also, comparisons between the wild type and the other genotypes would require 
much higher numbers of subjects (e. g. 420 subjects to achieve 80% power in 
discriminating pharmacokinetics between wild-type and *2/*3 under the 'uniform 
dosage' condition). Study sizes of this order are uncommon in traditionally designed 
studies, although they may be achieved in population pharmacokinetic studies using 
sparse data analysis. Four studies assessing the impact of genetic variation in CYP2C9 
on (S)-warfarin pharmacokinetics using randomly selected subjects have been 
reported. One of these (Takahashi et aL, 2003) used 47 subjects and, as predicted by 
our model, failed to detect a difference in pharmacokinetics between wild type and all 
the other genotypes. The three other studies were successful in discerning a difference 
between the wild type and some, but not other, genotypes (Kamali et aL, 2004; 
Loebstein et aL, 2001; Scordo et aL, 2002). For example, each study had 0% power to 
establish differences in the pharmacokinetics between the wild type and the *2/*2 
genotype, due to insufficient numbers of the latter (Table 5.10). 
With regard to pharmacodynamic outcome, the model prediction indicated 
that, under the assumptions of 'uniform dosage' and 'random recruitment', about 250 
subjects are required to achieve 80% power to detect a difference in AUEC between 
wild type and the combination of all other genotypes (Figure 5.7). Under the 'genotype 
related dosage' condition, the power decreased to 60% with 550 subjects. All reported 
studies assessing the impact of genetic variability in CYP2C9 on (S)-warfarin response 
and dosage requirements were sufficiently powered to detect the difference between 
wild type and the combination of all other genotypes (Table 5.10) However, like the 
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pharmacokinetic studies, the power of comparisons between specific genotypes was 
much lower. For example, with a study size of 121, Karnali et aL (2004) had a power 
of around 82% to differentiate the pharmacodynamics of (S)-warfarin between the wild 
type and the *1 /*3 genotype. All other comparisons had powers of less than 80%. The 
experimental observations were fully consistent with these values of power (Table 
5.10). 
When 'genotype adjusted' conditions were considered, a power of only 
60% to detect differences in the AUEC between the CYP2C9 wild type and a 
combination of any other genotype was reached at the maximum study size of 550. 
Thus, the simulations suggest that if INR is used by prescribers to adjust the dose of 
warfarin, any differences between genotypes in respect to pharmacological effects are 
likely to disappear. Of the four studies that investigated differences in the INR of 
warfarin between CYP2C9 genotypes, two were carried out during the initialization 
phase of therapy, before INR can be used to adjust dosage (Lindh et al., 2005; 
Peyvandi et al., 2004), and the other two studies find no significant difference in INR 
between the genotypes (Khan et al., 2004; Loebstein et al., 2001). Thus, when a good 
biomarker is available, as is the case for warfarin, emphasis should perhaps be on 
monitoring and adjustment the dose during maintenance therapy. However, the 
introduction of new methods to improve the prediction of initial dose requirements 
(e. g. genotyping) are likely to be useful. 
It has recently been shown that although other sources of variability such 
as polymorphism in the vitamin K epoxide reductase (VKORCl) gene can explain 
some of the variability in the maintenance dose of acenocoumarol (21.4%), the time to 
achieve adequate and stable anticoagulation was associated with CYP2C9 but not 
VKORC1 genotype (Schalekamp et aL, 2006). A similar outcome may apply to 
warfarin therapy. Our simulations have attempted to determine the increase in study 
power (with respect to the influence of CYP2C9 genotype) as a result of having prior 
knowledge of the VKORCI genotype (Figure 3). 
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Figure5.16A meta-analysis of CYP2C9 expression for wild type (*I*I), 
intermediate (*1*2 and *1*3) and poor (*2*2, *2*-') and *-')*3) 
metaboliser genotypes. Data are expressed as mean ± SD, and the size of 
the circles indicate the number of observations. 
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Even when the effect of CYP2C9 genotype on pharmacodynamics is 
known, the contribution of metabolic variability to overall variation in the 
pharmacological response could be small. Recent studies suggest that between 16.9 
and 19.8% of the variability in response to warfarin therapy is attributable to 
polyrnorphisms of the CYP2C9 gene-(Hillman et aL, 2004; Karnali et aL, 2004; Sconce 
et aL, 2005). Although this proportion may seem small, individualising the dose in the 
absence of good biomarker may require accounting for the sum of the effects of all the 
covariates. Aquilante et al. (2006) have reported that 51.4% of the variation in warfarin 
dose can be attributed to a combination of a number of different genetic and 
environmental factors. 
A simple threshold model, defining the steady state plasma (S)-warfarin 
concentration above which, serious ADRs to warfarin are thought to occur, was 
developed. The threshold total steady state concentration of 0.8 mg/L (0.0104 mg/L 
unbound) was obtained, and should be compared with the mean steady state 
concentration in patients of 0.347 ± 0.22 mg/L reported by (Henne et aL, 1998), and 
the unbound steady state concentration of 0.0036 ± 0.0019 mg[L reported by Scordo et 
aL (2002). The relatively small CV of 6% suggests that such a threshold value could 
prove useful in the clinic. It is perhaps surprising that, given the number of ADRs that 
occur as a result of warfarin treatment, a threshold concentration has not already been 
defined. This is possibly because a good biomarker is already available in the form of 
the INR. However, there is still a significant delay between the commencement of 
warfarin therapy and the availability of the first INR value. Thus, measurement of 
plasma concentrations may provide a faster approach to dosage adjustment. However, 
the threshold concentration calculated in this study and its potential use in preventing 
ADRs should be validated with Rullier studies. 
In conclusion, the results of this study have provided a new perspective for 
investigating the influence of CYP2C9 polymorphisms on the pharmacokinetics and 
pharmacodynamics of warfarin. The results on genotype adjusted dosage, demonstrate 
how the use of a biomarker will dampen any differences in response between CYP2C9 
genotypes and therefore calls into question the validity of genetic screening for dose 
maintenance. However, genotyping is undoubtedly of value for some individuals 
during the initiation of therapy with warfarin. 
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6 MIDAZOLAM 
6.1 Introduction 
Midazolarn (MDZ) is a benzodiazepine drug with several therapeutic 
properties including sedative, hypnotic, anticonvulsant, muscle-relaxant and anxiolytic 
effects (Pieri, et aL, 1981). The effects of MDZ on the human central nervous system 
can be quantified in a number of different ways as the drug affects performance on 
psychophysiologic tests such as reaction time (Mould, et al., 1995) or the 
electroencephalographic (EEG) effect (Koopmans, et aL, 1988) by several different 
mechanisms. 
The effect of MDZ on the EEG has proven useful as a measure of the 
central nervous system pharmacodynamic effects of the drug due to its accuracy, ease 
of quantification (Koopmans, et aL, 1988) and objective nature (Thakor, et aL, 2004). 
An EEG is a record of the electrical activity from the scalp, obtained with the aid of an 
array of electrodes (Tbakor, et aL, 2004). Such electrical activity is generally the result 
of excitatory postsynaptic potentials which may be suppressed by the administration of 
MDZ (Tbakor, et aL, 2004). 
CYP3A4 and CYP3A5 are the only enzymes which contribute to the 
metabolism of MDZ. As such, the metabolism of MDZ to its primary metabolite is 
used as a probe reaction for the activity of these enzymes both in vitro (He, et aL, 
2005; Masica, et aL, 2004; Tateishi, et aL, 2001) and in vivo (Tucker, et aL, 2001). 
CYP3A5, a polymorphic enzyme, has three common genetic variants in the Caucasian 
population which lead to reduced CYP3A5 expression and/or the expression of non- 
fanctional protein. If CYP3A5 is present in a human liver, it may contribute as much 
as 50% to hepatic CYP3A-mediated metabolism of MDZ (Kuehl, et al., 200 1). 
MDZ is metabolised to two metabolites in humans (Figure 6.1), the main 
metabolite, a-hydroxy midazolarn (a-OH MDZ) constitutes around 75 to 90% of the 
total metabolites with 4-hydroxy midazolarn (4-OH MDZ) with the secondary 
metabolite 1', 4-dihydroxymidazolam making up the rest (Desmeules, et aL, 1991; 
Manderna, et aL, 1992; von Moltke, et aL, 1996). 
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a-OH MDZ and 4-OH MDZ are both excreted in the urine, however, the 
main route of elimination is via glucuronidation of a-OH MDZ followed by excretion 
of the glucuronidate in urine (Fabre, et aL, 1988). The role of a-OH MDZ in eliciting 
the effects of MDZ is somewhat unclear and may vary depending on the method used 
to monitor outcome. However, while it is generally accepted that a-OH MDZ is likely 
to contribute to the nervous system effects of MDZ (Crevoisier, et aL, 1983; Ziegler, et 
aL, 1983), some authors have found evidence to the contrary (Greenblatt & Shader, 
1986; Koopmans, et aL, 1988). 
As discussed in the literature review (Chapter 2; Section 2.4.3.3), results 
from literature studies which describe attempts to characterise the relationship between 
the CYP3A5 polymorphism and the in vivo pharmacokinetics of MDZ are somewhat 
contradictory. While some studies have detected a significant influence of CYP3,45 
genotype on the pharmacokinetics of MDZ after an oral dose of the drug (Wong, et aL, 
2004), others have been unable to replicate these results (Eap, et aL, 2004; Floyd, et 
al., 2003). 
A possible reason for the conflicting results with regard to the effect of 
CYP3A5 genotype on the pharmacokinetics of MDZ is the differing size of the studies 
and therefore their possibly varying powers. Therefore, the aim of this section of the 
research project was to simulate the pharmacokinetics and pharmacodynamics of MDZ 
in virtual populations of human subjects. These simulations were used to mimic the in 
vivo studies and to estimate their power to differentiate the phan-nacokinetics and 
pharmacodynamics of MDZ between CYP3,45 genotypes. The effect of sample size on 
the power of such studies will be investigated. 
Since the activity of a-OH MDZ compared to MDZ is an issue of some 
contention, the models described in this chapter were also used to investigate the 
outcome of studies should the proportional pharmacological activity of OH MDZ 
relative to MDZ be altered. 
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Figure 6.1 The chemical structure of MDZ and its two primary metabolites, a-OH 
MDZ and 4-OH MDZ. 
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6.2 Materials and Methods 
6.2.1 The IVIVE Model Parameters 
As described in Chapter 3, as part of the IVIVE process, several key 
parameters are required for input into the model. These include both in vitro 
parameters (such as K.. and V.. ) and parameters gathered from in vivo experiments 
(such as CLR). These were collected from the literature and either entered directly into 
the model or utilised as part of a meta-analysis. The following section describes the 
parameters and their uses. 
6.2.1.1 In Vitro Data 
Data on the in vitro metabolism of MDZ (in the form of Km and V,,, a,, ) 
were collected from published reports (Galetin, et aL, 2004; Huang, et aL, 2004; 
Williams, et aL, 2002) (Table 6.1). 
Intersystem extrapolation factors (ISEFs), were applied as described by 
Proctor et al. (2004) to account for any differences between the intrinsic activity of 
recombinantly expressed CYP enzymes and human liver microsomes (Table 6.2). To 
account for the non-specific binding of MDZ in the experiments described in Table 
6.1, a value of fu,, & was calculated (Table 6.2) and applied to the data as described in 
Chapter 3 (Sections 3.1.1.2 and 3.3). A meta-analysis was then conducted to find the 
overall Vna., and K,,, values for the metabolism of MDZ by each relevant CYP isoform. 
6.2.1.2 Additional Parameters Required for IVIVE 
The additional parameters listed in Table 6.3 were required for scaling the 
in vitro data to human whole body clearance and to the elimination rate constant 
(Chapter 3). These values were then entered into the pharmacokinetic- 
pharmacodynamic model described below (Sections 6.2.2 & 6.2.3). 
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Table 6.1 Parameters describing the in vitro metabolism of MDZ. 
a-OH-MDZ 4-OH 
Reference CYP Vmax Km Vmax Km 
Galetin et al., 2004 3A4 1.96 2.69 2.52 29.0 
3A5 6.7 10.7 0.52 12.1 
Williams et al., 2002 3A4 35 5 40 59 
3A5 72 14 17 116 
Huang et al., 2004 3A4 5.18 2.82 1.35 8.44 
3A5 20 3.56 1.65 11.5 
pmol min-'pmol-' CYP; K, = gM. 
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Table 6.3 Mean pharmacokinetic parameter values of MDZ taken or calculated 
from the literature. 
Parameter Value References 
fu 0.034 Allonen, et aL, 198 1; DJ Greenblatt et al., 1986; D. J. 
Greenblatt et aL, 1984; Moschitto, et aL, 1983; 
Tbummel, et aL, 1996; Section 3.1.1.3. 
B: P 0.55 Allonen, et aL, 198 1; Heizmann, et aL, 1983; Section 
3.1.1.3. 
fUB 0.062 Section 3.1.1.3. 
CLR (L/h) 0.085 Allonen, et aL, 198 1; D. J. Greenblatt et aL, 1984; 
Heizmann, et aL, 1983; Ibrahim, et aL, 2002; Klot7, et 
aL, 1982; Thummel, et aL, 1996; Wandel, et aL, 2000; 
Section 3.3.3. 
V (L/kg) 1.11 (0.25)* Knoester, et al., 2002; Section 3.3.4. 
*Mean (SD); fu = fraction unbound in plasma; B: P = Blood to Plasma 
concentration drug ratio; fUB = fraction unbound in blood; CLR = renal clearance; V 
initial volume of distribution. 
Table 6.4 Additional literature values describing the pharmacokinetics of MDZ and 
a-OH-MDZ. All values are from Knoester et aL (2002) except for Qgý, t 
which was from Yang et aL (2004). 
Parameter Value* 
Qpt (L/h) 20 
V (L/kg) 1.11(0.25) 
k,, (h-1) 10.8(3.18) 
tlag (h) 0.014 (0.012) 
l) k12 (min 0.075 (0.018) 
_ k2l (min 1) 0.206 (0.069) 
KOH-MDZ (If 0.216 (0.09) 
*Mean (SD 
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6.2.2 Pharmacokinetic Model 
6.2.2.1 Concentration of MDZ in the Systemic Compartment 
Plasma concentrations of MDZ (C(t)j) in each individual were generated 
using a two compartment model with first order absorption and a lag time (Knoester, et 
al., 2002): 
C(t), 
D-k.., - FH, j - f,, - FG., -(All + A2i + A3j) V, 
Equation 6.1 
where f, is the oral bioavailability of drug (set to 1), D is the oral dose of 
MDZ (5mg), kaj, FHJ and Vi are the first order absorption rate constant (Table 6.4), 
fraction of the amount of drug reaching the liver escaping first pass hepatic metabolism 
(calculated using Simcyp algorithms; Chapter 3) and the central volume of distribution 
of drug (Table 6.4) respectively, in each individual and AIi, A2i and Mi are given by: 
Al, 
(k 
2 Equation 6.2 
A21 = 
(k2l, 
l - 
A2,, ). e -, 
12, *I, Iag, 
Equation 6.3 (Al. 
i - "12j )- (k 
., - 
ý2. 
i 
) 
A3 
(k21j 
- k,,, 
). e -k..,. 
t-flag. 
Equation 6.4 (Aj. 
j - k,. i) i-k, Ji 
where k2l, i is the transfer rate constant from the peripheral to the central 
compartment and ai and Pj are the hybrid rate constants associated with the distribution 
and elimination phases, respectively, as defined in Chapter 4; Equations 4.5 and 4.6 
6.2.2.2 Concentration of a-OH MDZ in the Systemic Compartment 
Equation 6.5 describes the plasma concentration - time course of a-OH 
MDZ: 
C(t)OH-MZ, 
j ý 
C(t)OH-MDZ(Istpass)j + C(t)OH-MDZ(systemic), l Equation 6.5 
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where C(t)OH-MDZ(Ist pass), j and C(t)OH-MDZ(systemic), j are first-pass and systemic 
components. These components were described by Equations 6.6 and 6.11, 
respectively: 
DM - f, - FG, 1 - FH, 1 - k., i - fm, - kl 0., C(t)OH-MDZ(systemic), 1 ý- VOH-MDZ, 
1 
. (Al m, + A2m, + A3m, + A4M1) E 6.6 
where VOH-MDZ, i is the volurne of distribution of a-OH MDZ (Table 6.4). 
Assuming a-OH MDZ is the only metabolite of MDZ [accounting for around 75 - 95% 
of the total (Desmeules, et aL, 1991; Mandema, et aL, 1992; von Moltke, et aL, 1996)] 
and that no further metabolism of a-OH MDZ occurs (Gorski, et aL, 1994), the 
following equation was used to determine the fraction of MDZ converted to a-OH 
MDZ after an iv bolus dose in P' individual (fin): 
fmj = 
CLMaMZJ 
CLi Equation 6.7 
where CLmmz, i is the total metabolic clearance of MDZ to a-OH MDZ in 
the P' individual, and CLi is the total clearance of MDZ, including renal clearance in 
the ih individual (both values were estimated using the Simcyp(R) algorithm). Almi, 
A2mi, A3mi and A4mi are given by: 
Alm 
(k2l. 
i - 6r) - e-- 
-t-flag, 
Equation 6.8 iý 0i - ai) * 
(kaj 
- ai) * (k(OH-MDZ), i a) 
A2m, = 
(k2l, 
i -, 8, 
). e-l"-t1ag, Equation 6.9 
(ai A) * 
(kaj 
-Aj * 
(k(OH-MDZ), 
i - 16) 
A3m, = 
(k2lj 
- 
kaj) -e -k,., -Wlag, Equation 6.10 (ai - k,,, ) - (fl. - 
ka, 
i)'(k(OH-MDZ), i - 
ka) 
A4m, = 
(k 
21J -k (amz), j) -e 
k(OH. m=., -t-tIag, 
Equation 6.11 (a, - 
k(OH-MDZ), 
i 
)' (fli 
- 
k(OH-MDZ), 
I 
)' (ka, 
j - 
k(OH-MDZ) 
where k(OH-MDZ), i is the elimination rate constant of a-OH MDZ (Table 
6.4). 
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The plasma concentration of a-OH MDZ contributed by its first-pass 
fonnation is given by: 
C(t)OH-MDZ(Istpass), 
l 'ý 
Dm - f, - 
(1 
- FG, j - FH,, 
). kaj - FH, l [e k,,,. t-Uag, _e kOH. mDLj-t-tlagj Equation 6.12 VOH-MDZ, 
l * 
(k 
OH-MDZj -k aj 
) 
6.2.2.3 Concentration of MDZ in the Effect Compartment 
The following equation was used to calculate the concentration of MDZ in a 
hypothetical effect compartment: 
Ce(t), =D-k,. i - 
k, o. i - FH,, - f, - FG., - (Ali + A2, + A3i + Mi V, 
Equation 6.13 
where kOj is the rate constant defining removal of drug from the effect 
compartment (Table 6.5). A1j, A2j, A3 i and Mi are given by: 
Ali = 
(k 
21,1 - a, 
) 
-e 
-a,. t-Uag, 
Equation 6.14 (8, 
- al) - 
(k,,, 
i -a, 
) 
- 
(kýO, 
j -a, 
) 
A2j 
(k2l. 
] -A). e-A-t-tlag, Equation 6.15 (ai - A). 
(kaj 
- A) - (k, O., - A) 
A3 
(k 
21.1 -ka, l) -ek,,. 
t-Uag, 
Equation 6.16 ' "ý (ai 
-ka, j 
)-(, 8, - k., j 
)- (k 
eo, j -ka, j 
A4j = 
(k2l. 
1 - keo, l) -ek. 
O. j-t-tlag, 
Equation 6.17 (a, 
- k, o,, 
). (, 61 - k, o,, 
)- (k,,, ----k-eoý. 
j 'i 
6.2.2.4 Concentration of a-OH MDZ in the Effect Compartment 
Equation 6.18 was used to calculate the concentration of a-OH MDZ in the 
same hypothetical effect compartment as MDZ: 
Ce(t)OH-MDZ, 
l = 
Ce(t)OH-MDZ(Istpass)j+ Ce(t)OH-MDZ(systemlc)j Equation 6.18 
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where Ce(t)OH-MDZ(Ist pass), j and Ce(t) OH-MDZ(systemic)j are first-pass and 
systemic components. These components were described by Equations 6.19 and 6.25, 
respectively: 
Dm - f. - F,., - F,., - k.,, - fm. - k,,. i Ce(t)OH-MDZ(systernjc)j ý 
VOH-MDZi . (Al m, + A2m, + A3mi + A4m, + A5m, 
) 
E 6.19 
where the rate of removal of a-OH MDZ from the effect compartment was 
assumed to be the same as that for MDZ (keo - Table 6.5). Almi, A2mi, A3mi, A4mi 
and A5mj are given by: 
Almi = 
(k 
21J -k (OH-MOZ), i e 
-k(OH-M=. i-t-tlag, 
mDz), i) - 
(pi - 
k(OH-MDZ). 
i)'(k.,, -k 
Ta-i k -(0 H (OH-MDZ), i 
A2m, = 
(k2l. 
1 - cc, 
) 
-e 
-a. -t-tiag, 
Cti)'(ka, i - aj. 
(k,, 
O. i - aj* 
(k(OH-MDZ)j -a 
A3m, = 
(k2l, 
i - 6, 
)- e-A-t-tlag, 
(ai (kaj -, 8. ) - (k. o, i - A) * 
(k(OH-MDZ),! 
A4m, = 
(k2l, 
i - k., j) -e 
-k.,,. t-tlag. 
(al - ka. i)- 
(fl, - 
ka, 
i)* 
(keO, 
i - ka, i). 
(k(OH-MDZ), 
i - 
Qi 
A5mi = 
(k2l, 
i - ke0j 
)-e 
(ai -k, o,, 
). (p, -keO, I)*(ka, i -k, o, i). 
(k(OH-MDZ), 
i -keO, I) 
Equation 6.20 
Equation 6.21 
Equation 6.22 
Equation 6.23 
Equation 6.24 
The contribution of the first-pass forination of a-OH MDZ to its effect 
compartment concentration was described by: 
Ce(t)OH-MDZ(Istpass), 
i = 
Dm - f, - 
(1 
- FG,, - FH,, 
). k. 
'j - 
FH, 
i - 
keo, 
j 
. 
(Alm, + A2m, + A3m, ) E 6.25 VOH-MDZj 
where: 
Ali =e (keO, 
i-k(aMZ), i 
)' (k 
a, j -k (aMZ),! 
Equation 6.26 
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A2i =e 
-k., -t-tlag, 
(k(, 
mz), i -keO, i 
F-k-, 
'I 
k e0j 
A3 e ýk 
e0j - k,, i) - 
(k(, 
Mz), i - k, j) 
6.2.3 Pharmacodynamic Model 
Equation 6.27 
Equation 6.28 
Concentrations of MDZ and a-OH MDZ were calculated in a hypothetical 
effect compartment (Equations 6.13 & 6.18). The pharmacokinetic and 
pharmacodynamic data were linked assuming an excitatory sigmoidal EInax (EEG 
activity) model such that the combined effects of MDZ and a-OH MDZ on the human 
central nervous system (E(t)i) were modelled assuming an additive interaction between 
the two chemical moieties (Mandema, et aL, 1992) (Equation 6.29): 
E(t)i = Ea + 
(Emax. 
1 -Eo). (Ce(t)i)" + 
(E 
max. 2 -E0)- 
(Ce(t) 
OH-MDZ, i 
YJ 
Equation 6.29 
(EC50.1, 
I)YI + 
(Ce(t)i)r' (EC50.2.1)r' + (Ce(t)OH-mozj) Y, 
where EO is the baseline EEG effect (%) in the absence of drug (Table 6.5), 
E.,,, is the maximum drug effect (Table 6.5) and Ce(t)j, and CC(t)OH-MDZ, i are the 
concentration of active moiety (N4DZ) and metabolite ((x-OH MDZ), respectively, 
EC501, j, and EC502j are the concentrations of parent and metabolite, respectively, in the 
effect compartment which are associated with half the E. (Table 6.5) and yi is the 
Hill-coefficient (Table 6.5), in each individual. 
6. Z4 Study Design 
Individual plasma MDZ and a-OH MDZ concentration and response vs. 
time Profiles following administration of oral MDZ were simulated for all time points 
between 0 and 5h. For the purposes of data-analysis, samples were taken every 15 
minutes (20 samples). Simulated plasma drug concentration- and response-time 
profiles in expressors and non-expressors of CYP3A5 were compared using a range of 
population sizes (n). For all the simulations n was set at 5,10,20,50,100,200 or 400. 
Twenty simulations were run for each study size. 
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Table 6.5 Literature values describing the pharmacodynamics of MDZ. All 
parameters were from Mandema et aL (1988), except for EO and Em. 
which were from Koopmans et aL (198 8). 
Parameter Value* 
Eo (1/o) 100 
Em,,, l (%) 36 
Em. 2 (0/o) 42 
ECsoi (ng/ml) 77(15) 
EC502 (ng/Ml) 98(17) 
ni 3.1(0.3) 
n2 3.1(0.5) 
k, ol (min-') 0.77(0.23) 
ke02 (Min7l) 0.56(0.08) 
*Mean (SD) 
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6.2.5 Sensitivity of Study Po wer to th eA ctivity of a- OH MDZ 
In addition to the simulations and analysis described above (which will 
now be referred to as the 'default setting'); further simulations were carried out to 
assess the sensitivity of study power to the activity of a-OH MDZ. 
Simulations were carried out under two separate conditions: (i) a-OH 
MDZ was assumed to be pharmacologically inactive and have no effect on the EEG 
measurement and, (ii) a-OH MDZ was assumed to be active and have a different ECso 
value to MDZ. Based on the analysis of Mandema et aL (1992) the activity of a-OH 
MDZ was assumed to be 78% that of MDZ. 
Overall, 140 simulations were carried out using up to 400 subjects in each 
study set (a total of 15,700 virtual subjects). 
6. Z6 DataAnalysis 
Values of AUC and AUEC (decrease in amplitude of the EEG measure) 
up to 5 hours were calculated using the trapezoidal rule. For the purposes of this study 
we assumed that no measurement error occurred. The probability of detecting 
statistically significant differences in pharmacokinetics and pharmacodynamics 
between phenotypes was assessed using ANOVA (SPSS v 12; SPSS Inc. 2003). The 
number of studies out of the 20 simulations that led to a statistically significant 
difference in AUC (or AUEC) between expressors and non-expressors of CYP3A5 
was recorded as the power of that particular trial. 
Clearance values and other pharmacokinetic parameters obtained from the 
IVIVE model were compared with those values observed in vivo. The accuracy of the 
resulting concentration- and effect-time profiles were assessed by comparing them 
with those observed in vivo by Manderna et aL (1992) and Wandel et aL (2000). The 
EEG effect of MDZ vs time was validated by comparison with that observed in vivo by 
Koopmans et aL (1988). In this case, the metabolite was assumed to be inactive to 
match the assumptions of Koopmans et aL (198 8) in their study. 
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6.3 Results 
6.3.1 Model Validation 
Comparisons of observed (Mandema, et aL, 1992; WandeL et aL, 2000) 
and simulated plasma concentration - time curves in a Caucasian population of MDZ 
are shown in Figure 6.2 and Figure 6.3, respectively. 
A comparison of observed (Koopmans, et aL, 1988) and simulated effect - 
time curves (in randomly selected individuals) is shown in Figure 6.4. 
A summary of some mean (± SD) simulated pharmacokinetic parameters 
that describe the data in Caucasian populations of subjects compared with the weighted 
means of those reported in the literature are given in Table 6.6. 
6.3.2 Power of Studies 
The power of studies to detect a statistically significant difference in the 
AUC of MDZ between CYP3A5 expressors and non-expressors was around 80% with 
240 subjects (Figure 6.5). 100% power was reached when 400 subjects were used. 
Around 320 subjects were needed to differentiate a difference in the phannacokinetics 
of OH-MDZ between expressors and non-expressors of CYP3A5 (Figure 6.5). 
6.3.2.1 Midazolarn Only Active 
When MDZ itself was assumed to be the only active moiety, around 360 
subjects were required to achieve 80% power to observe a difference in the 
phannacodynarnic effect (AUEC) of MDZ between expressors and non-expressors of 
CYP3A5 (Figure 6.6). 
6.3.2.2 Midzolam and a-OH MDZ Contribute to EEG Effect 
When a-OH MDZ was assumed have 78% the activity of MDZ 
(Manderna, et aL, 1992), the power of studies to differentiate a difference in the 
pharmacodynarnics of MDZ between expressors and non-expressors of CYP3A5 was 
reduced. Power was 55% with the maximum number of subjects studied, 400 (Figure 
6.6). 
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Figure 6.2 Observed (Mandema, et al., 1992); (in 8 real subjects; -) and 
predicted (in 20 virtual subjects; ) plasma concentration-time profiles 
of MDZ over 5 hours in Caucasian individuals of unspecified phenotype. 
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Figure 6.3 Observed (Wandel, et al., 2000); (in 15 real subjects; -) and 
predicted (in 20 virtual subjects; ) plasma concentration-time profiles 
of MDZ over 5 hours in Caucasian individuals of unspecified phenotype. 
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Figure 6.4 Observed (Koopmans, et al., 1988); (in 6 real subjects; -) and 
predicted (in 20 virtual subjects; ) effect (EEG inhibition)-time 
profiles of MDZ over 5 hours in Caucasian individuals of unspecified 
phenotype. 
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Table 6.6 A summary of observed and predicted pharmacokinetic parameter values 
of MDZ. Predicted values are the average of the mean values from 10 
clinical trial simulations. 
Parameter 
Q 
0. L. C5 
ý14 C 
d. 
Cj 
Allonen et al., 1981 16.98 (2.58) 
Greenblatt et al., 1984 
33.06 (9.54) 
3 . 31.8 (8.892) 
C He et al., 2005 88.2 Heizmann et al., 1983 - 1938 (5.16) 0 C 
-14 
Ibrahim et al., 2002 29(6) 
C Klotz et al., 1982 27.92 (10.29) 
Koopmans et al., 1988 88.9 (38.2) 
'A v Lepper el aL, 2005 22.3 Manderna et al., 1992 165.7 (93.67) 331.3 8 (5.29) 0.24 (0.108) 25(14.7) 
Masica et al., 2004 91.98 (45.54) 22.98 (4.38) 0.301 (0.135) 14.5(7.4) 
Tateishi et al., 2001 103.7 (60.3 )) 24.72 (7.44) 0.28 (0.094) 10.3(5.4) Z Thummel et al., 1996 84.78 (48.42) 22.2(6.84) 0.32(0.10) 
Wandel et al., 2000 68.58 (24.78) 18.6(3.36) 0.30(0.12) 
Wong et al., 2004 71.28 (36.6) 26.04 (13.02) 
Yu et al., 2004 28.4(12.5) 
WEIGHTED MEAN 77.4(33.5) 24.1(6.1) 0.29(0.11) 14.5(7.8) 
SIMULATED MEAN 100.3 (96.0) 25.6(9.0) 0.22(0.11) 8.6(5.2) 
He et al., 2005 115.5 - - - 
0 Lepper et al., 2005 - 26.8 - - 
Won- et al., 2004 115.1 (41.88) 36.12 (4.92) - - 
Yu el al., 2004 32.3 (12.4) - - 
WEIGHTED MEAN 115.3 (41.9) 30.8(10.5) - - 
SIMULATED MEAN 146.7 (123.5) 30.4(7.6) 0.17(0.09) 6.6(4.5) 
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Table 6.7 Powers of the reported studies to detect difference in the 
pharmacokinetics and pharmacodynamics of MDZ compared with the 
reported outcomes (only pharmacokinetics is reported by the in vivo 
studies). Cases where prediction matched observation are highlighted in 
green, those where it did not are highlighted in red. Crosses (Y-) indicate 
failure of the study to show a statistically significant difference between 
phenotypes (v) indicate success of the study in showing a statistically 
significant difference between the phenotypes. 
Power PD 
Reference n PK Power without active with active 
difference? - PK metabolite metabolite 
Lepper et aL, 2005 58 x 10 76 
Wong et aL, 2004 67 V/ 20 12 7 
Shih et aL, 2002 42 x555 
Eap et al., 2004 21 x005 
Floyd et aL, 2003 57 x 10 78 
Yu et aL, 2004 19 x005 
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Figure 6.5 The power (%) of simulated studies to show significant differences in the 
AUC of parent drug (MDZ; 0) and its metabolite (OH-MDZ; o) between 
different CYP33A5 phenotypes vs the number of subjects in each study 
(n). 
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Figure 6.6 The power (%) of simulated studies to show significant differences in the 
AUEC of parent drug between different CYP3A5 phenotypes, assuming 
(i) no activity of OH-MDZ (0) and, (11) 78% activity (Mandema, et al., 
1992) of MDZ (o) vs the number of subjects in each study (n). 
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6.4 Discussion 
Clinical trial simulations that incorporated data on in vitro drug 
metabolism into a mechanistic population based pharmacokinetic-phannacodynarnic 
model for EEG response after oral administration of MDZ were implemented. We 
have used these simulations to examine the power of in vivo studies to determine 
differences in the disposition of MDZ and its central nervous system effects (as 
measured by EEG response) in relation to CYP3A5 phenotype. 
The derivation of oral clearance, systemic clearance, oral bioavailability 
and Cm. from in vitro data recovered that reported from in vivo studies with good 
accuracy (within two-fold for all parameters) in both expressors and non-expressors of 
CYP3A5 (Table 6.6). Figure 6.2 and Figure 6.3 demonstrate good concordance 
between the mean observed (Mandema, et aL, 1992; Wandel, et aL, 2000) plasma 
MDZ concentration-time profiles and the expected range of profiles predicted by our 
simulations. 
The effect-time profiles also matched those observed in vivo with good 
accuracy (Figure 6.4) as the magnitude and time course of response was consistent 
with that observed by Koopmans et aL, 1988 (Figure 6.4). 
In general, our data are consistent with the published studies on the impact 
of the CYP3A5 polymorphism on MDZ pharmacokinetics (Table 6.7). Of the 6 studies 
that have been conducted to determine the impact of the CYP3A5 polymorphism on 
MDZ pharmacokinetics, 5 have been unsuccessful. We estimated that these studies 
would have needed to employ at least 240 subjects to reach 80% power, and around 
120 subjects to reach greater than 50% power. However, the in vivo studies used much 
smaller numbers of subjects, ranging from 19 to 67 (Table 6.7) and hence achieved 
powers of only 0- 10% (Table 6.7). The single study that was successful in 
determining a difference in pharmacokinetics between genotypes used the largest 
sample size of 67 (Wong, et aL, 2004), achieving the highest power of all the studies of 
20% (Table 6.7). Nevertheless, this outcome is a false negative and suggests that either 
the model underpredicts study power or that the study in question produced a false 
positive result. The latter explanation is the most likely, given the consistency of the 
simulated outcomes and predicted powers with what is observed in vivo. 
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Recently published data have described polymorphic CYP3A5 expression 
in the gut (Paine, et aL, 2006). However, at the time of model construction, the latter 
information was not available, neither was any data on the relative abundance of 
CYP3A5 in the gut published in the literature. As a result, the CYP3A5 content of the 
gut is incorporated into a general 'CYP3A' content (Chapter 3; Section 3.3.1.2) and no 
consideration is given to the polymorphic expression of CYP3A5 within the gut. Given 
the low bioavailability (F) of MDZ (0.29 in non-expressors of CYP3A5; Table 6.6) it 
is clear that, had such enteric, polymorphic expression been incorporated into the 
model, the relationship between CYP3A5 phenotype and MDZ pharmacokinetics may 
have been more apparent in the simulations and the power to determine such 
differences would have increased. However, given the consistency of the predicted 
powers with the outcomes observed in vivo, it may be postulated that such an increase 
may not have affected the results to any great degree. Furthermore, using a recent 
version of the Simcyp9 software (version 6; www. simcyp. com) it was possible to 
carry out a simulation to predict the change in FG when CYP3A5 is assumed to be 
absent from the gut as it is in a non-expressor of the enzyme. The simulation 
demonstrated an increase in the average value of FG from 0.41 to 0.54. This is further 
evidence to suggest that had such polymorphisms been incorporated into the model, 
the impact on the results is likely to have been minimal. 
In conclusion, the results of this study have provided some explanation as 
to why there is an apparent discrepancy in the results of published in vivo studies to 
discern a difference in the pharmacokinetics of MDZ between CYP3A5 phenotypes. 
Where some studies are successful, others fail. This may be due to the fact that study 
sizes are generally low compared to what would be required to achieve 80% power to 
discern such differences (240 subjects). The powers, therefore all fall short of 80%, or 
even 50% (0 to 20%). Any reported success (e. g. Wong et aL, 2004) may be the result 
of type II statistical errors or simply luck. It is interesting to note the lack of 
pharmacodynamic studies of MDZ in the literature. Given the general abundance of 
pharmacokinetic-related studies of MDZ this is unusual and may perhaps be due to 
underreporting of negative results by prominent journals in the literature (See 
Discussion; Section 9.3). 
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7 OMEPRAZOLE 
7.1 Introduction 
71.1 H+, kA TPase 
The pH of gastric acid is approximately between 2 and 3 in the stomach 
lumen when in the fasting state (Neymour, 1993). This acidity is maintained by the 
enzyme H, Ký ATPase, also known as the proton pump. H+, Ký ATPase is situated in 
the parietal cells of the gastric mucosa, the enzyme transports one hydrogen ion into 
the stomach lumen against a concentration gradient of up to 3 million to 1 in exchange 
for one Potassium ion (Sachs et al., 1995). 
The reduction of acid secretion by W, K" ATPase inhibition is a target for 
two different categories of drugs. 142-receptor antagonists inhibit the signalling 
pathway that leads to activation of the enzyme whilst proton pump inhibitors directly 
inhibit the enzyme (Klotz et al., 2004). 
7.1.2 Proton Pump Inhibitors 
Proton pump inhibitors are a group of drugs that, when activated, form a 
disulphide bond with, and irreversably deactivate, 11+, W AT? ase (Klotz et al., 2004). 
In doing so they may lower acid secretion by as much as 99% (Junghard et aL, 2002; 
Lind et aL, 1983). This mechanism is utilised in the treatment of a number of diseases 
which are associated, either directly or indirectly, with an excess of acid secretion in 
the stomach (e. g. peptic ulcer disease and gastroesophageal reflux disease) (Klotz et 
al., 2004). The lack of acid also helps to ease the pain associated with indigestion and 
heartburn when they occur as a result of excess acid secretion (Klotz et al., 2004). A 
member of the proton pump inhibitor family of drugs, omeprazole (OMZ) is also used 
in combination with antibiotics (e. g. amoxicillin with clarithromycin or metronidazole) 
to eradicate Helicobacter pylori (H. pylori), which is the causative factor in the 
majority of peptic and duodenal ulcers (Beil et al., 2001). 
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7.1.3 Omeprazole 
Omeprazole (OMZ) was the first proton pump inhibitor to be successfully 
developed and marketed as such (Kendall, 2003). It is acid-transformed in the parietal 
cells of the stomach to its active form, a sulphenamide. The latter compound binds 
tightly to W, Ký-ATPase, deactivating it, thus increasing stomach pH in gastric acid 
disorders (Klotz et al., 2004). This reaction is reversible, although dissociation occurs 
very slowly. 
There is wide interindividual variability both in the pharmacokineties of 
OMZ and in response to the drug. CYP2C 19 is responsible for between 71 and 99% of 
the metabolism of the drug (Abelo et aL, 2000; Karam et aL, 1996; Yamazaki et aL, 
1997), and its 5-Hydroxylation pathway is often used as a probe reaction for CYP2C 19 
both in vitro (Tucker et al., 2001) and in vivo (Wedlund & Wilkinson, 1996). 
Many studies have attempted to define the relationship between CYP2C 19 
phenotype and OMZ pharmacokinetics and/or pharmacodynamics. All of the studies 
which report attempts to discern the relationship between OMZ pharmacokinetics and 
CYP2C 19 genotype have been successful (Fu et aL, 2004; Hu et aL, 2005; Kita et aL, 
2001; Qiao et aL, 2006; Yin et aL, 2004). In contrast, reports attempting to explain the 
wide interindividual. variability in response to OMZ based on CYP2Cl9 phenotype 
have been conflicting. However, this inconsistency may be due to the different 
endpoints used in the various studies, while successful studies have generally utilised 
stomach acid secretion as a measure of response (Egan et aL, 2003; Hu. et aL, 2005; 
Kita et aL, 2001; Shimatani et aL, 2003), others have investigated cure rates of 
helicobacter pylori infection, gastric acid reflux. disease or the occurrence of adverse 
events as the endpoint (Egan et al., 2003; Ohkusa et al., 2005). 
The aim of this study was to simulate the pharmacokinetics of OMZ and 
acid inhibitory response to the drug in virtual populations of human subjects. These 
simulations were used to mimic the in vivo studies and to estimate their power to 
differentiate the pharmacokinetics and pharmacodynamics of OMZ between CYP2C 19 
phenotypes. The ultimate aim was to help explain the failure of in vivo studies to detect 
such differences in pharmacodynamics, by assessing the effect of sample size and 
other aspects of study design, on the power of such studies. 
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7.2 Materials and Methods 
72.1 The IVIVE Model Parameters 
As described in Chapter 3, as part of the IVIVE process, several key 
parameters are required for input into the model. These include both in vitro 
parameters (such as K. and V. ax) and parameters gathered from in vivo experiments 
(such as CLR). These were collected from the literature and either entered directly into 
the model or utilised as part of a meta-analysis. The following section describes the 
parameters and their uses. 
7.2.1.1 In Vitro Data 
Data on the in vitro metabolism of OMZ (in the fonn of K,, and V.. ) 
were collected from published reports (Abelo et aL, 2000; Karam et aL, 1996; 
Yamazaki et aL, 1997) (Table 7.1). 
Intersystem extrapolation factors (ISEFs), were applied as described by 
Proctor et al. (2004) to account for any differences between the intrinsic activity of 
recombinantly expressed CYP enzymes and human liver microsomes (Table 7.2). To 
account for the non-specific binding of OMZ in the experiments described in Table 
7.1, a value of fuý,, ic was calculated and applied to the data as described in Chapter 3; 
Sections 3.1.1.2 and 3.3. ISEF values and values of fumic are shown in Table 7.2. A 
meta-analysis was then conducted to find the overall Vmax and Km values for the 
metabolism of OMZ by each relevant CYP isoform. 
7.2.1.2 Additional Parameters Required for IVIVE 
The additional parameters listed in Table 7.3 were required for scaling the 
in vitro data to human whole body clearance and to the elimination rate constant 
(Chapter 3). These values were then entered into the pharinacokinetic- 
pharmacodynamic model described below (Sections 7.2.2 & 7.2.3). 
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Table 7.1 Parameters describing the in vitro metabolism of OMZ. 
5-Hydroxylation O-Demethylation Sulfoxidation 
Reference CYP Vmax Kn VMRX K Vn,,, Kn 
Abelo et aL, 2000 2C9 1.71 209 0.77 107 
2C19 6.95 5 1.48 3.04 - - 
3A4 4.04 342 0.74 262 7.3 82.9 
Yamazaki et aL, 1997 2CI9 8.3 6.6 - - - - 
3A4 2.4 60 - - 13 140 
Karam et aL, 1996 2C8 3.3 300 - - - - 
2C19 10.2 12.2 - - - - 
3A4 10.9 50 - - 18.2 71 
Vmax - pmol/min/pmol P450; Km - gM. 
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Table 7.3 Mean pharmacokinetic parameter values of OMZ taken or calculated 
from the literature. 
Parameter Value References 
fu 0.064 Regardh et aL, 1985; Section 3.1.1.3. 
B: P 0.6 Regardh et aL, 1985; Section 3.1.1.3. 
fUB 0.11 Section 3.1.1.3. 
CLR (L/h) 0.034 Andersson et aL, 1990a; Andersson et aL, 1990b; 
Regardh et aL, 1990; Section 3.3.3. 
V (L/kg) 0.236 (0.708)* Regardh et aL, 1990; Section 3.3.4. 
*Mean (SD); fu = fraction unbound in plasma; BT = Blood to Plasma concentration 
drug ratio; fUB = fraction unbound in blood; CLR = renal clearance; V= initial volume 
of distribution. 
Table 7.4 Additional literature values describing the pharmacokinetics of OMZ. 
Parameter Value* Reference 
Vomz (L/kg) 0.236 (0.708) Regardh et aL, 1990 
k,, (h-1) 6(1.8) Andersson et aL, 1990 
*Mean (SD) 
198 
Chapter 7: Omeprazole 
Z22 Pharmacokinetic Model 
Values for klo, i, FHJ and FGj (Calculated using SimcypS algorithms - 
Chapter 3) were entered into a phannacokinetic-phannacodynarnic model, adapted 
from Katashima et aL (1998). In the latter model, plasma concentrations of OMZ in 
each individual (C(t)(omz), j) were described using a one-compartment model with first 
order absorption: 
D-ka,, , FH, j - f,, - 
FG, 
j [e, klo,, -t -ký, -t] C(t)(Omz), i xe Equation 7.1 VOMZ, l '(ka, l-klOj 
T 
wheref, is the oral bioavailability of OMZ (set to 1), D is the oral dose of 
OMZ (20mg), kaj, and Vomz, i are the absorption rate constant and the steady state 
volume of distribution in the ifl' individual, respectively (Table 7.4). 
72.3 Pharmacodynamic Model 
The pharmacokinetic and pharmacodynamic data were linked assuming a 
pharmacokinetic-pharmacodynamic model including the apparent turnover process of 
H+Ký-ATI? ase (Katashima et al., 1998). In this model, the drug in the plasma is 
transformed in the parietal. cells to the active form, which reacts with active ffKý- 
ATPase with a second rate constant, K, to inactivate the H+Ký-ATI? ase (Figure 7.1). 
The total amount of H+Ký-ATPase (Et) is kept at a constant level, assuming that active 
ff'-ý-ATPase (Ea) is biosynthesized at a constant rate (Ks), and that H+Ký-ATPase is 
eliminated with a first order rate constant (ki) (Figure 7.1). 
Assuming that the inhibitory effect on gastric acid secretion is proportional 
to the ratio of Ei to Et, the response to OMZ in each individual could be described by 
Equation 7.2 (Katashima et d, 1998): 
dEc 
-Tt = 
(K 
* C(t)(Omz), i 
[(k, + k2 Equation 7.2 
where K, c, ki, k2 and cc are a constant for the reaction of orneprazole with 
IT'Ký-ATPase (Table 7.5), the gastric acid secretion ratio (Ea/Et), the apparent 
elimination rate constant of H+Ký-ATPase, the apparent recovery rate constant of 
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H+Ký-ATPase and the gastric acid inhibition ratio (Ei/Et), respectively. The apparent 
turnover rate constant of ffKý-ATPase (k; Table 7.5) is equal to the sum of k, and k2. 
By definition: 
cc= 1-c 
therefore: 
d. -c 
-Tt = (K -C (t), Oý., j - [I - --CD - (k - EC) 
Equation 7.3 
Equation 7.4 
Since the initial value for cc can be assumed to be 0 (no inhibition of cc 
11+Ký-ATPase prior to administration of OMZ), the above equation was solved for a 
series of time points. 
72.4 Study Design 
Individual plasma OMZ concentration and response vs. time profiles 
following administration of oral OMZ were simulated between 0 and 8h. For the 
purposes of data-analysis, samples were taken every 15 minutes (32 samples). 
Simulated plasma drug concentration- and response-time profiles in EMs and PMs 
(with equal numbers of each phenotype in each study arm) were compared using a 
range of population sizes (n). For all simulations n was set at 25,50,100,200,300 or 
400. Twenty simulations were run for each study size. 
Study size and the number of subjects of a given phenotype/genotype in 
the study population where chosen using two different techniques: 
(i) Study sizes were chosen arbitrarily and the proportion of PM subjects 
within the study population was set according to their natural occurrence in the 
Caucasian population, and 
(ii) To our knowledge, there are 17 literature studies which investigate the 
relationship between CYP2C19 phenotype and the pharmacokinetics and/or 
pharmacodynamic of OMZ (Table 7.6). Since the majority of these studies are carried 
out in oriental populations, the abundance of poor metaboliser phenotypes in these 
studies tends to be different to that seen in the Caucasian population, study sizes and 
the proportion of each phenotype/genotype were also chosen in order to mimic those 
seen in the literature studies. 
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Overall, 580 simulations were carried out using up to 400 subjects in each 
study set (a total of 57,200 virtual subjects). 
7. Z5 Data Analysis 
Values for (i) the area under the concentration-time curve (AUC) of OMZ, 
and (ii) the area under the effect-time curve for OMZ (AUEC; defined as the area 
associated with the decrease in acid secretion with time), were calculated using the 
trapezoidal rule. For the purposes of this study we assumed that no measurement error 
occurred. The probability of detecting a statistically significant difference in 
pharmacokinetics and pharmacodynamics between phenotypes was assessed by 
comparing values for the AUC and AUEC, respectively, using ANOVA (SPSS v 12; 
SPSS Inc. 2003). The number of studies out of the 20 simulations that led to a 
statistically significant difference in AUC (or AUEC) between phenotype groups was 
recorded as the power of that particular trial. 
Clearance values and other pharmacokinetic parameters resulting from the 
IVIVE model were compared with those values observed in vivo (Andersson et al., 
1990a; Andersson et al., 1990b; Regardh et al., 1990). It should be noted that for the 
purposes of this study it was assumed that H+Ký-ATPase inhibition is comparable to 
stomach PH. However, due to the nature of the pharmacodynamic outcome of the 
simulations (percentage HK-ATPase inhibition), and the lack of adequate conversion 
information in the literature, it was not Possible to validate the simulations by 
comparison with what is observed in vivo (commonly, stomach PH rather than % acid 
inhibition). 
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Figure 7.1 A schematic representation of the pharmacokinetic-pharmacodynamic 
model for the action of OMZ on H'K'-ATPase in parietal cells. Ks = 
biosynthesis rate of active H+K+-ATPase; Ea = amount of active H+K+- 
ATPase; Ej = amount of inactive H+K+-ATPase; K= apparent reaction 
rate constant of omeprazole with active H'K+-ATPase; k, = elimination 
rate constant of both active and inactive H'K+-ATPase; k2 = apparent 
recovery rate constant of inactive to active H+K+-ATPase. 
Table 7.5 Literature values describing the phannacodynamics (inhibition of acid 
secretion) of OMZ (Katashima el al., 1998). 
Parameter Value* 
K (ýtM-'. h-') 1.3 )43 ) (0.172) 
k (h-1) 0.0252 (0.0019) 
*Mean (SD). 
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7.3 Results 
Z3.1 Model Validation 
Table 7.7 shows a comparison of simulated vs observed pharmacokinetic 
parameters of OMZ in both extensive (Table 7.7 (A)) and poor metabolisers (Table 7.7 
(B)). All simulated parameters are within two-fold of the observed data (Table 7.7). 
Mean simulated concentration vs. time profiles in EMs and PMs are shown 
in Figure 7.2. Unfortunately, no observed concentration-time data were available in 
PM subjects. Andersson et aL (1990a) provided concentration-time data but did not 
specify the phenotype of the subjects. Accordingly, the data from Andersson et aL 
(1990a) is compared with that simulated from both EMs and PMs, respectively in 
Figure 7.3 (A) and (B). 
7.3.2 Power of Studies Using Natural Caucasian Abundance of PM 
Phenotypes 
Using natural abundances of genotypes, around 250 subjects were required 
to detect a difference in the pharmacokinetics (AUC) of OMZ between CYP2C 19 EMs 
and PMs (Figure 7.4). The number of subjects required to detect similar differences in 
the pharmacodynamics of OMZ was 300 (Figure 7.4). 100% power for detecting 
differences in both the pharmacokinetics and the pharmacodynamics of OMZ was 
reached with 400 subjects. 
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Figure 7.2 Mean simulated response-time profiles in 100 poor (*) and 100 
extensive (0) metabolisers. 
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(A) 
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Figure 7.4 The power (%) of simulated studies to show significant differences in (A) 
AUC and (B) AUEC of OMZ between different CYP2CI9 phenotypes 
vs. the number of subjects (n). The predicted power of both studies 
involving subjects randomly selected from the Caucasian population (0) 
and those using the proportion of PM subjects detailed in the in vivo 
studies are shown (the green and red symbols indicate whether the in vivo 
study was positive (0) or negative (A)). 
208 
Chapter T Omeprazole 
7.3.3 Power of Reported Studies 
The powers calculated for the published studies are shown in Table 7.6. 
With respect to pharmacokinetic studies, there was good consistency between the 
predicted powers and the observed outcomes. All of the twelve literature 
pharmacokinetic studies were successful in determining a difference in the 
pharmacokinetics of OMZ between CYP2CI9 phenotypes/genotypes. According to 
our simulations, all but one of these studies had powers of 50% or greater and were 
therefore more likely to be successful than unsuccessful (Table 7.6). A chi-squared test 
for these data resulted in a p-value of 0.30 indicating no significant difference between 
observed and expected. With respect to the pharmacodynamic, studies, the prediction 
matched the observed outcome in 6 cases out of 9. The Chi-squared derived p-value 
for these data was 0.42, indicating no difference between the observed and predicted 
values. There were 2 false positive results and 1 false negative (Table 7.6). 
Figure 7.4 shows the power of the reported studies vs. the size of the 
studies and Figure 7.6 demonstrates the relationship between power and the proportion 
of PMs employed in the study. 
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Figure 7.5 The power (%) of (i) of simulated studies that use subjects randomly 
selected from a Caucasian population (*), and (ii) of simulated studies 
that use proportions of PM subjects comparable to those reported in the 
in vivo studies (o) to detect significant differences in the AUC of OMZ 
vs. the proportion of CYP2C19 PMs employed in the study (%). 
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Figure 7.6 The power (%) of (i) of simulated studies that use subjects randomly 
selected from a Caucasian population (*), and (ii) of simulated studies 
that use proportions of PM subjects comparable to those reported in the 
in vivo studies (symbol indicates whether the outcome of the in vivo 
study was positive (o); or negative (&)) to detect significant differences in 
the AUEC of OMZ vs. the proportion of CYP2C 19 PMs employed in the 
study (%). 
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7.4 Discussion 
Using clinical trial simulation the power of in vivo studies to determine 
differences in the disposition of OMZ and its acid inhibitory effect in relation to 
CYP2Cl9 phenotype has been examined. The derivation of metabolic clearance from 
in vitro data recovered the pharmacokinetic parameters such as CL, AUC and 
bioavailability (F) with good accuracy both in EM and in PM individuals (within 2- 
fold) (Table 1.7). 
It should be noted that two of the studies used for the comparison in Table 
7.7 (Kita et aL, 2001; Qiao et aL, 2006) were carried out in oriental subjects. Several 
differences between Japanese and Caucasian populations have been identified 
including demography (Age/height/weight relationships) liver size and CYP 
abundance (Inoue et aL, 2006). Therefore, the comparison made in Table 7.7 may be 
associated with a certain amount of error. However, this is likely to be relatively small 
(approximately 10-20%; Inoue et al., 2006) and the comparisons are still valid in this 
context. In the case of the power calculations, it was assumed that the relative 
differences in both pharmacokinetics and pharmacodynamics between CYP2Cl9 
phenotypes is the same for Caucasian and oriental populations since it is independent 
of demographical and physiological differences between the populations. The 
calculations of power in Caucasians will hence be applicable to oriental groups. 
, 
The plasma concentration-time profiles were comparable with those 
observed by Andersson et aL (1990a), although the CYP2C19 phenotype/ genotype of 
the individuals included in the study was not specified. If it is assumed that the 
simulated plasma concentration-time profiles are representative of the in vivo situation 
then it may be inferred that one or more PM individuals were present in the study 
(Figure 7.3). 
Had natural abundances of CYP2Cl9 PMs in the Caucasian population 
been relied upon, lower powers than those calculated for the reported studies would 
have resulted (Figure 7.4). For example, 250 and 300 subjects would have been 
required to detect a difference in the pharmacokinetics and pharmacodynamics of 
OMZ, respectively if such populations had been used. Perhaps this explains the 
absence of such reports in the literature while those carried out in oriental populations 
212 
Chapter 7. Omeprazole 
are abundant since Japanese populations have much higher frequencies of CYP2Cl9 
PMs than Caucasian populations (2.8 vs 21.3%; Wedlund et aL, 2000). 
Figure 7.4 and Figure 7.6 demonstrate the usefulness of study enrichment. 
The higher proportions of CYP2Cl9 PMs present in the reported studies have much 
higher powers than those simulated using a Caucasian population of subjects (Figure 
7.4). However, Figure 7.6 is a reminder of the importance of study size, given that 
studies with similar proportions of PMs can have widely varying powers. 
The estimates of study power are consistent with the findings of published 
reports. At least 12 literature studies have been successful in linking OMZ 
pharmacokinetics to CYP2Cl9 phenotype. We calculated their powers to be between 
40% and 90% (Fu et aL, 2004; Furuta et aL, 1999a; Furuta et aL, 1999b; Hu et aL, 
2005; Kita et aL, 2001; Ohnishi et aL, 2005; Qiao et aL, 2006; Sakai et aL, 2001; 
Shirai et aL, 2001; Tybring et aL, 1997; Yasuda et aL, 1995; Yin et aL, 2004). Of the 
12 studies, 11 were predicted to have a power greater than 50% and therefore be more 
likely to succeed than fail to determine a difference in OMZ pharmacokinetics between 
CYP2Cl9 phenotypes. Despite the above consistency between the predicted and 
observed powers, it is not possible to make inferences about the ability of the model to 
predict the failure of an in vivo study effectively. This is because only 3 negative 
studies have been reported in the literature. While the model is clearly capable of 
predicting study success, the same cannot be said for the converse situation. 
Of the 6 studies which were able to determine a difference in the 
pharmacodynamics of OMZ between CYP2Cl9 pheno/genotypes (Furuta et aL, 
1999b; Hu et aL, 2005; Kita et aL, 2001; Shimatani et aL, 2003; Shirai et aL, 2001; 
Tanigawara. et aL, 1999), we predicted that 5 had a power greater than 50% and were 
therefore likely to succeed. Three pharmacodynamic studies were unsuccessful in 
differentiating OMZ pharmacokinetics between CYP2Cl9 pheno/genotype (Egan et 
aL, 2003; Miyoshi et aL, 2001; Ohkusa et aL, 2005), we predicted that these studies 
would have powers of 45 to 100%. In the two cases where a false positive outcome 
was predicted, this could be due to the use of endpoints such as cure rates of 
oesophageal reflux disease (Miyoshi et aL, 2001) and adverse reactions to OMZ 
(Ohkusa et aL, 2005) in the reported studies. Since the endpoint used in the simulation 
studies was gastric acid secretion (assumed to be comparable to gastric pH), the 
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variability may be lower in the simulated PD than in in vivo. This would hence lead to 
a lower power in vivo than was indicated by the simulations. 
The estimated powers were similar for pharmacokinetic studies and 
pharmacodynamic studies because stomach pH is highly dependent on plasma OMZ 
concentration due to the low variability in PD parameters. The absence of any non- 
linearity in the effect should also be noted. According to the model, concentration 
increases approaching infinity, lead to an infinite increase in gastric acid secretion. 
This lack of a maximum effect is somewhat unrealistic since in reality, feedback 
mechanisms within the body would prevent the effect increasing indefinitely. In 
addition to the latter, a ftn-ther limitation of the model is the lack of time delay between 
drug concentration in the systemic compartment and acid secretory response in the 
stomach. This is unrealistic given the indirect nature of the pharmacodynamic response 
mechanisms (enzyme inhibition). In addition to the above limitations, the model does 
not allow for the possibility of acid inhibition occurring in the parietal cells of the 
stomach before the drug passes through the gut wall and enters the systemic 
circulation. 
In the case of OMZ, much higher powers to detect differences in both the 
pharmacokinetics and the pharmacodynamics of the drug between CYP phenotypes 
are in evidence than for the other model drugs that have been researched within this 
thesis. In addition to the limitations discussed above ' ftirther reasons for the 
latter 
effect may include, the large difference in the abundance and hence activity of 
CYP2Cl9 between EMs and PMs, and the lack of any significant involvement from 
other enzymes in the overall metabolism of OMZ. 
As mentioned in the methods, the majority of the reported studies of the 
impact of CYP2C19 genotype on OMZ pharmacokinetics and pharmacodynamics are 
carried out in oriental populations. As discussed above, several differences exist 
between Japanese and Caucasian populations. However, for the purposes of this study, 
it was assumed that the relative differences between CYP2C 19 phenotypes in Japanese 
populations would be similar to that for Caucasians and hence, the calculated powers 
would still be applicable. The only difference incorporated into these simulations was 
the abundance of CYP2Cl9 PM subjects in the population which was altered to 
correspond with that seen in each individual study. Future work could involve the 
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incorporation of ethnic differences between Japanese and Caucasian populations into 
the Simcyp& algorithms. 
In conclusion, the results of this study have demonstrated the value of 
study enrichment with respect to rarer CYP phenotypes by the wide difference in 
power between studies that are enriched, and those that are not. The study has also 
investigated some possible explanations for the apparent discrepancy between the 
success of published in vivo studies to discern a difference in the pharmacokinetics of 
OMZ between CYP2C 19 phenotypes and the apparent failure of studies to consistently 
replicate the corresponding differences in the pharmacodynamics of OMZ response. 
215 
Chapter 8: Tolbutamide 
CHAPTER 8 
The Propagation of Pharmacogenetic 
Differences in Cytochrome P450 into 
Pharmacokinetic & Pharmacodynamic 
Measures: The Example of CYP2C9 & 
Tolbutamide 
216 
Chapter 8: Tolbutamide 
8 TOLBUTAMME 
8.1 Introduction 
Blood glucose levels are maintained in the body by negative feedback 
mechanisms involving pancreatic hormones (Figure 8.1). Insulin is the hormone 
responsible for stimulating the liver to take up glucose and store it as glucagons, 
thereby reducing blood sugar levels (Figure 8.1). 
Tolbutamide (TLB) is a member of the sulfonylurea family of drugs, 
which stimulate insulin secretion from pancreatic P-cells and are often used in the 
treatment of type II diabetes mellitus (Kirchheiner et al., 2002). It is mostly 
metabolised by cytochrome P450 2C9 (CYP2C9) [around 64% - (Lasker et al., 1998)] 
to hydroxytolbutamide. This pathway is widely used as a probe reaction for measuring 
CYP2C9 activity both in vitro (Tucker et al., 2001) and in vivo (Jetter et al., 2004). 
CYP2C19 has also been shown to contribute to the metabolism of TLB (Lasker et al., 
1998). 
As discussed in the Literature Review (Chapter 2), it is clear that the 
CYP2C9 polymorphism is important for determining differences in the 
pharmacokinetics of TLB between subjects (Jetter et al., 2004; Kirchheiner et al., 
2002; Lee et al., 2003; Lee et al., 2002b; Shon et al., 2002; Wang et al., 2005). 
However, it is uncertain whether these differences in pharmacokinetics between 
genotypes translate into differences in response to the drug (Holstein et al., 2005; 
Kirchheiner et al., 2002; Shon et al., 2002) where response measures included plasma 
insulin and glucose concentration (Kirchheiner et al., 2002) and glucose tolerance and 
serum glucose concentration (Shon et al., 2002). A possible reason for this disparity is 
the size of the study populations involved in the studies. In both cases, the same study 
size has been employed for both the pharmacokinetic and the pharmacodynamic study. 
Although the sample size may be sufficient to observe differences in 
pharmacokinetics, it may result in a much lower power for observing significant 
difference in pharmacodynamics and hence a lower chance of the study being 
successful in that respect. 
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Two studies have investigated the relationship between TLB 
phannacokinetics and pharmacodynamics and CYP2Cl9 phenotype, however, no 
correlation has been observed (Kirchheiner et aL, 2002; Shon et aL, 2002). 
The aim of the study represented in this chapter was to simulate the 
pharmacokinetics of TLB and insulin secretory response to the drug in virtual 
populations of human subjects. These simulations were used to mimic the in vivo 
studies and to estimate their power to differentiate the pharmacokinetics and 
pharmacodynamics of TLB between CYP2C9 genotypes. These simulations were used 
to mimic the in vivo studies and to estimate their power to identify differences in the 
pharmacokinetics and pharmacodynamics of TLB between CYP2C9 genotypes. The 
ultimate aims of the work were to facilitate a more comprehensive understanding of 
the relationship between drug pharmacokinetics/phannacodynarnics and CYP2C9 
genotypes, using TLB as a model drug, and to investigate the impact of study size on 
the likelihood of success in defining differences in the pharmacokinetics and response 
of TLB between CYP2C9 genotypes. 
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Figure 8.1 Regulation of blood glucose levels by negative feedback mechanisms 
involving the hormones insulin and glucagon. The drugs that act on these 
processes are shown. Adapted from Marieb (1997) with additional 
elements from Rendell (2004). 
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8.2 Materials and Methods 
8. ZI The IVIVE Model Parameters 
As described in Chapter 3, as part of the IVIVE process, several key 
parameters are required for input into the model. These include both in vitro 
parameters (such as Km and Vm. ) and parameters gathered from in vivo experiments 
(such as CLR). These were collected from the literature and either entered directly into 
the model or utilised as part of a meta-analysis. The following section describes the 
parameters and their uses. 
8.2.1.1 In Vitro Data 
Data on the in vitro metabolism of TLB (in the form of K,,, and V. E,, ) were 
collected from published reports (Iwata et aL, 1998; Lasker et aL, 1998; Palamanda et 
aL, 2000; Sullivan-Klose et aL, 1996; Takanashi et aL, 2000) (Table 8.1). 
Intersystem extrapolation factors (ISEFs), were applied as described by 
Proctor et aL (2004) to account for any differences between the intrinsic activity of 
recombinantly expressed CYP enzymes and human liver microsomes (Table 8.2). To 
account for the non-specific binding of TLB in the experiments described in Table 8.1, 
a value of fuý, Iic was calculated and applied to the data as described in Chapter 3; 
Sections 3.1.1.2 and 3.3. ISEF values and values of funic are shown in Table 8.2. A 
meta-analysis was then conducted to find the overall Vm. and K. values for the 
metabolism of TLB by CYP2C9 and CYP2Cl9. 
8.2.1.2 Additional Parameters Required for IVIVE 
The additional parameters listed in Table 8.3 were required for scaling the 
in vitro data to human whole body clearance and to the elimination rate constant 
(Chapter 3). These values were then entered into the pharmacokinetic- 
pharmacodynamic model described below (Sections 8.2.3 & 8.2.4). 
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Table 8.1 Parameters describing the in vitro metabolism of TLB. 
Reference CYP Vmwc Km 
lwata et aL, 1998 2C9 4.59 192 
Palainanda et aL, 2000 2C9 4.7 115 
Lasker et aL, 1998 2C9 8.36 523 
2C19 12.51 395 
Takanashi et aL, 2000 2C9 9.2 151 
Sullivan-Klose et aL, 1996 2C9 0.61 145 
Vmax - pmol/min/pmol P450; Km - jiM. 
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Table 8.3 Mean pharmacokinetic parameter values of TLB taken or calculated from 
the literature. 
Parameter Value References 
fu 0.102 Miners et al., 1984; Rostarni-Hodjegan et al., 1998; 
Tremaine et al., 1997; Wilner et al., 1995; Section 
3.1.1.3. 
B: P 0.55 Obach, 1999; Section 3.1.1.3. 
fuB 0.056 Section 3.1.1.3. 
CLR (L/h) 0.0015 Lee et al., 2002; Miners et al., 1984; Tremaine et al., 
1997; Section 3.3.3. 
V (L/kg) 0.112 (0.03 4)* Kirchheiner et al., 2002; Peart et al., 1987; Section 
3.3.4. 
*Mean (SD); fu = fraction unbound in plasma; B: P = Blood to Plasma 
concentration drug ratio; fuB = fraction unbound in blood; CLR = renal clearance; V 
initial volume of distribution. 
Table 8.4 Results of a meta-analysis to calculate the relative activity of each of the 
CYP2C9 genotypes. All studies are carried out in yeast microsomes 
except for Guo et aL (2005) and Veronese et aL (1993) which were 
carried out in Cos cells and Rettie et aL (1994) which used HepG2 cells. 
The overall decrease in CLint for the variant alleles is shown in bold. 
Km ýý gK 2 
rt f Allele E z 0 
E 0.6 > W) 
E -6 "S > -ý u -ý 0 ý C 
5 Re erences 
5 
E 
0 1 li. - rL C4 u 
3 0.611 145 1.63 0.0112 Sullivan-Klose et aL, 1996 
3 9.2 151 24.5 0.162 Takanashi et aL, 2000 
2 73.2 286 195 0.682 Hanatani et aL, 2003 
3 7.96 105 0.0758 Guo et aL, 2005 
2 620 90.5 6.85 Veronese et aL, 1993 
1 1.93 106 0.0182 Rettie et aL, 1994 
3 0.442 122 0.000344 Sullivan-Klose et aL, 1996 
*2 2 189 94.4 2.00 132.7 Veronese et aL, 1993 
1 1.15 72 0.0160 Rettie et aL, 1994 
3 0.373 745 0.992 0.00133 Sullivan-Klose et aL, 1996 
3 10 1730 26.6 0.0154 Takanashi et aL, 2000 
*3 2 3.40 431 9.04 0.0210 180.5 Hanatani et aL, 2003 
3 8.04 397 0.0203 Guo et aL, 2005 
2 467 132 3.54 Veronese et aL, 1993 
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8.2.2 Genotype Frequencies andActivities 
A meta-analysis of the published literature was carried out to determine the 
relative activity of the enzyme expressed by each CYP2C9 allele with respect to the in 
vitro metabolism of TLB. Mean values of the activity of each allelic form were 
weighted for study size. Percentage decreases in intrinsic clearance (CLuint) with 
respect to wild type (*1/*1) enzyme were calculated as described for (S)-warfarin in 
Chapter 5; Section 5.2.2 by assuming that the in vitro activities of heterologously 
expressed variant enzymes represented those in the respective homozygous genotype. 
Values of CLuint in heterozygous genotypes were assumed to be the mean of those for 
homozygotes. A summary of the studies included in the meta-analysis is given in 
Table 8.4 (Guo et aL, 2005; Hanatani et aL, 2003; Rettie et aL, 1994; Sullivan-Klose et 
aL, 1996; Takanashi et aL, 2000; Veronese et aL, 1993). The results of this meta- 
analysis are shown in Table 8.5. The prevalence of each of the 6 established, common 
CYP2C9 genotypes in Caucasians were taken from a review by Lee et aL (2002) 
(Table 8.5). 
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Table 8.5 Frequency and relative activity of each of the common CYP2C9 
genotypes. Frequencies taken from (Lee et al., 2002a) relative activities 
calculated from a meta-analysis of the literature (Guo et al., 2005; 
Hanatani et al., 2003; Rettie et al., 1994; Sullivan-Klose et al., 1996; 
Takanashi et al., 2000; Veronese et al., 1993). 
Genotype Frequency (%) 
Relative 
Activity 
*1*1 65.3 100 
*1*2 20.4 84 
*1*3 11.6 60 
*2*2 0.9 68 
*2*3 1.4 44 
*3*3 0.4 20 
Table 8.6 Literature values describing the pharmacokinetics of TLB. 
Parameter Value* References 
V,, (L) 6.9(1.59) Rostaini-Hodjegan et al., 1998 
ka (h7l) 0.52(0.30) Kivisto & Neuvonen, 1992; Peart et al., 1987 
tlag (h) 0.08(0.1) Nishimura et al., 1998 
k12 (Min7l) 0.071 (0.080) Rostami-Hodjegan et al., 1998 
k2l (mid I) 0.087 (0.064) Rostami-Hoqi egan et al., 1998 
*Mean (SD) 
Table 8.7 Mean pharmaeodynamic parameter values of TLB taken from the 
literature. All parameters are taken from Rostami-Hodjegan et aL (1998) 
except EO which was from Polonsky et aL (1986). 
Parameter Tolbutarnide* 
Eo (pmol/min) 89. l(13.4) 
E ..  (pmol/min) 164l(279) 
Emax, 2 (pmol/min) 2480(595) 
EC5o. 1 (ng/ml) 1.78 X 108 (1.96 X 107) 
EC5O. 2 (ng/M1) 1.49 X 108 (7.45 X 106) 
ni 10(2.3) 
n2 43(35) 
koi (min- 0.045 (0.0085) 
*Mean (SD) 
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8.2.3 Pharmacokinetic Model 
Plasma concentrations after oral administration of TLB were generated 
using a two compartment model with first order absorption after a lag time (tlag - 
Table I) (adapted from the model given for the intravenous administration of TLB 
reported by Rostarni-Hodjegan et al., (1998) (Figure 8.2). Equation 8.1 describes the 
plasma concentration of TLB (C(t)i). 
D-ka, Ff C(t)TLBj '* HL ' -(Ali+ A2i + A31) V, 
Equation 8.1 
where f, is the oral bioavailability of TLB (set to 1), D is the dose of TLB 
administered (set to a 500mg oral dosage), kai, FH, i and Vi are the first order absorption 
rate constant (Table 8.6), fraction of TLB escaping first pass metabolism (calculated 
using the Simcyp@ model) and the steady state volume of distribution of TLB (Table 
8.3) respectively, in each individual and AIj, A2i and A3 i are given by: 
Al 
(k2lJ 
- aj) -e 
-ai-t 
Equation 8.2 (fl, - a) - (k., j - aj) 
A2 
(k2l. 
i -, 6, 
) 
- e-, 6, *' Equation 8.3 'ý (al 
-A) - 
(kz,. 
i 
---, 8j) 
(k2l. 
1 - k., j) -e A3, =_ Equation 8.4 (a, -ka, l)'(fli -T,, 
ýj 
where k2jj is the transfer rate constant from the peripheral to the central 
compartment (Table 8.6) and ai and Pi are the hybrid rate constants associated with the 
distribution and elimination phases, respectively, defined as shown in Chapter 4; 
Equations 4.5 & 4.6. 
8. Z4 Pharmacodynamic Model 
The following equation was used to calculate the concentration of TLB in 
a hypothetical effect compartment: 
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Ce(t) 
D- ka, , 
ke0j 
- FH'i - fa 
- (Ali + A21 + A31 + A4i) Equation 8.5 TLIBJ ý Vi 
where ko, i is the rate constant defining removal of TLB from the effect 
compartment (Table 8.7). Ali, A2i, Mi and Mi are given by: 
Ali = 
(k 
21, i - a, 
) 
-e 
-a,, t 
Equation 8.6 (fli 
- a, 
)- (k.. 
i - ai 
)- (k 
e0j - al 
A2j = 
(k2l. 
i -, 8j) - e", 6, *t Equation 8.7 (a, A) (k,. i A) 
(k 
e0j -, 85 
A3, 
(k2l, 
l - k, j) -ek.. 
I-t 
Equation 8.8 
k,,, ) - (8, - k-T. Ck-, O. l - k, 'j) 
A4j = 
(k2l, 
l - k,, O, I) -e 
-k. ýyt 
Equation 8.9 (a, 
-k e0j)'(fli - ko., ) - (k,. i --k-, 
-Oý., 
The pharmacokinetic data were linked with the phannacodynamic data by 
assuming that TLB in both the systemic and effect compartments can cause insulin 
secretion (Figure 8.2), resulting in a biphasic response-time profile. Response was 
modelled using a sigmoidal E. model for the effect of TLB on insulin secretion (E) 
(Rostami-Hodjegan et al., 1998): 
Ej =EO+ 
Emaxjj '(C(t)TLB, i 
)n,, 
)n, -+ 
Eax, 
2, i *(Ce(t)TLB, I) 
nz, 
)n2, Equation 8.10 (EC. 
5ojjý" +(C(t)TLB. i 
(EC50,2,1ýzl 
+(Ce(t)TLB, i 
where E0, is the average baseline level of insulin secretion (Polonsky et al., 
1986) (Table 8.7), the numbers '1' and '2' refer to TLB contained within the systemic 
and effect compartments, respectively. 
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Figure 8.2 Schematic representation of the pharmacokinetic-pharmacodynamic 
model used to describe the biphasic insulinergic effect of tolbutamide. 
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8.2.5 Study Design 
Individual plasma TLB concentration and response vs. time profiles 
following the oral administration of TLB were simulated for all time points between 0 
and 3h. For the purposes of data-analysis, samples were taken every 15 minutes (12 
samples). The simulated concentration- and response-time profiles in the different 
CYP2C9 genotypes were compared using a range of population sizes (n). The value of 
n was set to 10,25,50,100,200 or 300. 
Study size and the number of subjects of a given genotype in the study 
population where chosen using two different techniques: 
(i) Study sizes were chosen arbitrarily and the proportion of subjects of 
each genotype was chosen according to that of the general Caucasian population, this 
will be referred to as 'random selection' of subjects, and 
(ii) To our knowledge, there are 8 literature studies which investigate the 
relationship between CYP2C9 genotype and the pharmacokinetics and/or 
pharmacodynamic of TLB. The size of these studies ranged from 15 to 63 with varying 
proportions of the different non-wild type genotypes within the study populations. 
Details of these are reported later in Table 8.10. As the majority of these studies are 
carried out using populations of subjects with a higher than the Caucasian average 
frequency of rarer CYP2C9 genotypes, they will be referred to as 'enriched'. Study 
sizes and the proportion of each phenotype/genotype were also chosen in order to 
mimic those seen in the literature studies and their powers were, hence, calculated. 
8.2.6 Data Analysis 
Twenty simulations were run for each study size involving 120 simulations 
and a total of 13,700 virtual subjects. Values of the areas under the plasma drug 
concentration-time curves (AUC) and effect (insulin secretion)-time curves (AUEC) 
were calculated up to 3h (trapezoidal rule) for consistency with the reported, in vivo 
studies. For the purposes of this study we assumed that no measurement error 
occurred. The probability of detecting statistically significant differences in 
pharmacokinetics and pharmacodynamics between the wild type (*I/*I) and the 
combination of the other CYP2C9 genotypes was assessed by comparing values of 
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AUC and AUEC, respectively, using ANOVA (SPSS v 12; SPSS Inc, Chicago 2003). 
The corresponding probabilities of detecting differences in AUC or AUEC between 
the wild type and any other single genotype were calculated using Tukey's post hoc 
test for multiple comparisons. The percentage of studies out of the 20 simulations that 
led to a statistically significant difference in AUC (or AUEC) between CYPC9 
genotypes was recorded as the power of that comparison. 
Clearance values and other pharmacokinetic parameters obtained from the 
IVIVE model were compared with those values observed in vivo (Jetter et aL, 2004; 
Kirchheiner et aL, 2002; Lee et al., 2002b; Shon et aL, 2002). The accuracy of the 
resulting plasma TLB concentration-time profiles was assessed by comparison with the 
profiles reported in the literature by Shon et aL (2002) and Lee et aL (2002). 
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8.3 Results 
8.3.1 Model Validation 
The meta-analysis of the enzyme activities associated with the variant 
alleles of CYP2C9 indicated mean decreases in CLui,, t of 16% and 40% compared to 
wild-type activity, respectively, for every *2 and *3 allele present in an individual. The 
results for the different CYP2C9 genotypes are shown in Table 8.5. Propagation of 
these values through the SimcypqD algorithm resulted in mean values of unbound oral 
clearance for TLB from 100 individuals of 0.72 (* I* 1), 0.63 (* 1 *2), 0.48 (* 1 *3), 0.52 
(*2*2), 0.39 (*2*3) and 0.26 (*3*3) A which were all within 2 fold of the in vivo 
values available in the literature (Jetter et aL, 2004; Kirchheiner et aL, 2002; Lee et aL, 
2002b) as shown in Figure 8.3. 
Table 8.8 is a summary of simulated pharmacokinetic parameters for TLB 
in all CYP2C9 genotypes compared with those observed by Jetter et al. (2004); 
Kirchheiner et al. (2002); Lee et al. (2002b) and Shon et al. (2002). 
Figure 8.4 shows concentration-time profiles in each of the CYP2C9 
genotypes. The profiles for wild-type, *1 *2 and *1 *3 individuals were compared with 
those observed by Shon et aL (2002) and Lee et al. (2002) (Figure 8.5). 
Representative response (insulin secretion)-time profiles are shown in 
Figure 8.6. The biphasic nature of the response-time curve can be observed, 
particularly in the *2/*3 and *3/*3 genotypes. No literature reports were available to 
compare the simulated insulin secretion-time profiles with those observed in vivo. 
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and *3* _3 ) 
(13) genotypes after oral administration of 5 00mg TLB 
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8.3.2 Power of Studies 
The power of studies to detect a statistically significant difference in AUC 
of TLB between the wild type and a combination of the other CYP2C9 genotypes was 
around 80% with about 50 subjects (Figure 8.1). 100% power was reached when 200 
subjects were used (Figure 8.7). 
The corresponding power to observe a difference in the AUEC of TLB 
between the wild type and a combination of any other genotype did not increase above 
45% with the maximum sample size investigated of 300 subjects (Figure 8.7). 
The power to differentiate between wild type and any other single 
genotype was less than that for the comparison between wild type and a combination 
of all non-wild type genotypes, to a degree depending on the genotype (Figure 8.8 
(A)). For example, about 300 subjects were required to detect a difference in AUC 
between the *2/*3 genotype and the wild type with a power of 80% (Figure 8.8 (A)) 
while, with the same number of subjects, a power of only about 30% was achieved 
when comparing the *2/*2 genotype with the wild type (Figure 8.8 (A)). 
Corresponding powers to detect differences in AUEC between CYP2C9 
genotypes are shown in Figure 8.8 (B). The power to detect differences in AUEC 
between specific genotypes was low (Figure 8.8 (B)). For example only around 20% 
was reached to detect a difference between the *2/*3 genotype and the wild type 
subjects with the maximum study size investigated of 300. By comparison, the same 
number of subjects gave a power of 5% when comparing the *3/*3 genotype with the 
wild type (Figure 8.8 (B)). 
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Figure 8.7 The power (%) of simulated studies to show significant differences in 
AUC (0) and AUEC (Zý) of TLB between the wild type and a 
combination of all other CYP2C9 genotypes vs the number of subjects in 
each study (n). The dashed lines represent 80% power, commonly used in 
in vivo studies, and 50% power, above which, there is more chance of 
success than failure. 
237 
Chapter 8. - Tolbutamide 
100 13 a 
50 
0A 
0A 
0 100 200 300 
Study size (n) 
100 
10 .1 
50 
0 
0 100 200 300 
Study size (n) 
Figure 8.8 The power (%) of simulated studies to show significant differences in (A) 
AUC, and (B) AUEC between the wild type and any single other 
CYP2C9 genotype vs the number of subjects in the study population (n). 
Wild type is compared with the following: *1/*2 (A), *1/*-'3 (0), *2/*2 
(+), *2/*-') (0), (9). Dashed line represents 80% power which is 
typically used in designing clinical studies, the arrows demonstrate the 
number of subjects required to achieve this power. 
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8.3.3 Power of Reported Studies 
Table 8.9 shows that there was good agreement between the predicted 
powers and the study outcomes. Of the 21 comparisons made in pharmacokinetic and 
pharmacodynamic studies between the wild type and any single other genotype, 8 
(38%) were significantly different. This is compared with the predicted number of 
comparisons having 50% or greater power, i. e. more likely to succeed than fail, of 4 
(19%). More specifically, 17 (81%) of the comparisons were predicted correctly (Table 
8.9). A chi-squared test of these data resulted in a p-value of 0.69 indicating no 
significant difference between observed and expected. 
Figure 8.9 shows the power of the reported studies vs the size of the 
studies compared with the power of studies in which subjects are randomly selected 
from the Caucasian population. In Table 8.10, the focus is on the particular comparison 
between the wild type and *1*3 genotypes. The proportion of *1*3 genotype subj ects, 
is shown and the predicted power for that particular comparison is given. This power is 
compared with that which would have resulted from selecting subjects randomly from 
a Caucasian population. Figure 8.10 further explores the comparison between wild 
type and *1*3 genotypes by comparing the proportion of *1*3 subjects in the study 
population with the predicted power of the study. 
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Figure 8.9 The power (%) of simulated studies to show significant differences in (A) 
AUC and (B) AUEC of TLB between different CYP2C9 wild type and 
genotypes vs the number of subjects (n). The predicted power of 
both studies involving subjects randomly selected from the Caucasian 
population (0) and those using the proportion of *1 *35 subjects detailed 
in the in vivo studies are shown (the green and red symbols indicate 
whether the in vivo study was positive (0) or negative (A)). 
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Figure 8.10 The power (%) of (i) simulated studies that use subjects randomly 
selected from a Caucasian population (*), and (ii) simulated studies that 
use proportions of *1*33 subjects comparable to those reported in the in 
vivo studies (symbol indicates whether the outcome of the in vivo study 
was positive (o); or negative (A)) to detect significant differences in (A) 
the AUC, and (B) the AUEC of TLB vs the proportion of CYP2C9 *I*-') 
subjects employed in the study (%). 
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8.4 Discussion 
Using CTS that incorporated data on in vitro drug metabolism into a 
mechanistic population based pharmacokinetic-pharmacodynamic model, we have 
examined the power of in vivo studies to determine differences in the disposition of 
TLB and its insulin secretory effect in relation to CYP2C9 genotype. The derivation of 
metabolic clearance associated with different genotypes from in vitro data recovered 
that reported from in vivo studies with good accuracy (within 2-fold) (Table 8.8 & 
Figure 8.3). All other predicted pharmacokinetic parameter values were within two 
fold of the weighted mean experimental values except for the t1/2 in *3*3 genotype 
subjects which was within 4-fold (Table 8.8). Figure 8.5 demonstrates good 
concordance between the observed and expected plasma TLB concentration-time 
profiles in wild type, *1*2 and *1*3 individuals. 
It was not possible to compare the response (insulin secretion) vs time 
outputs with those seen in vivo due to a lack of available information. However, the 
consistency of the concentration-time profiles with the in vivo data (Figure 8.5) and the 
resulting power estimations (Table 8.9) with the in vivo observations provide 
convincing evidence that the response outputs are accurate. 
The model projection indicated that at least 50 subjects would be required 
to detect a difference (80% power) in the AUC of TLB between the wild type 
genotype and the combination of all other genotypes (Figure 8.7). Comparisons 
between the wild type and specific genotypes would require much higher numbers of 
subjects (e. g. 100 subjects to achieve 80% power in discriminating phan-nacokinetics 
between wild-type and *1/* 3 genotype; Figure 8.8 (B)). 
Five studies assessing the impact of genetic variation in CYP2C9 on TLB 
pharmacokinetics have been reported. One of these, Lee et al. (2002) used only 15 
subjects but 5 of these were wild type and these were compared with the same number 
of *1*3 genotype subjects. According to our simulations, this combination resulted in 
a power of 55% to observe a difference in pharmacokinetics between the two 
genotypes and accordingly, a difference was observed (Table 8.9 & Figure 8.9). Four 
other studies were successful in discerning a difference between the wild type and 
some of the genotypes but not others (Jetter et al., 2004; Kirchheiner et al., 2002; Shon 
et al., 2002; Wang et al., 2005). For example, according to our simulations, three of the 
studies had 55% or greater power to differentiate the pharmacokinetics between the 
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wild type and the *1/*3 genotype (Table 8.9). Accordingly, each of the studies was 
successful in observing a significant difference between these genotypes (Jetter et aL, 
2004; Kirchheiner et aL, 2002; Wang et aL, 2005) (Table 8.9). One study did not 
observe such a difference with a predicted power of 45% (Shon et aL, 2002). 
With regard to pharmacodynamic outcome, the model projection indicated 
that even with 300 subjects, the power to detect a difference in AUEC between wild 
type and the combination of all other genotypes did not increase above 45% (Figure 
8.7). 
Three literature studies have described attempts to differentiate the 
pharmacodynarnics of TLB between different CYP2C9 genotypes. Only one of the 
three was successful in this aim. Our simulations indicated that none of the reported 
studies were sufficiently powered to detect the contrast between wild type and the 
combination of all other genotypes (Table 8.9). Furthermore, as with the 
pharmacok-inetic studies, the power for comparisons between specific genotypes was 
much lower (Figure 8.8 (B)). The outcome of most of the reported studies were 
consistent with the calculated powers (Table 8.9) except for one result from the Shon 
et aL study (2002) which demonstrated a significant difference in the 
pharmacodynamics of TLB between the wild type and the *1/*3 genotype with a 
predicted power of 35%. This may be a result of an overprediction of 
pharmacodynamic variability in the model. However, given the success of the model 
with regard to the majority of the predictions, another possible reason may be the 
significance level used in the reported studies of 5%. A consequence of this 
significance level is that 5% of observations will result in false positive results. 
Table 8.10 shows that had the aforementioned studies relied on natural 
occurrences of CYP2C9 genotypes in the Caucasian population, they would have had 
lower power and been less successful in determining a significant difference in 
pharmacokinetics between the genotypes. This is also demonstrated by Figure 8.10 
which shows the general increase in power that occurs when studies are enriched with 
regard to the *1*3 genotype. 
It should be noted that the endpoint employed in this study, i. e. insulin 
secretion, is used as a surrogate for the true clinical endpoint resulting from treatment 
with TLB i. e. decrease in blood glucose concentration. Literature studies of TLB 
pharmacodynamics generally measure blood glucose concentration. To allow comment 
on the power of such studies, it has been necessary to assume that the power to 
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differentiate differences in insulin secretion between genotypes is comparable to that to 
differentiate blood glucose concentration. However, if the model had been extended to 
allow prediction of blood glucose levels, the power to differentiate differences in such 
pharmacodynamic response between individuals would have been lower. Since the 
power to detect differences in pharmacodynamics is already well below the 80% level 
(Figure 8.7) it was deemed unlikely that much more information would be gained from 
this. The use of the pharmacodynamic model demonstrated in this chapter may be 
simplistic but it has given an indication of its possible uses and applications. 
No false positive outcomes have been predicted using this model. 
However, 5 false negative cases have been predicted. A possible reason for these false 
negative outcomes could be related to the fact that the effect -time profiles in different 
CYP2C9 genotypes are relatively similar during early time points when compared to 
the later time points (Figure 8.6). Given that the AUECs in the current study were 
calculated only up to 3h, it follows that this may be a reason for the low calculated 
powers. However, the in vivo studies tend to use similar time scales and so consistency 
should still be expected. 
In conclusion, the results of this study have provided some explanation as 
to why there is an apparent discrepancy in the results of published in vivo studies to 
discern a difference in the pharmacokinetics and/or pharmacodynamics of TLB 
between CYP2C9 genotypes. Where some studies are successful (particularly 
pharmacokinetics studies), others (pharmacodynamic studies) fail. This may be due to 
the fact that the sizes of studies, particularly pharmacodynamic studies, are generally 
low compared to what would be required to achieve 80% power to discern such 
differences. 
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9 DISCUSSION 
9.1 Background 
This chapter briefly summarises the work described in this thesis and 
makes suggestions for subsequent work. Section 9.2 discusses the main findings of the 
experimental work using IVIVE within clinical trial simulation to investigate the 
impact of CYP polymorphisms on the pharmacokinetics and pharmacodynamics of 
various drugs. Section 9.3 discusses the results of one aspect of the literature review 
involving the reporting of pharmacogenetic studies in the literature. Section 9.4 is an 
outline of further work that could be carried out to extend the work in this thesis. 
As outlined in the Introduction (Section 1.4.1), there has been much 
concern expressed within the pharmaceutical industry with regard to the increasing 
cost and perceived decreasing productivity of the drug development process (FDA, 
2004). It has been suggested that many of the studies carried out both during and after 
the drug development process may be avoided without any compromise in safety or 
efficacy and in their commentary, Johnsson & Sheiner (2002) advocated 'smarter' 
clinical trial design. 
Recently, there have been calls to improve these aspects of drug 
development by utilising the processes of modelling and simulation more effectively 
(FDA, October 1,2004; Jonsson & Sheiner, 2002; Williams et aL, 2006). At present, 
there is increasing interest in the use of clinical trial simulation in the drug 
development process as these are powerful tools to integrate all the available 
information relevant to clinical trial design. Indeed, the FDA's latest draft guidance on 
drug interaction studies states that "simulations can provide valuable insights into 
optimizing the study design" (FDA, October 1,2004). 
In the early stages of drug development it may not be possible to build a 
full picture of events that may happen in real clinical trials since many pieces of 
information may be missing. However, incorporating all available knowledge can help 
to ask "what if' questions and to understand the importance of missing information. 
Once all relevant data are gathered it becomes possible to characterise individuals most 
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likely to be "at risk7 or those expected to gain the "highest benefif'. This has got 
potential cost saving implications. 
To our knowledge, there have not been any systematic attempts to use 
clinical trial simulation for identifying the possible impact of genetic polymorphisms 
in drug metabolising enzymes. The functional and clinical relevance of genetic 
polymorphisms in major drug metabolising enzymes such as the CYP enzymes are the 
bases for a large volume of research. A number of studies have shown the effects of 
functional allelic variants of CYP enzymes on inter-individual variation in plasma drug 
concentrations. However, the consequence of these genetic variations for the 
pharmacodynamics of drugs is unclear and the promise of pharmacogenetics for 
individualised medicine, at present, remains unfulfilled. While retrospective trials and 
case studies are abundant in the literature, they are often contradictory and prospective 
clinical trials are rare. In the absence of such prospective studies, clinical trial 
simulation provides a feasible alternative. In this thesis we have used 
dextromethorphan, warfarin, midazolam, orneprazole and tolbutamide as model drugs 
to examine some applications of clinical trial simulation in determining 
pharmacokinetic and pharmacodynamic differences between different CYP 
phenotypes/genotypes. 
We have shown that clinical trial simulation is a useful tool for identifying 
a priori underpowered and thus, unsuccessful studies which are likely to be a waste of 
resources. The results of the current studies show how in vitro data can be integrated 
together with information on variability in genetic, physiological and demographic 
features into clinical trial simulation. This can help to design and implement more 
effective and conclusive clinical studies. 
9.2 Discussion of Results 
9.2.1 CYP2D6 & Dextromethorphan 
The simulations in this chapter incorporated a two-compartment 
pharmacokinetic model for both parent drug and metabolite with first order absorption. 
This was linked via an effect compartment to an inhibitory Em, _, model where 
the 
parent drug and the metabolite competitively inhibited cough response. 
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As discussed in Chapter 2 (Section 2.4.3.1), there is an apparent 
inconsistency between literature studies of the effect of CYP2D6 phenotype on the 
pharmacokinetics of dextromethorphan which show significant differences between 
phenotypes and the equivalent pharmacodynamic studies which appear to show no 
such difference. The simulations carried out in this section provided some explanation 
for this observation by demonstrating that the latter studies were severely 
underpowered to detect differences in the pharmacodynamics of dextromethorphan 
between CYP2D6 EMs and PMs. 
Some possible reasons for the large numbers of subjects that would be 
required to detect such differences were also put forward. These included (i) the 
contribution of other, non-polymorphic, enzymes to the overall metabolism of 
dextromethorphan, (ii) the pharmacological activity of dextrorphan, the main 
metabolite of dextromethorphan and its contribution to the antitussive activity of 
dextromethorphan, and (iii) the large interindividual variability in pharmacodynamic 
parameters describing the antitussive effect of dextromethorphan. The importance of 
these three factors was demonstrated by further simulations that showed the 
hypothetical change in power which would occur if any of the conditions were altered. 
However, the relative pharmacological activity of dextrorphan compared 
to dextromethorphan had only a small influence on the power of studies to detect 
differences in the AUEC of DEX when it was reduced to 0% or increased to 100% and 
200%. This result is interesting given the keen attention which is paid to active 
metabolites during the drug development process. 
9.2.2 CYP2C9 & (S)-Warfarin 
In addition to differing from the previous section in the particular substrate 
and CYP enzyme investigated, this section of the work also differed in that the 
pharmacokinetic-pharmacodynamic model incorporated a one-compartment model for 
concentrations of (S)-warfarin with first order absorption after a lag time. This was 
linked to an indirect model of anticoagulant response to the drug. 
Simulating the pharmacokinetics and pharmacodynamics of warfarin in 
virtual populations of individuals with different CYP2C9 genotypes revealed some 
interesting results. It is clear that the power to detect differences between specific 
genotypes was as much related to the frequency of the genotypes in the population as it 
was to the activity of the genotype relative to the wild-type. 
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Good consistency was evident between the results observed in 19 literature 
studies and those predicted by the current simulations. The simulations have helped to 
explain the apparent inconsistency between the success of studies in determining a 
significant effect of CYP2C9 genotype on warfarin pharmacodynamics and the 
perceived failure to define a similar relationship between CYP2C9 genotype and 
warfarin pharmacokinetics. The latter inconsistency may be related to the limited 
numbers of subjects employed in pharmacokinetic (and to some extent 
pharmacodynamic) studies and the low prevalence of some of the rarer CYP2C9 
genotypes in the Caucasian population. 
It is probable that, in the case of warfarin, all but the largest studies will be 
underpowered at least for determining differences between some of the genotypes. For 
this reason, the use of populations which are enriched with respect to certain 
genotypes, allowing a great increase in statistical power using lower smaller study 
populations is a possible solution to the problem. However, the use of such recruitment 
methods does have some practical and ethical problems associated with it. 
9. Z3 CYP3A5 & Midazolam 
In order to simulate concentration- and response- time profiles for MDZ, a 
two-compartment pharmacokinetic model was used with first order absorption after a 
lag time for both parent drug and metabolite. This was linked to response using an 
effect compartment and an excitatory Ema,, model where the parent and the metabolite 
compete to exert their effect on the central nervous system as measured by the EEG. 
Although this model is very similar to that employed for modelling the 
pharmacokinetics and pharmacodynamics of DEX, there is a more significant 
contribution from gut first pass metabolism in this case, which has necessitated 
differences in the metabolite pharmacokinetic model. 
All except one of the studies investigating the impact of the CYP3A5 
polymorphism on the pharmacokinetics of MDZ have failed to detect any influence of 
genotype or phenotype. The only study which did detect an impact was the largest, 
employing 63 subjects. However, the current study predicted that the aforementioned 
studies had powers of 0- 20%. This is not consistent with the one successful study. 
Although the success of this study may be the result of a type one error, it is also likely 
that the model is at fault in that it does not take into account polymorphic expression of 
CYP3A5 within the gut. Had this been considered, the calculated powers may have 
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been slightly higher and the predictions more accurate. This is discussed further in 
Chapter 6; Section 6.4. 
9.2.4 CYP2C19 & Omeprazole 
In this section a one compartment model with first order absorption was 
used to model the pharmacokinetics of OMZ. This was linked directly to a mechanism 
based (indirect) inhibitory model for the effect of OMZ on acid secretory response to 
the drug. The pharmacokinetic-pharmaeodynarnic model did not incorporate any lag 
time or effect compartment, which is unusual for an indirect model since the responses, 
by definition do not occur instantly as the effect is indirect. In addition to the latter 
limitation, there were other problems associated with the response model including the 
lack of incorporation of any feedback mechanism so that the response was able to 
increase indefinitely towards infinity. Furthermore, the elimination rate of both active 
and inactive I4+W-ATPase was assumed to be the same. All these factors potentially 
contributed to an inaccuracy in the power predictions. Nevertheless, the overall 
consistency between the predictions and the outcomes observed in vivo was good. 
The importance of study enrichment for increasing the statistical power of 
studies to detect CYP-mediated differences in the pharmacokinetics or 
pharmacodynamics of drugs can be clearly observed in this chapter. Large increases in 
power were evident when studies were enriched with CYP2Cl9 poor metabolisers 
compared to the powers that were calculated for studies where subjects were selected 
randomly from a Caucasian population. 
9.2.5 CYP2C9 & Tolbutamide 
This section of the work was similar to Chapter 5 ((S)-warfarin) in that 
both Chapters investigated the effect of CYP2C9 genotypes on the pharmacokinetics of 
a substrate. However, there were two main differences between them. Firstly, the 
pharmacokinetic-pharmacodynamic model for this chapter incorporated a two- 
compartment model with first order absorption after a lag time linked via an effect 
compartment to a stimulatory E,,, a,, model whereby TLB stimulated insulin secretion 
from both the systemic and the effect compartments. A second difference between this 
model and the (S)-warfarin model was in the decreased activity of CYP2C9 mutants 
relative to the wild type genotype. Evidence was available to suggest that the 
percentage reduction in the intrinsic clearance between different genotypes was 
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different depending on the substrate being investigated (Lee et aL, 2002; Xie et aL, 
2002). Therefore, a separate analysis was undertaken for TLB and the resulting 
reductions in intrinsic clearance by genotype for both substrates are different to those 
observed for (S)-warfarin (Table 9.1). It should also be noted that as was the case for 
the (S)-warfarin IVIVE model, possible differences in the expression of CYP2C9 
between genotypes were not taken into account due to lack of available data or 
evidence of such differences (Chapter 5; Section 5.4 for details). 
Good agreement was apparent between the predicted powers of the 
reported in vivo studies and the outcomes observed in those particular studies. The 
simulations thereby helped to explain some of the inconsistencies whereby some 
studies have detected differences in the phannacokinetics or pharmacodynarnics of 
TLB between certain CYP2C9 genotypes whereas others have not. 
A further outcome of this section of the thesis was the observation of 
differences in power between enriched studies and those that utilise subjects selected 
randomly from the Caucasian population. The work has shown that increases in power 
to differentiate differences between CYP2C9 genotypes can be expected when studies 
are enriched with respect to those genotypes. 
9.2.6 Study Limitations 
The present study does not address variability in the fuB of the model drugs 
owing to lack of prior information. Such variability will influence variability in some 
pharmacokinetic parameters, particularly in FH, and therefore AUC, C., and tm.. 
However, the outcome of the pharmacodynamic simulations is not expected to be 
influenced by a lack of individual variability in fuBin our model. This follows because 
unbound plasma drug concentrations in different individuals are not affected, and they 
reflect differences only in intrinsic clearance. 
A further limitation involves the intense sampling of data that has been 
necessary to analyse the large amount of information resulting from the simulations 
detailed within this thesis. Such techniques are time-consuming and restricting when 
compared with population modeling methods. However, such methods have not been 
the subject of this thesis since the majority of literature studies of the impact of CYP 
polymorphisms on the pharmacokinetics and pharmacodynamics of drugs have been 
carried out using similar methods to those simulated in this work. 
253 
Chapter 9: Discussion 
Table 9.1 Relative activity of each of the common CYP2C9 genotypes in the 
metabolism of SWF and TLB. 
Activity Relative to *I*I 
Genotype (S)-Warfarin Tolbutamide 
*1*1 100 100 
*1*2 85 84 
*1*3 55 60 
*2*2 70 68 
*2*3 40 44 
*3*3 10 20 
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9.3 Bias in Reportinjj of NeLyative Outcomes within Pharmaco- 
genetic Studies 
At various stages throughout this thesis, it has been necessary to comment 
on the relationship between the genetics of certain CYP enzymes and drug 
pharmacokinetics and pharmacodynamics. As was pointed out in the Literature 
Review (Section 2.1), current opinion on the usefulness and applicability of 
pharmacogenetics to drug development is varied and many are inclined towards the 
view that "the promise of pharmacogenetics remains largely unfulfilled" (Tucker, 
2004). Because of such opinion, it is interesting to look at the reporting of 
pharmacogenetic studies in relation to CYP enzymes in the literature. Tables 2.10 and 
2.11 in the Literature Review detail studies which have investigated the relationship 
between CYP polymorphisms and drug pharmacokinetics (Table 2.10) and 
pharmacodynamics (Table 2.11). The journals in which the studies were reported are 
listed. It is interesting to note in which journals the proportions of studies with positive 
and negative results are reported and this was investigated in an extension to the work 
detailed below. 
When the results reported in specific j oumals are analysed, the percentage 
of negative results does not necessarily reflect the average over all journals. For 
example, while 36% (8/22) of the pharmacokinetic reports presented in the European 
Journal of Clinical Pharmacology were negative (Figure 9.1) which constitutes higher 
than average (29%; 38/184) negative reporting, the corresponding number for the 
Journal of Clinical Pharmacology was only 13% (1/8) (Figure 9.1) which suggests an 
over-reporting of positive results in studies of the influence of CYP polymorphisms on 
drug PK. 
Analysis of the results of pharmacodynamic studies reported in specific 
journals revealed that again, the percentage of negative results does not necessarily 
reflect the average over all j ournals. For example, whilst only 23 % (3/13) of the reports 
presented in Pharmacogenetics were negative (Figure 9.2), which is much lower than 
the average value (37%; 41/111), 39% (14/36) of those published in Clinical 
Pharmacology and Therapeutics were negative (Figure 9.2). 
Although no general trend for higher numbers of positive results being 
reported in high impact j ourrials is seen, it is apparent that there may be some bias and 
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this may be the result of two factors: (i) certain journals may be biased towards 
publishing positive results, or (ii) investigators may be reluctant to submit negative 
results to certain j oumals because of a perceived lower chance of acceptance. 
Such underreporting of negative results by certain journals could 
potentially lead readers to assume that CYP polymorphisms are of greater importance 
for drug PK than is really the case. This becomes an even greater problem when the 
possibility of certain studies never being reported due to their portrayal of negative 
results is taken into account. It is clear that in many cases, the 'promise' of 
pharmacogenetics portrayed by some high impact journals may remain 'unfulfilled' by 
the evidence when all studies are taken into account. 
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Figure 9.1 The percentage of studies into the effect of CYP polymorphisms on drug 
pharmacokinetics which report negative (0) and positive (0) results in 
different journals compared to the percentage across all journals. EJCP = 
European Journal of Clinical Pharmacology; BJCP = British Journal of 
Clinical Pharmacology; JCP = Journal of Clinical Pharmacology; CPT 
Clinical Pharmacology & Therapeutics. 
Overall Averagle 
, 
63% 
FJCP oo/ 
0 
Pha rmac 0 L, en ct ics 
3% 
77% 
BJCP 600o 
401, 
CPT 
610, o 
Figure 9.2 The percentage of studies into the effect of CYP polymorphisms on drug 
pharmacodynarnics which report negative (0) and positive (E) results in 
different journals compared to the percentage across all journals. EJCP = 
European Journal of Clinical Pharmacology; BJCP = British Journal of 
Clinical Pharmacology; CPT = Clinical Phannacology & Therapeutics. 
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9.4 Further Work 
An obvious extension to the work described within this thesis would be the 
systematic investigation of further drug substrates, investigating different CYP 
enzymes and varying the types of pharmacokinetic-pharmacodynamic model used. It 
would also be interesting to incorporate non-P450 mediated metabolism into the model 
and, if sufficient information were available, to investigate the impact of drug 
transporters such as P-GP on the pharmacokinetics and hence pharmacodynamics of 
drugs. 
In addition to investigating the impact of study size and enrichment on the 
power of clinical trials, it would also be of interest to incorporate other aspects of study 
design into the model such as demographic or physiological characteristics of the study 
participants or the timing and frequency of the drug dosage. Furthermore, the impact of 
disease states or ethnicity of individuals on the pharmacokinetics and 
pharmacodynamics of drugs could be incorporated. 
Each of the five results chapters of this thesis have investigated the impact 
of certain aspects of study design on the power of studies to detect differences in the 
pharmacokinetics or pharmacodynamics of drugs as a result of CYP polymorphisms. 
In some of the chapters (Chapters 4,5 and 6), the impact of certain characteristics of 
the drug substrate on the power of such studies has also been investigated. A useful 
extension to this work would be to conduct some analyses of the sensitivity of study 
power to certain drug characteristics. These could be utilised during drug development 
to judge the impact of a polymorphic metabolic pathway on drug response and toxicity 
before making go/no go decisions. 
An issue that has not been addressed by the work within this thesis is the 
impact of genetic variability in drug metabolism on the extent of drug-drug 
interactions and their consequences for drug toxicity and response. Such models could 
be used in a similar way to those detailed in this thesis to investigate the impact of 
certain drug characteristics and aspects of study design on the power of studies to 
detect differences in the magnitude of drug-drug interactions between individuals of 
different CYP phenotype/genotype. It would be possible to investigate the impact of 
CYP polymorphisms on the likelihood of non-response to drugs or drug toxicity as a 
result of interactions. 
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Furthermore, recently there has been a move within the literature towards 
examining the impact of pharmacodynamic polymorphisms on drug response. This has 
been touched on in Chapter 5 with the VKORC I polymorphism simulations. However, 
where data is available it would be possible to incorporate a great many more 
pharmacodynamic polymorphisms and investigate the impact of these on drug 
response. A further dimension to such work would be to compare the impact of 
pharmacokinetic polymorphisms with those in pharmacodynamics. 
Finally, in the current work, a number of parameters were taken from in 
vivo studies (e. g. V) however the most important determinant of exposure (CL) was 
simulated using in vitro data. In general, it may be possible to use further in vitro 
information. For example, estimates of volume of distribution in individuals could be 
made from physicochernical characteristics and variations in organ sizes and 
composition (Poulin & Theil, 2002) and for some drugs, it is possible to use in vitro 
receptor binding data to estimate pharmacodynamic effects associated with a given 
concentration at the receptor site (Jonker et aL, 2005). Thus, in the future, clinical trial 
simulation may increasingly use prior in vitro data. The approach exemplified by the 
current study, to calculate statistical power avoids assumptions about the distributions 
and variation of primary pharmacokinetic parameters required by less mechanistic 
models used as the basis of clinical trial simulation. 
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